Document:

EX-10.7

 Exhibit 10.7 

ASSIGNMENT, ASSUMPTION, AMENDMENT AND CONSENT 

75 Kneeland Street, Lease of 6th Floor 

This Assignment, Assumption, Amendment and Consent (this “Agreement”) is made as of September 1, 2001, by and among the TRUSTEES OF TUFTS
COLLEGE, a Massachusetts not-for-profit corporation (the “Assignor”), PARATEK PHARMACEUTICALS, INC., a Delaware corporation (“Assignee”) and KING
REAL ESTATE CORPORATION, AS TRUSTEE OF KNEELAND STREET REAL ESTATE TRUST (“Landlord”). 
 Assignor is the tenant under a certain lease dated
November 10, 1993, as amended by amendment to lease dated March 31, 1998 (the “Lease”), entered into between Assignor and Landlord consisting of all of the rentable space on the
6th floor of the building located at 75 Kneeland Street in Boston, Massachusetts, containing approximately 15,088 rentable square feet of space (the “Premises”). A copy of the Lease is
attached hereto as Exhibit A. 
 Assignor desires to assign its interest as tenant in the Lease to Assignee, and Assignee desires to accept the
assignment thereof. 
 In accordance with the provisions of the Lease, Landlord’s consent to such assignment is required and Landlord is willing to
give such consent subject to the terms and conditions of this agreement. 
 Now, therefore, in consideration of the promises and conditions contained
herein, the parties hereby agree as follows: 
 1. Assignment. Assignor hereby assigns to Assignee all of its right, title and interest in and to the
Lease, and Assignee hereby accepts the assignment, transfer and conveyance of such right, title and interest from the Assignor, at the rentals and upon all the other terms and conditions set forth in the Lease for the unexpired term of the Lease.

 2. Assumption. Assignee agrees with Assignor and with Landlord to assume and does hereby assume all of tenant’s obligations under the Lease
arising from and after the date hereof, including the payment of all rent, additional rent and other financial obligations of the tenant as set forth in the Lease and further assumes liability and responsibility for the due punctual performance of
all the covenants, terms, conditions and provisions to be kept, observed and performed by the tenant as set forth in the Lease arising from and after the date hereof. 

3. Assignor’s Obligations. Notwithstanding any other provisions of this Agreement, Assignor affirms and agrees that it shall remain fully and
primarily liable to Landlord for the payment and performance of all obligations of the tenant under the Lease and that this Agreement shall not relieve Assignor of such liability; provided, however, that Assignor shall not be bound by any
modifications to the Lease which are made without Assignor’s prior written consent and Assignor shall not be bound by the amendment to Article 35 of the Lease set forth in Section 8 of this Assignment (“Revised Article 35”). 

4. Indemnity. Assignor hereby agrees to indemnify and hold Assignee harmless from and against all claims, demands, losses, damages, expenses and costs
including, but not limited to, 

  
 - 1 - 

 
reasonable attorneys’ fees and expenses actually incurred, arising out of or in connection with Assignor’s failure, prior to the date of this Assignment, to observe, perform and
discharge each and every one of the covenants, obligations and liabilities of the tenant under the Lease, to be observed, performed or discharged on, or relating to, or accruing with respect to the period prior to the date of this Assignment. 

Assignee hereby agrees to indemnify and hold Assignor harmless from and against all claims, demands, losses, damages, expenses and costs
including, but not limited to, reasonable attorneys’ fees and expenses actually incurred, arising out of or in connection with Assignee’s failure, from and after the date of this Assignment, to observe, perform and discharge each and every
one of the covenants, obligations and liabilities of the tenant under the Lease, to be observed, performed, or discharged on, or relating to, or accruing with respect to, the period from and after, but not before, the date of this Assignment,
including, without limitation, all such covenants, obligations and liabilities under Revised Article 35. In addition, Assignee hereby agrees that its indemnity of Landlord under Section 35.11.1 of Revised Article 35 shall also run in favor of
Assignor, substituting “Assignee” for “Tenant” and “Assignor” for “Landlord,” where applicable, including in the definitions of capitalized terms used in said Section 35A 1.1. 

5. Certification. Landlord and Assignor hereby certify that: the Lease is in full force and effect; the copy of the Lease attached hereto is true,
accurate and complete; there have been no modifications or amendments thereto; Assignor has fulfilled all of its obligations under the Lease and there exist no defaults under the Lease by Assignor; and Landlord has fulfilled all of its obligations
under the Lease and there exist no defaults under the Lease by Landlord. 
 6. Notice. The tenant’s notice address under the Lease shall, from
and after this date, be: 
 Paratek Pharmaceuticals, Inc. 

75 Kneeland Street 
 Boston, MA
02110 
 7. Landlord’s Costs. Assignee shall pay all of Landlord’s $1,000 fee for its review and approval of this Agreement and shall also
reimburse Assignor for reasonable attorneys’ fees and costs actually incurred (not to exceed $1,000) for the review and final execution of this Assignment and obtaining Landlord’s consent to the same. 

8. Amendment to Lease. Assignor, Assignee and Landlord hereby agree that the Lease shall be amended, effective as of the date of this Agreement, by
deleting the provisions of Article 35 in its entirety (however, such Article 35 shall be in full force and effect with respect to the obligations of the tenant thereunder arising prior to the date hereof), and the following shall be substituted in
place thereof: 
 35. ENVIRONMENTAL HAZARDS 
  

	 	35.1.	TENANTS USE OF HAZARDOUS MATERIAL. 

 Tenant and Tenant’s Agents, shall not use, maintain,
generate, allow or bring on the Premises or Landlord’s Property or transport or dispose of, on or from the Premises or Landlord’s Property (whether into the ground, into any sewer or septic system, into the

  
 - 2 - 

 
air, by removal off-site or otherwise) any Hazardous Matter (as hereinafter defined), except only for Hazardous Matter of types and in quantities as are
used in connection with the chemical, medical or biological research occurring in the laboratories located within the Premises, provided such use and storage is in strict compliance with all Environmental Requirements (as hereinafter defined) and
with the provisions of this Article. 
  

	 	35.2	GENERAL STANDARDS OF COMPLIANCE. 

 Tenant shall inspect, use, store, generate, and dispose of
all Hazardous Matter in compliance with all Environmental Requirements and shall cause its agents to so comply. Tenant shall take all reasonable measures to prevent any third party from releasing Hazardous Matter on or in the Premises. Tenant shall
not release, or permit to be released, on, in or from the Premises or Property or in connection with Tenant’s use of the Premises any Hazardous Matter in violation of the Environmental Requirements. 

 

	 	35.3.	SPECIFIC STANDARDS OF COMPLIANCE. 

 Without limiting Tenant’s obligations under
Section 35.2, Tenant shall comply, and cause Tenant’s Agents to comply, with the specific requirements set forth in this Section 35.3. 

35.3.1. New Chemicals. Tenant shall provide advance, premanufacture notice to the federal Environmental Protection
Agency of the distribution of new chemicals as required under the Toxic Substances Control Act, 15 U.S.C. §21.01 et seq. and 40 CFR Part 700 to 799, and shall also notify Landlord in writing of same. 

35.3.2. Laboratories. Tenant shall comply with 29 CFR Part 910 promulgated under the OSHA pertaining to occupational
exposure to hazardous chemicals in laboratories. 
 35.3.3. Discharges to Sanitary Sewer. Tenant shall obtain an
industrial use permit from the Massachusetts Water Resource Authority (“MWRA”) if required to do so by law or regulation and a state sewer permit from the state Division of Water Pollution Control and shall comply with the discharge
regulations contained in 314 CMR Part 12 and 360 CMR Part 10 and any pretreatment conditions contained in the applicable sewer permit and shall cause its agents to so comply. 

35.3.4. Handling Hazardous Wastes. Tenant shall comply, and shall cause its Agents to comply, with 310 CMR Part 30 and
105 CMR Part 480 relating to the handling, storage, generation, transportation, and disposal of hazardous waste and infectious waste. As soon as Tenant or its agents generates hazardous waste, Tenant shall provide Tenant’s generator number and
copies of permits required under 310 CMR Part 30 to Landlord, and shall make available upon oral or written request of Landlord within seven (7) days of the date of such request, copies of all manifests used for the transportation and disposal
of hazardous waste. 
 35.3.5. Inventories of Hazardous Material. Tenant shall comply with all notification, filing,
reporting and inventory requirements with respect to Hazardous 

  
 - 3 - 

 
Matter at the Premises, and Tenant shall make available to Landlord within seven days of the date of oral or written request: (a) copies of all inventories of Hazardous Matter and safety
plans filed with the Fire Department under the Emergency Planning and Community Right-To-Know Act, 42 U.S.C. Section 11001 et seq. and applicable
Massachusetts laws, (b) copies of material safety data sheets (“MSDS”) that accompany any product used or stored at the Premises, pursuant to the hazard communications standard under the Occupational Safety and Health Act
(“OSHA”) and evidence that the MSDSs have been made available to Tenant employees, (c) reports related to radioactive and biological materials at the Premises, and (d) all other plans and reports required to be prepared pursuant
to the Environmental Requirements. 
 Promptly following the request of Landlord, if Tenant or Tenant’s Agents generate hazardous or
infectious waste, Tenant shall provide Tenant’s generator number and copies of permits required under 310 CMR Part 30 and 105 CMR Part 480 to Landlord, and shall make available upon oral or written request of Landlord within 7 days of the date
of such request, copies of all manifests used for the transportation and disposal of hazardous and infectious waste. 
 Promptly following
the request of Landlord, if Tenant or Tenant’s Agents generates, treats, stores or transports radioactive material, Tenant shall provide to Landlord all applicable licenses under 42 U.S.C. §2011 et seq. and M.G.L. c.11111, §§1 to
48. Tenant shall handle and dispose of radioactive materials in accordance with 10 CFR Parts 0 to 17, and 105 CMR Parts 120 to 122. 
  

	 	35.4.	NOTICES. 

 Landlord and Tenant shall promptly deliver to the other any notices, orders or
similar documents received from any governmental agency or official affecting the Premises and concerning the alleged violation of the Environmental Requirements. Tenant shall give prompt notice to the Landlord of any violation or potential
violation of the Environmental Requirements. 
  

	 	35.5.	TENANT’S OBLIGATION TO PAY COSTS AND FINES 

 Tenant shall bear the full cost of, and be
solely responsible for, carrying out its obligations under this Article. Tenant shall pay forthwith any fine assessed in connection with any violation by Tenant or its agents of the Environmental Requirements. 

Any cost or fine required under this Article to be borne by Tenant not promptly paid by Tenant that Landlord elects to pay shall be reimbursed
by Tenant to Landlord within 30 days of written demand therefor and may at Landlord’s election be treated as additional rent hereunder; and Landlord shall have the same rights and remedies for the nonpayment thereof as for the nonpayment of
rent. 
 During the investigation and cleanup of any release and during any restoration, maintenance, or repair work that is the
responsibility of Tenant under this Article, Tenant shall continue to pay rent even though part or all of the Premises may be unusable. 

  
 - 4 - 

	 	35.6.	TENANTS RESPONSIBILITY TO CLEAN UP ANY RELEASE. 

 Upon demand by Landlord (whether oral or
written), if Hazardous Matter has been released by Tenant or Tenant’s Agents at or from the Premises, in connection with their use of the Premises or otherwise, Tenant shall take all actions which are necessary to attain cleanup levels in
accordance with the Environmental Requirements, to mitigate Environmental Damages, and to allow full economic use of the Premises and Property. These actions shall include, without limitation, investigation and cleanup as may be required under
CERCLA, Chapter 21E, RCRA, or Chapter 21C, whichever is applicable. All such investigation and remedial work shall be performed by contractors reasonably acceptable to Landlord in accordance with the Environmental Requirements. Any such action shall
be performed in good, safe and workmanlike manner and shall minimize any impact on other tenants occupying the Property and the businesses conducted thereon. Tenant shall promptly provide to Landlord copies of testing results and all other reports.

 Following such cleanup, Tenant shall promptly take all actions as are necessary to return the Premises, Property and any areas outside the
Premises and Property to the condition existing prior to the presence or introduction of any such hazardous material or oil including the repair of any damage caused by the investigation or remediation. 

 

	 	35.7.	REMOVAL. 

 Tenant shall remove all Hazardous Matter and the containers in which such substances
were ever packaged or stored from the Premises prior to the termination of this Lease and prior to vacating; and such removal and disposal of such substances and containers shall be performed in accordance with 310 CMR Part 30. 

 

	 	35.8.	INSPECTION. 

 Three months prior to the termination of this Lease, and if this Lease terminates
other than by expiration of the term, within 30 days after the termination, and in all events not later than 30 days after the Tenant vacates the Premises, and at any other time that Landlord reasonably deems appropriate, Tenant shall retain an
environmental site assessment firm acceptable to Landlord in its sole discretion who shall complete the following no later than 30 days after the firm is retained: (a) inspect the Premises for storage of hazardous waste, or release of Hazardous
Matter in violation this Article; and (b) provide a report on the results of such inspection reasonably satisfactory to Landlord. No testing or sampling of soil, groundwater or building materials shall be performed without Landlord’s prior
written approval. 
 Tenant, through a duly authorized officer if Tenant is a corporation and if Tenant is not a corporation, through a
person empowered to bind Tenant, and any employee responsible for the proper handling and disposal of Hazardous Matter, shall give an annual certification, and a certification prior to the termination of this Lease and prior to vacating, to the
effect that the requirements of this Article, and any other of the Environmental Requirements for which Landlord has requested a certification, have been satisfied. 

  
 - 5 - 

 Tenant grants Landlord, upon reasonable written notice, the right to inspect the Premises
throughout the term of this Lease to determine whether Tenant is in compliance with the provisions in this Article; and Tenant shall provide Landlord with all information deemed by Landlord necessary for Landlord to ascertain whether Tenant so
complies. 
  

	 	35.9.	INTENTIONALLY OMITTED. 

  

	 	35.10.	SELF HELP. 

 If Landlord reasonably determines that Tenant has not proceeded diligently to cure
any default under this Article within a reasonable time period, as determined by Landlord in its sole, but reasonable, discretion, or in the event of an emergency as determined by Landlord in its sole, but reasonable, judgment, Landlord, in addition
to any other remedy under this lease, shall have the right, but not the obligation, to enter upon the Premises and to perform Tenant’s obligations hereunder, including the payment of money and the performance of any other act. All reasonable
sums so paid by Landlord and all incidental costs and expenses in connection therewith shall be reimbursed by Tenant to Landlord, promptly following demand therefor, as additional rent. Not-withstanding any
such performances by Landlord, Tenant shall remain liable for any violation of the provisions in this Article. 
  

	 	35.11.	INDEMNIFICATION. 

 35.11.1. Tenant’s Indemnification. Tenant and its
successors, assigns and guarantors shall release, defend (with an attorney reasonably acceptable to Landlord), indemnify and hold harmless Landlord and its successors and assigns and the officers, directors, stockholders, partners, beneficial
owners, trustees, employees, agents, contractors, attorneys, and mortgagees of Landlord or of its successors and assigns or of any of the foregoing from and against all Environmental Damages which may be asserted by Tenant, any other person or
entity, or government agency on account of the presence or release of any Hazardous Matter upon, in or from the Premises or Property related to the activities conducted by Tenant or its agents, or to other action by Tenant or its agents in violation
of the Environmental Requirements or on account of breach of any of Tenant’s obligations under this Article. 
 35.11.2.
Landlord’s Indemnification. Landlord shall indemnify and hold Tenant harmless from and against all injury, loss, claim or damage relating to the cost of cleanup (including reasonable attorneys’ fees but exclusive of any indirect or
consequential damages) arising during or after the Term of this Lease in connection with any release of Hazardous Matter upon, in or from the Premises or Landlord’s Property or other action in violation of Environmental Requirements, where such
release or action occurred prior to the Term Commencement Date (or, if earlier, the date of Tenant’s initial entry onto the Premises) or was caused by the Landlord, its agents, employees or contractors after the Term Commencement Date;
provided, however, that this indemnification by Landlord expressly excludes any release, action or violation caused in whole or in part by any prior, current or future tenant of the Building or any contractor, agent, employee or invitee of any of
same. 

  
 - 6 - 

	 	35.12.	DEFINITIONS. 

 The following terms as used herein shall have the meanings set forth
below: 
 “Hazardous Matter” shall mean any substance (i) which is toxic, explosive, corrosive, flammable, infectious,
radioactive, carcinogenic, mutagenic, biological or otherwise hazardous substance which is or becomes regulated by any governmental authority, agency, commission or instrumentality of the United States, the Commonwealth of Massachusetts or any
political subdivision thereof including city or town in which the Premises are located; or (ii) which is or becomes defined as a “hazardous substance” pursuant to Section 101 of the Comprehensive Environmental Response,
Compensation and Liability Act, 42 U.S.C. Section 9601 et seq. (“CERCLA”); as well as any material or substance which is or becomes defined as hazardous material or oil under M.G.L. Ch. 21E (“Chapter 21E”),
Section 2 and the Massachusetts Contingency Plan, 310 CMR Part 40; or (iii) which is or becomes a pollutant regulated under the Clean Air Act, 42 U.S.C. Section 7401 et seq. and 40 CFR Parts 50 to 85 or the Massachusetts Clean
Air Act, M.G.L. c. 111, Section 142 et seq. and 310 CMR Parts 6 to 8; or (iv) which is or becomes defined as “hazardous waste” below; or (v) the presence of which requires investigation or remediation under any
present or future federal, state or local statute, regulation, ordinance, by-law, order, action, policy or common law; or (vi) which contains gasoline, diesel fuel, oil or other petroleum hydrocarbons; or
(vii) the presence of which causes or threatens to cause a nuisance or poses or threatens to pose a hazard to the health or safety of persons on or about or adjacent to the Premises or Property. 

“Environmental Damages” shall mean all liabilities, injuries, losses, claims, damages (whether special, consequential or
otherwise), settlements, attorneys’ and consultants’ fees, fines and penalties, interest and expenses, and costs of environmental site investigations, reports and cleanup, including without limitation costs incurred in connection with: any
investigation or assessment of site conditions or of health of persons using the Building or Landlord’s Property; risk assessment and monitoring; any cleanup, remedial, removal or restoration work required by any governmental agency or
recommended by Landlord’s environmental consultant; any decrease in value of Landlord’s Property; any damage caused by loss or restriction of rentable or usable space in Landlord’s Property; or any damage caused by adverse impact on
marketing or financing of Landlord’s Property. 
 “Environmental Requirements” shall mean all Applicable Laws
(including without limitation the laws and regulations referenced in this Article), common law principles pertaining to nuisance, tort, and strict liability, the provisions of any and all Approvals, all recommendations by manufacturers, trade
associations and governmental bodies, and the terms of this lease; in so far as such laws and regulations, orders, permits and approvals, recommendations, and terms relate to the release, maintenance, use, keeping in place, or disposal of Hazardous
Matter, including those pertaining to reporting, licensing, permitting, housekeeping, upgrading of equipment, health and safety of tenant’s agents and other persons, investigation, remediation, and disposal; and shall include both present and
future laws and regulations, orders, permits and approvals, recommendations, and rules and regulations. 

  
 - 7 - 

	 	35.13.	OTHER 

 35.13.1. The provisions of this Article shall be in addition to any
other obligations and liabilities Tenant may have to Landlord under this lease or at law or in equity. 
 35.13.2. In the
case of conflict between this Article and other provisions of this Lease, the provisions imposing the most stringent requirement as to Tenant shall control. 

35.13.3. The obligations of Tenant under this Article shall survive the expiration or termination of this Lease and the
transfer of title to the Property. 
 9. Utility Closet. Assignee agrees that Assignor may, at reasonable times and upon reasonable notice, (except
that advanced notice shall not be required in event of an emergency) access the utility closet located in the Premises currently housing Assignor’s telephone center (the “Utility Closet”) at any time during the remaining term of the
Lease and to continue to maintain voice and/or data communications equipment in the Utility Closet. Assignor shall maintain a comprehensive general liability policy in reasonable amounts as well as a policy covering Assignor’s fixtures,
property and equipment installed in the Utility Closet, which policies shall name Assignee as an additional insured. Assignor hereby consents to Assignee’s relocation of the Utility Closet within the Premises, at Assignee’s sole cost and
expense, subject to prior approval by Landlord, as required by the Lease. Notwithstanding any provisions in the Lease or this Assignment to the contrary, Assignor shall, at its sole cost and expense, at the end of the remaining term of the Lease,
remove its property from the Utility Closet in accordance with the terms of the Lease. The foregoing arrangement is between Assignor and Assignee and does not affect in any way the Lease or the obligations of Assignee to Landlord under the Lease.

 10. Landlord’s Consent. Landlord hereby consents to the foregoing assignment of the Lease by Assignor to Assignee. 

11. Ratification. The Lease, as amended by this Agreement, is hereby ratified and confirmed by the parties. 

12. Binding. This Agreement shall be binding upon and inure to the benefit of the parties hereto, their heirs, executors, administrators, successors,
in interest and assigns. 
 [signatures on next following page] 

  
 - 8 - 

 In witness whereof, the undersigned have duly executed this Agreement as of the day and year
first above written. 
  

									
	ASSIGNOR;				ASSIGNEE:
	TRUSTEES OF TUFTS COLLEGE				PARATEK PHARMCEUTICALS, INC.
					
	By:		 /s/ Steven S. Manos
				By:		 /s/ George Hillman

			Name: Steven S. Manos						Name: George C. Hillman
			Title: Executive V.P						Title: Executive Vice President
			Duly authorized						Duly authorized
				
	LANDLORD:						
	 KING REAL ESTATE CORPORATION,
 As
Trustee of
 KNEELAND STREET REAL ESTATE TRUST
 and Not
Individually
						
					
	By:		 /s/ Karl Greenman
						
			Name: Karl Greenman						
			Title: President and Treasurer						
			Duly authorized						

  
 - 9 - 

 EXHIBIT A 

Lease 

 LEASE 

of 
 6th Floor, 75
Kneeland Street, Boston, MA 
 This lease (hereinafter “Lease”), entered into by and between: 

KING REAL ESTATE CORPORATION, a Massachusetts corporation, Trustee of KNEELAND STREET REAL ESTATE TRUST under Declaration of Trust dated April 1, 1980,
filed with Registry District of Suffolk County as Document No. 351241 and noted on Certificate of Title No. 92936 (hereinafter “Landlord”), 
 and

 TRUSTEES OF TUFTS COLLEGE, a Massachusetts nonprofit corporation with a present mailing address of Ballou Hall, Medford, Massachusetts 02155, Attention:
Executive Vice President (hereinafter “Tenant”). 
 In consideration of the rents, covenants and agreements hereinafter reserved
and contained on the part of Tenant to be observed and performed, Landlord demises and leases to Tenant and Tenant leases from Landlord the following premises upon the following terms, covenants and conditions. 

 

	1.	DEMISED PREMISES 

 The demised premises consisting of the entire sixth floor of the
building (hereinafter “Building”) located at 75 Kneeland Street, Boston, Massachusetts, which demised premises are shown on Exhibit A attached hereto, containing 15,088 square feet of rentable floor area (hereinafter the
“Premises”). Said Building contains an aggregate total rentable area of 211,232 square feet. 
 Tenant shall have, as appurtenant
to the Premises, the non-exclusive right and easement to use in common with others entitled thereto (a) common facilities (hereinafter “Common Facilities”) in the Building and on the land on
which it is located (said Building and land are hereinafter “Landlord’s Property”) including without limitation, sidewalks, lobbies, hallways, stairways, entranceways, exterior spaces, common washrooms and such other facilities
available to all tenants of the Building as may be designated from time to time by the Landlord (subject to the last sentence of this paragraph), and (b) the pipes, ducts, conduits, utility lines, wires, sewerage system and appurtenant
equipment serving the Premises. Tenant’s rights hereunder shall always be subject to the reasonable rules and regulations from time to time established by Landlord, as provided in Section 23B hereof, provided such rules and regulations
shall not materially interfere with Tenant’s Permitted Use (hereinafter defined) of the Premises. Landlord reserves and shall have the unrestricted right to change the location, size or character of any of the Common Facilities, provided such
changes do not materially decrease the size of the Premises or materially adversely affect Tenant’s use of the Premises for the Permitted Use. 

EXCEPTED AND EXCLUDED from the Premises are the exterior walls and any space currently or (if same does not materially decrease the size of
the Premises or materially adversely affect Tenant’s use of the Premises for the Permitted Use) in the future necessary to install, 

 
maintain and operate, by means of pipes, ducts, wires, meters, vents, flues, conduits, utility lines, fan rooms, shafts, stacks, utility closets, janitor closets, stairways or otherwise those
utilities and services required for Landlord’s Property, Common Facilities thereof and tenant premises (including the Premises). Landlord, its agents, contractors and employees shall have the right of access to and entry on the Premises for the
purposes of such installation, maintenance or operation or for the purposes of making repairs, alterations or additions to the Premises or to the Building if Landlord so elects. Except in cases of emergency, Landlord shall exercise the foregoing
rights upon reasonable notice to the Tenant and in such a manner as not to interfere unreasonably with Tenant’s use of the Premises between the hours of 8:00 a.m. and 6:00 p.m. Monday through Friday and between the hours of 8:00 a.m. and 1:00
p.m. on Saturday, excluding all legal holidays (hereinafter “Business Hours”). Landlord further reserves the right to change the street address and the name of the Building at any time and from time to time upon sixty (60) days prior
notice to Tenant, without liability to Tenant. 
  

	2.	TERM 

 2.1 Term. Subject to the conditions herein stated, Tenant shall hold the
Premises for a term of approximately five (5) years (hereinafter the “Term” or the “original Term”) commencing on the later of (i) the Substantial Completion Date (as defined in Article 3) or (ii) January 1,
1994 (the later of such dates being hereinafter referred to as the “Term Commencement Date”) and terminating December 31, 1998. The Term may be extended by Tenant upon and subject to the terms of Article 41 hereof, in which event the
“Term”, as used herein, shall include the original Term together with the extension period. 
  

	3.	CONSTRUCTION AND CONDITION OF THE PREMISES 

 3.1 Condition of Premises. Except for
the construction of the Initial Tenant Improvements as provided herein, the Tenant accepts the Premises and the Building in their present “as is” condition, without representation or warranty, express or implied, in fact or in law, by
Landlord and without recourse to Landlord as to the nature, condition or usability thereof and agrees that Landlord has no work to perform in or on the Premises; and Tenant agrees further that any and all work to be done in or on the Premises
(except as provided herein with respect to the construction of the Initial Tenant Improvements and for those items of repair and other work which are expressly the responsibility of Landlord hereunder) will be at Tenant’s sole cost and expense.

 3.2 The Initial Tenant Improvements. 

(a) Tenant has provided Landlord with preliminary plans, and based upon such plans Landlord has caused its architect to prepare final plans
and specifications (the “Plans”) for the layout of Tenant’s leasehold improvements to a portion of the Premises (the “Initial Premises”) as depicted on such Plans (the “Initial Tenant Improvements”). The Plans have
been approved by the Tenant and are attached hereto as Exhibit B. The Initial Tenant Improvements shall not include Tenant’s furniture, trade fixtures, equipment and property and are limited to normal
fit-up construction as depicted on the Plans. It is agreed that the Initial Tenant Improvements shall not include, and Landlord shall not be responsible for, any construction or
build-out except within the Initial Premises, and (except only for the work described in clause 3 below) the 

  
 - 2 - 

 
balance of the Premises (the “Balance of the Premises”) shall be delivered to the Tenant in its current “as is” condition. As part of the Initial Tenant Improvements, Landlord
shall also perform the following work on the sixth floor of the Building: 
 1. The refinishing of the common restrooms, including making
accessibility improvements thereto; 
 2. The refinishing of the common hallway; and 

3. The installation of new thermopane windows in both the Initial Premises and in the Balance of the Premises. 

Landlord agrees to remove, encapsulate or abate any asbestos in concentrations greater than one percent (1%) found in the Initial Premises during the
process of the construction of the Initial Tenant Improvements; however, the foregoing shall not require Landlord to test the Premises or any portion thereof for the presence of asbestos and shall be limited to the removal, encapsulation or
abatement of materials actually known by Landlord to contain such concentrations of asbestos. 
 Landlord agrees, in constructing the Initial Tenant
Improvements, to reasonably cooperate with Tenant in coordinating its work with fit-up work to be performed in the Initial Premises by Tenant, such as telephone and communications cabling and the delivery and set-up of furniture and fixtures, provided such cooperation and coordination does not increase the cost of constructing, or time for completing, the Initial Tenant Improvements. 

(b) Based upon the approved Plans, the Landlord shall proceed, promptly upon the execution hereof, using reasonable efforts, to obtain all
necessary permits and approvals for the construction of the Initial Tenant Improvements, to engage a contractor to perform the construction and to proceed to complete the construction of the Initial Tenant Improvements in substantial conformance
with the Plans. The Initial Tenant Improvements shall be performed in a good and workmanlike fashion using new materials and in a first-class manner; and the Initial Tenant Improvements shall be performed in accordance with, and when completed shall
in all respects comply with all Applicable Law (as defined in Article 23) and the terms and conditions of all permits and approvals. Landlord reserves the right to make minor changes and substitutions to the Plans in connection with the construction
of the Initial Tenant Improvements, provided same do not materially adversely modify the Plans. Landlord agrees to use all reasonable efforts to substantially complete the Initial Tenant Improvements by December 31, 1993. Landlord agrees to
schedule bi-weekly meetings with Tenant during the construction period for the Initial Tenant Improvements in order to update Tenant as to the progress of construction and the estimated time of substantial
completion of the work. If the Substantial Completion Date (as defined in subsection (c) below) has not occurred by January 15, 1994, Tenant shall be entitled to a credit against its rent obligations hereunder in the amount of one
month’s rent (meaning in such event Tenant’s obligation to pay rent hereunder shall begin on the date one month following the Term Commencement Date). If the Substantial Completion Date has not occurred by June I, 1994, the Tenant shall
have the option to terminate this Lease by giving written notice thereof to Landlord at any time thereafter but prior to the Substantial Completion Date occurring, and this Lease shall thereupon be terminated and of no force and effect. 

  
 - 3 - 

 (c) The Initial Tenant Improvements shall be deemed substantially complete on the date as of
which a certificate of occupancy has been received from the City of Boston and delivered to Tenant and a certificate of Landlord’s architect has been delivered to Tenant stating that the Initial Tenant Improvements have been substantially
completed in accordance with subsection (b) above, and only punch-list type items remain to be completed, which punch-list items are to be completed by Landlord as soon as reasonably practicable thereafter (the “Substantial Completion
Date”). Notwithstanding the foregoing, if any delay in the substantial completion of the Initial Tenant Improvements by Landlord is due to: (i) any change in the Plans requested by Tenant; (ii) any request by Tenant for a delay in the
commencement or completion of the Initial Tenant Improvements for any reason; or (iii) any other act or omission of Tenant or its employees, agents or contractors; then; for the purposes of establishing the Term Commencement Date only, the
Substantial Completion Date shall be deemed to be the date the Initial Tenant Improvements would have been substantially completed, if not for the foregoing. Landlord agrees to provide Tenant with the benefit of any manufacturer’s warranties
for equipment and fixtures in the Premises, the maintenance and repair of which are Tenant’s responsibility hereunder. 
 (d) Tenant
shall give Landlord specific written notice of any defects or incomplete remaining items of work with respect to the Initial Tenant Improvements, such notice to be given to Landlord not later than the date ten (10) days after the Term
Commencement Date. Except with respect to the items contained in such notice, Tenant shall be deemed satisfied with the Initial Tenant Improvements, Landlord shall be deemed to have completed all of its obligations under this Article 3 and Tenant
shall have no claim that Landlord has failed to perform in full its obligations hereunder. Landlord agrees to use all reasonable efforts to correct or complete such items of work as soon as reasonably practicable after the Term Commencement Date.
Landlord agrees to provide Tenant with the benefit of any warranty or guaranty received by Landlord from the contractor performing the construction of the Initial Tenant Improvements, Landlord agreeing to obtain customary construction warranties
from its general contractor. Landlord agrees that if such construction warranties from its general contractor do not include a one year warranty regarding HVAC balancing and adjusting, Landlord shall be responsible, at its expense, for having any
necessary balancing and adjusting performed during such one-year period. 
 (e) This lease is
subject to the Landlord obtaining all permits, licenses and approvals necessary to allow Landlord to construct the Initial Tenant Improvements and obtain a certificate of occupancy with respect thereto; and if Landlord shall be unable to obtain
same, and is therefore unable to commence or complete the Initial Tenant Improvements, then this lease may be terminated by Landlord by written notice to Tenant. 

3.3 The Additional Tenant Improvements. 

(a) Tenant shall be responsible, at its sole cost and expense, for the performance of all work, if any, necessary in Tenant’s discretion
to prepare the Balance of the Premises for Tenant’s occupancy (the “Additional Tenant Improvements”). If Tenant desires to perform such work, Tenant shall complete the Additional Tenant Improvements in accordance with the

  
 - 4 - 

 
Additional Plans, as defined below, and in accordance with the requirements of Article 9 and Article 23 hereof; and the Additional Tenant Improvements shall only be performed by contractors and
subcontractors who have been approved in writing by Landlord, such approval not to be unreasonably withheld or delayed. 
 (b) Tenant shall
be solely responsible for the preparation and submission to Landlord for approval, of all architectural, electrical and mechanical drawings, plans and specifications necessary for the construction of the Additional Tenant Improvements, should Tenant
desire to construct the same; and all such plans and specifications shall be subject to Landlord’s prior written approval, which shall not be unreasonably withheld or delayed (such plans and specifications, when approved by Landlord, are
hereinafter referred to as the “Additional Plans”). Landlord shall not be deemed unreasonable in not approving matters therein which, among other things, in Landlord’s reasonable judgment, would cause additional delay or any expense
or unreasonable inconvenience to Landlord in the construction, operation or maintenance of or insurance upon the Premises or Building or any related machinery, equipment or other property, or which are aesthetically inappropriate to the Building, or
which would conflict with the design or function of the balance of the Building. 
 (c) Intentionally Deleted. 

(d) All work to be done hereunder by Tenant in connection with the Additional Tenant Improvements shall be done in a good and workmanlike
fashion using new materials and in a first-class manner; and the Additional Tenant Improvements shall be performed in accordance with, and when completed shall in all respects comply with, all Applicable Law (as defined in Article 23), including the
applicable provisions of the Americans With Disabilities Act, the terms and conditions of all permits and approvals, and with all insurance requirements which may be then applicable. 

(e) Tenant understands that certain tenant fit-up work is to be performed in the Building with respect
to premises leased to New England Medical Center Hospitals, Inc. (the “NEMC Work”). Tenant agrees that, until the NEMC Work has been completed, but not later than July 1, 1994, Tenant shall use labor compatible with that being
employed for the NEMC Work and shall not employ or permit the use of any labor or otherwise take any action which might result in a labor dispute involving personnel providing work or services in connection with the NEMC Work. If Tenant believes
that compliance with the preceding sentence during such period will require Tenant to expend extra funds or pay a premium for labor and materials in connection with the Additional Tenant Improvements or any other Alterations, Landlord shall
reimburse Tenant for the reasonable additional cost, if any, in complying with the preceding sentence, provided the following procedure shall apply and be followed: 

(1) Before proceeding with any such construction work (the “Work”), Tenant shall notify Landlord and provide Landlord with plans and
specifications for such work prepared by an architect and sufficient to bid, permit and construct the Work (the “Bid Plans”). The Bid Plans shall be subject to Landlord’s approval, as provided in subsection (b) above, and the
Work as depicted on the Bid Plans shall in all respects comply with all Applicable Law, including the applicable provisions of the Americans with Disabilities Act (which compliance shall be and remain the responsibility of Tenant). 

  
 - 5 - 

 (2) Tenant shall promptly obtain from an appropriate and reputable contractor a bid for the
construction of the Work as depicted on the Bid Plans (the “Bid Amount”), and the contractor’s reasonable charge for providing such bid shall be borne by the Landlord. 

(3) Based upon the Bid Plans, the Landlord shall thereafter proceed using reasonable efforts to obtain all necessary permits and approvals for
the construction of the Work, and shall cause the construction of the Work to be performed under its direction with contractors of Landlord’s choosing (which may involve construction activity occurring during night hours and on weekends only),
and such work shall be completed by Landlord’s contractor in substantial conformance with the Bid Plans, and shall be performed in a good and workmanlike fashion using new materials and in a first-class manner and within the time provided for
completion specified in Tenant’s contractor’s bid. Landlord reserves the right to make minor changes and substitutions to the Bid Plans, provided same do not materially adversely modify the Bid Plans. The Work shall be deemed substantially
complete on the date as of which a certificate of occupancy has been received from the City of Boston and delivered to Tenant for the Work and the Work has been substantially completed in accordance with this paragraph, with only punch-list type
items remaining to be completed, which punch-list items are to be completed by Landlord’s contractor as soon as reasonably practicable thereafter. Tenant shall give Landlord specific written notice of any defects or incomplete remaining items
of work with respect to the Work within ten (10) days of the substantial completion of the Work; and except with respect to the items contained in such notice, Tenant shall be deemed satisfied with the Work and Landlord shall be deemed to have
completed all of its obligations under this subsection (e) and Tenant shall have no claim that Landlord has failed to perform in full its obligations hereunder. Landlord agrees to provide Tenant with
the-benefit of any warranty or guaranty received by Landlord from the contractor performing the Work, Landlord agreeing to use reasonable efforts to obtain customary construction warranties from its
contractor, including the balancing and adjusting of the HVAC system for a period of one year 
 (4) Tenant shall pay to Landlord, promptly
upon the presentation of bills or invoices from time to time for work performed or materials supplied pursuant to the construction contract (which shall be certified by Landlord as due under the construction contract), the cost of construction of
the Work, provided the aggregate of Tenant’s payments to Landlord shall not exceed the Bid Amount (so that if the total cost of construction of the Work is less than the Bid Amount, Tenant shall only have paid such lesser amount), and any costs
over the Bid Amount (subject to the following sentence) shall be borne by the Landlord. The Tenant shall remain responsible, and shall promptly pay or reimburse Landlord, for all permit and approval costs and other costs of the Work not included in
the Bid Amount, and for any costs and expenses of construction due to: (i) any change in the Bid Plans requested by Tenant; (ii) any request by Tenant for a delay in the commencement or completion of the Work for any reason; or
(iii) any other act or omission of Tenant or its employees, agents or contractors. Landlord’s construction obligations hereunder shall be conditioned upon prompt payment by Tenant of the costs of construction, as provided herein, and such
payments shall be deemed additional rent hereunder and, in case of any nonpayment thereof, Landlord shall have in addition to any other rights and remedies, all of the rights and remedies provided by law or provided for in the Lease for the
nonpayment of Fixed Rent 

  
 - 6 - 

	4.	RENT 

 The fixed rent (hereinafter “Fixed Rent”) payable by the Tenant during
the original Term shall be the annual rent of Two Hundred Eleven Thousand Eight Hundred Thirty Five and 52/100 ($211,835.52) Dollars ($14.04 per square foot of rentable floor area) payable in equal monthly installments of $17,652.96. Tenant’s
obligations to pay Fixed Rent shall begin on the Term Commencement Date. Tenant shall deposit the first month’s rent with Landlord upon execution hereof, to be held as advance rental and security to be forfeited, without limitation or other
remedies, for any default by Tenant occurring prior to the Term Commencement Date. If no default occurs, the payment shall be applied to the first monthly installment due hereunder. 

Tenant shall also pay as additional rent without notice, except as required under this Lease, and without any abatement, deduction or setoff,
all sums, impositions, costs, expenses and other payments which Tenant in any of the provisions of this Lease assume or agrees to pay, and, in case of any nonpayment thereof, Landlord shall have in addition to any other rights and remedies, all of
the rights and remedies provided by law or provided for in the Lease for the nonpayment of Fixed Rent. 
 All Fixed Rent payments are due in
advance without demand, deduction or set-off on the first day of each and every month during the Term and any extension or renewal thereof. Fixed Rent for any partial month shall be prorated. 

In the event any Fixed Rent, additional rent or any other payments are not paid within ten (10) days of the due date thereof, Tenant
shall be charged a late fee of 1.5% of such late payment for each late payment for each month or portion thereof that said payment remains outstanding. Said late fee shall be payable in addition to and not in exclusion of additional remedies herein
provided to Landlord. 
  

	5.	PLACE OF PAYMENT OF RENT 

 All payments of rent shall be made by Tenant to Landlord
without notice or demand at such place as Landlord may from time to time designate in writing. The initial place for payment of rent shall be Whittier Partners, 155 Federal Street, Boston, Massachusetts 02110. Any extension of time for the payment
of any installment of rent, or the acceptance of rent after the time at which it is due and payable shall not be a waiver of the rights of Landlord to insist on having all other payments made in the manner and at the times herein specified. 

 

	6.	OPERATING EXPENSES AND REAL ESTATE TAXES 

 6.1 Operating Expenses Payment. 

In the event that the total Operating Expenses (hereinafter defined) for any calendar year (beginning with calendar year 1994) increase above
the Operating Expenses for calendar year 1993 (hereinafter “Operating Expenses Base”), Tenant shall pay to Landlord, as additional rent hereunder, 7.143% of any such increase (hereinafter “Proportionate Share”), in the manner
hereinafter set forth. The Operating Expenses and the Operating Expenses Base shall be pro-rated for any partial calendar year within the Term hereof. 

  
 - 7 - 

 Landlord shall deliver to Tenant approximately ninety (90) days after the close of each
calendar year in which any portion of the Term may fall, an itemized statement certified by the Landlord’s managing agent and allocating expense items in reasonable detail, setting forth: 

a. The Operating Expenses for the preceding calendar year; 

b. The total amount of Tenant’s Proportionate Share of the increase in Operating Expenses for the preceding calendar year; and 

c. The balance, if any, due from or overpaid by Tenant for the preceding calendar year. 

Tenant shall pay to Landlord the balance due from Tenant within thirty (30) days of the receipt of such statement. In the event such
statement shows an overpayment by Tenant, Landlord shall refund the amount of such overpayment to Tenant within 30 days of the delivery of such statement or shall credit same against future additional rent payments, provided Tenant is not then in
default in the performance of any of its obligations under-this Lease. 
 In addition, commencing January 1, 1994 or at any time
thereafter designated by Landlord, on the first day of each month throughout the Term, Tenant shall pay to Landlord, on account towards Tenant’s share of anticipated increases in Operating Expenses,
one-twelfth of the total amount reasonably estimated by Landlord to be Tenant’s share thereof for the current calendar year. 

The Tenant shall also pay to the Landlord, within thirty (30) days of receipt of any invoice therefor, as additional rent hereunder, 100%
of any Operating Expenses which are incurred by Landlord and either caused by any act or negligence by the Tenant or Tenant’s Agents or are performed as special services to Tenant beyond those normally provided by Landlord, including without
limitation additional after-hours security, facilities and personnel (“Special Services”). 
 6.2 Operating Expenses
Definition. 
 The term Operating Expenses shall mean only those costs reasonably incurred with respect to the operation,
administration, cleaning, repair, management, maintenance, protection and upkeep (hereinafter “Operation”) of Landlord’s Property that are consistent with those provided at comparable buildings located in Boston, Massachusetts,
including without limitation expenses for the following: 
 A. Compensation and all fringe benefits, workmen’s compensation,
unemployment insurance, insurance premiums, wages and taxes paid to, for, or with respect to all persons engaged in the Operation of Landlord’s Property; 

B. All utilities and services furnished and supplied to the Common Facilities; 

C. All utilities and services furnished and supplied generally to tenants in the Building utilizing the Building’s common systems; 

  
 - 8 - 

 D. Cost of services, materials, supplies and equipment furnished or used in the Operation of
Landlord’s Property; 
 E. Cost of maintenance, cleaning and repairs to Landlord’s Property; 

F. All legal, accounting and other professional fees and charges directly related to the Operation of Landlord’s Property; 

G. Expenses for or on account of the upkeep and maintenance of equipment, including payments under service contracts for maintenance of
equipment such as, but not limited to, security, air-conditioning, heat or elevator equipment; 
 H.
Premiums for any insurance carried by Landlord covering Landlord’s Property, including but not limited to fire, casualty, boiler, sprinkler, machinery, rental interruption and general liability insurance to the extent carried by Landlord, in
its sole discretion; 
 I. Personal property sales and use taxes on material, equipment, supplies and services, the cost of all permits and
licenses and all fees for fire, security and police protection; 
 J. Customary and reasonable management fees, which shall not exceed five
(5%) percent of the gross rents for the Building per year; and 
 The net amount of any insurance proceeds received by Landlord on
account of any items included as a part of the Operating Expenses shall be included as a credit against the Operating Expenses in the year in which such proceeds are received by Landlord. 

Operating Expenses shall not include the following: leasing commissions and costs incurred in preparing leasable space in the Building for the
occupancy of other tenants; interest, principal or other payments under any mortgage or other financing of the Building or Landlord’s Property; any inheritance, estate, succession, transfer, gift, franchise, income or earnings, profit,
corporate or similar tax to the extent applicable to Landlord’s general or net income; and any fines or penalties payable by Landlord as a result of its violations of law. 

Depreciation and costs incurred for the exclusive benefit of a specific tenant shall not be included in Operating Expenses. Expenditures which
are not properly chargeable against income shall not be included in Operating Expenses, except that the annual charge off (hereinafter defined) of the following shall be included: (a) those capital improvements required to be made by federal,
state or local regulation or ordinance not in effect as of the Term Commencement Date and (b) those capital items acquired by Landlord which, in Landlord’s reasonable judgment, should reduce the Operating Expenses whether or not such
reduction occurs. There shall be included in Operating Expenses for the calendar year in which such capital expenditure is made and each succeeding calendar year, the amount of the annual charge-off of such
capital expenditure together with interest at an annual rate equal to 2% over the prime rate of the Bank of Boston in effect at the time of making such capital expenditure (less insurance or other proceeds, if any, collected by Landlord by reason of
damage to, or destruction of, any capital item so replaced). Annual charge-off shall be determined by dividing the original cost of the capital expenditure made during the Term of this Lease by the number of
years of useful life of the item acquired. The useful life shall be determined by Landlord’s accountants in accordance with generally accepted accounting principles and practices in effect at the time of the capital expenditure. 

  
 - 9 - 

 6.3 Real Estate Taxes Payment. 

In the event that the Real Estate Taxes (hereinafter defined) for any tax year increase above $336,995.73, (hereinafter “Tax Base”),
Tenant shall pay to Landlord as additional rent hereunder, its Proportionate Share of any such increase. Such payments shall be made in monthly installments on the first day of each month, in an amount reasonably estimated by Landlord to be
Tenant’s share thereof. 
 Landlord shall deliver to Tenant approximately ninety (90) days after the close of each tax year in
which any portion of the Term may fall, an itemized statement setting forth: 
 a. The Real Estate Taxes for the preceding tax year; 

b. The total amount of Tenant’s Proportionate Share of the increase in Real Estate Taxes for the preceding tax year; and 

c. The balance, if any, due from or overpaid by Tenant for the preceding tax year. 

Tenant shall pay to Landlord the balance due from Tenant within thirty (30) days of the receipt of such statement. In the event such
statement shows an overpayment by Tenant, Landlord shall refund the amount of such overpayment to Tenant within 30 days of the delivery of such statement or shall credit same against future additional rent payments, provided Tenant is not then in
default in the performance of any of its obligations under this Lease. 
 In the event that Landlord obtains an abatement, reduction or
refund of any Real Estate Taxes for a tax period during which Tenant was obligated to pay a share of the increase in Real Estate Taxes, then Tenant shall receive its Proportionate Share of the net proceeds of such abatement, reduction or refund, and
any interest paid to the Landlord on account of such abatement, reduction or refund, (after deduction of all reasonable costs, including legal and appraisal fees, incurred by Landlord in obtaining the same) but only to the extent and not in excess
of any payments made by Tenant for such increase as required under this Article 6. Landlord shall be under no obligation to seek such an abatement, reduction or refund. Tenant shall not contest—by any proceedings the assessed valuation of
Landlord’s Property or any part thereof for purposes of obtaining a reduction of its assessment or of any taxes. 
 6.4 Real Estate
Taxes Definition. 
 The term “Real Estate Taxes” shall mean the sum of all taxes, rates and assessments, general and special,
levied or imposed against the Landlord’s Property and any improvements constructed thereon (including the Building), including all taxes, rates and assessments, general and special, foreseen and unforeseen, levied or imposed for school, public
betterment, general or local improvements. If the system of real estate taxation shall be altered or varied and any new tax shall be levied or imposed in the jurisdiction wherein Landlord’s Property is located, then any such new tax or levy
shall be included within the term “Real Estate Taxes”. The amount of 

  
 - 10 - 

 
the Real Estate Taxes which shall be deemed to have been levied or imposed with respect to Landlord’s Property and improvements shall be such amount as the legal authority imposing Real
Estate Taxes shall have attributed thereto. In the absence of such attribution or if such legal authority shall include immovables other than Landlord’s Property and improvements in imposing such Real Estate Taxes, then such amount shall be
established by Landlord in Landlord’s reasonable judgment. The term “Real Estate Taxes” shall not include any inheritance, estate, succession, transfer, gift, franchise, income or earnings, profit, corporate or similar tax to the
extent applicable to Landlord’s general or net income. 
 Tenant shall pay prior to delinquency, all municipal, county, state or
federal taxes which shall be levied, assessed or due and unpaid on any leasehold interest, on any investment of Tenant in the Premises, or on any personal property owned, installed or used by Tenant, or on Tenant’s right to occupy the Premises.
Notwithstanding anything to the contrary, Tenant shall have the right at its sole cost and expense to contest the validity of and to seek an abatement of any of the foregoing taxes, excluding Real Estate Taxes. 

6.5 Miscellaneous. 
 Any
payment due under this Article for any portion of a tax year shall be appropriately prorated. Landlord shall have the same rights and remedies for the non-payment by Tenant of any amounts due hereunder as
Landlord has for the failure of Tenant to pay rent. 
  

	7.	QUIET ENJOYMENT 

 Tenant, upon payment of the rent herein reserved and upon the
performance of all the terms and conditions of this Lease, shall at all times during the Term and during any extension or renewal term, peaceably and quietly enjoy the Premises without any disturbance from Landlord or from any other person claiming
through Landlord, subject, nevertheless, to the terms and conditions of this Lease and to the mortgages hereinafter mentioned. 
  

	8.	USE OF THE PREMISES 

 A. The Premises may be used solely by Tenant for the purposes of
general office purposes including educational research and training and associated office uses, and for no other purpose (hereinafter “Permitted Use”). 

B. Tenant shall not at any time use or occupy the Premises in violation of the certificate of occupancy or building permit issued for the
Building or any applicable zoning ordinance. The statements in the Lease of the nature of the business to be conducted by Tenant in the Premises does not constitute a representation or guaranty by Landlord that such business may be conducted on the
Premises or is lawful under the certificate of occupancy or building permit or is otherwise permitted by law; however, Landlord shall deliver to Tenant a Certificate of Occupancy for the Premises, as provided in Article 3 hereof. 

C. Notwithstanding the foregoing, if Tenant is using the Premises for the Permitted Use and the City of Boston or its zoning authority
notifies the Tenant that such use is in violation of the applicable provisions of the zoning ordinance, and, as a result, Tenant is duly ordered to cease its operations at the Premises, the Tenant shall have the option to terminate this Lease by

  
 - 11 - 

 
giving written notice thereof to Landlord prior to such order to cease operations being lifted or vacated, and this Lease shall thereupon be terminated and of no force and effect; provided,
however, such termination shall only be effective if Tenant timely makes the Termination Payment (as defined below). The Termination Payment shall be made within 30 days of the date of Tenant’s notice of termination. The “Termination
Payment” shall mean an amount equal to unamortized portion (as of the date of such termination) of the costs and expenses incurred by Landlord in constructing the Initial Tenant Improvements, which costs are to be amortized on a straight line
basis evenly over the original Term. The parties agree that, for the purposes of the calculation of the Termination Payment, the costs and expenses of constructing the Initial Tenant Improvements shall be deemed to be $240,000, which amount shall
amortize over the original term, commencing on the Term Commencement Date, at the rate of $4,000 per month. 
  

	9.	ALTERATIONS 

 Except for those items specified elsewhere herein, no alterations,
additions or improvements (hereinafter “Alterations”) to the Premises shall be made by Tenant without the prior written consent of Landlord, which shall not be unreasonably withheld. Landlord shall not be deemed unreasonable for
withholding its consent to any Alteration which may affect the structural, mechanical, exterior or common facilities of the Building, nor for making its approval conditional upon Tenant’s agreement to restore the Premises at the expiration or
earlier termination of the Term to its condition prior to such Alteration. 
 All work done in connection with any Alteration shall be done
in a good and workmanlike manner employing materials of good quality and in compliance with laws, rules, orders and regulations of governmental authorities having jurisdiction thereof, by contractors approved by Landlord. Tenant shall be responsible
that its contractors abide by all reasonable procedures, rules and regulations as promulgated by Landlord. All Alterations shall be performed in such a manner so as to maintain harmonious labor relations and not to damage the Building or
unreasonably interfere with the construction or operation of the Building. Tenant shall indemnify and hold Landlord harmless from additional costs incurred in supplying service or repairing damage caused by Tenant’s contractors. Tenant shall
cause each contractor to carry workmen’s compensation insurance in statutory amounts covering the employees of all contractors and subcontractors, and comprehensive general liability insurance with such limits as Landlord may reasonably require
from time to time during the Term of this Lease, but in no event less than the minimum amount of comprehensive general liability insurance Tenant is required to maintain as set forth in Article 11 hereof (all such insurance to be written in
companies reasonably approved by Landlord and insuring Landlord, Landlord’s mortgagee and Tenant as well as the contractors) and to deliver to Landlord certificates of all such insurance prior to commencement of any work. Any Alteration made by
Tenant after such consent shall have been given, and any fixtures installed as part thereof shall, at Landlord’s option, become the property of Landlord upon the expiration or other sooner termination of this Lease. If Landlord shall fail to
exercise such option, Tenant shall remove such Alterations at Tenant’s cost upon expiration or termination of this Lease. Tenant shall yield up the Premises in good order and repair, reasonable wear and tear and damage by fire or casualty
excepted. 

  
 - 12 - 

	10.	MAINTENANCE AND REPAIR 

 Except as otherwise provided in this Article and Articles 12 and
13, Landlord shall keep and maintain in good order and repair (in accordance with standards of office buildings of similar age, condition and character in Boston, Massachusetts) the Common Facilities and structural portions of the Building including
but not limited to the roof, exterior walls, floor slabs, columns, elevators, public stairways and corridors, lavatories and common utility systems and equipment external to the Premises (specifically excluding any such equipment installed by or on
behalf of Tenant). Landlord’s obligations hereunder shall exclude reasonable wear and tear and damage by fire or other casualty. 

Tenant shall make all other repairs necessary to maintain the Premises in good order and repair, including, without limitation, all glass,
doors and all utility systems and equipment serving the Premises exclusively and Tenant shall return the Premises to Landlord at the end of the Term in good condition, reasonable wear and tear and damage by fire or other casualty excepted. Tenant
shall also be responsible for the cost of any repairs to the Premises or the Building (to the extent not reimbursed by insurance proceeds), which repairs may be structural or non-structural in nature,
necessitated as the result of the negligence or fault of Tenant or Tenant’s subtenants, licensees, concessionaires, employees, agents, contractors or anyone else claiming by, through or under Tenant (hereinafter “Tenant’s
Agents”) Tenant shall keep the interior of the Premises neat and in good order, repair and condition, shall keep all interior glass in good condition and shall replace any exterior glass broken by Tenant or Tenant’s Agents with glass of
the same quality. 
 All repairs made by either Landlord or Tenant shall be done in a good and workmanlike manner in accordance with all
applicable laws. 
  

	11.	INSURANCE  

 11.1 Tenant’s Insurance. Tenant shall save Landlord harmless and
indemnified from and against all injury, loss, claim or damage to any person or property while (a) on the Premises or (b), if arising out of the use or occupancy of the Premises by Tenant or Tenant’s Agents, on Landlord’s Property
(unless caused by the act, neglect or default of Landlord, its employees, agents, licensees or contractors), and from and against all injury, loss, claim or damage to any person or property anywhere on the Premises or Landlord’s Property
occasioned by any act, neglect or default of Tenant or Tenant’s Agents. Tenant shall maintain with respect to the Premises and Landlord’s Property liability insurance equivalent to comprehensive general liability and property damage
insurance including the broad form comprehensive general liability endorsement and a contractual liability coverage endorsement in amounts not less than $3,000,000.00 combined single limit and an annual aggregate of at least $5,000,000.00. Landlord
shall have the right, from time to time, to increase said insurance amounts to amounts customarily required of tenants in comparable buildings in the greater Boston area. Such insurance shall insure Landlord and Landlord’s mortgagees as
additional insureds (with respect to their respective interests in the Premises) as well as Tenant against injury to persons or damage to property as herein provided, and shall contain a provision that the Landlord and Landlord’s mortgagees,
although named as additional insureds, shall nevertheless be entitled to recovery under said policy for any loss occasioned to them, their servants, agents and employees by reason of the negligence of the Tenant or Tenant’s Agents. 

  
 - 13 - 

 Tenant shall maintain, at its sole cost and expense, fire and extended coverage insurance for all
of its contents, furniture, furnishings, equipment, improvements, funds, personal property, floor coverings and fixtures located within or about the Premises, providing protection in an amount equal to One Hundred (100%) percent of the
insurable value of said items. 
 All of Tenant’s insurance shall be with companies qualified to do business in Massachusetts, and
shall be issued by insurance companies with a general policyholder’s rating of not less than A- and a financial rating of not less than Class X as rated in the most current “Best’s”
Insurance Reports. Such insurance may be maintained by Tenant under a blanket policy or policies so-called, provided the coverage afforded Landlord is not reduced or diminished by reason of the use of such
blanket insurance policy, and provided further that the requirements set forth herein are otherwise satisfied. 
 Tenant shall deposit with
Landlord certificates of insurance that it is required to maintain under this Lease, at or prior to the Term Commencement Date, and thereafter, within thirty (30) days prior to the expiration of each such policy. Such policies shall provide
that the policies may not be changed or cancelled without at least thirty (30) days’ prior written notice to Landlord. 
 Tenant
covenants that in the event it violates Article 35 hereof or in the event it keeps upon the Premises or Landlord’s Property any substance of dangerous, inflammable or explosive character or makes any use of the Premises which increases the rate
of insurance on the Premises or Landlord’s Property, Tenant shall promptly pay to Landlord upon demand any such increase resulting therefrom, which shall be due and payable as additional rent hereunder. 

11.2 Landlord’s Insurance. Landlord shall maintain general liability insurance with respect to the Common Areas and fire and
extended coverage insurance on the Building providing protection In an amount reasonably determined by Landlord to be adequate. Landlord shall not be responsible for any damage to Tenant’s contents, furniture, furnishings, equipment,
improvements, funds, personal property or fixtures. 
 11.3 Waiver of Subrogation. Any insurance carried by either party with respect
to the Premises or property therein or occurrences thereon shall, if it can be so written without additional premium or with an additional premium which the other party agrees to pay, include a clause or endorsement denying to the insurer rights of
subrogation against the other party. Neither Landlord nor Tenant shall be liable to the other or to any insurance company (by way of subrogation or otherwise) insuring the other party for any loss or damage to any building, structure or other
tangible property, or any resulting loss of income, or losses under worker’s compensation laws and benefits, even though such loss or damage might have been occasioned by the negligence of such party, its agents or employees if any such loss or
damage is covered by insurance benefiting the party suffering such loss or damage or which is customarily covered by any insurance required to be carried hereunder, to the extent of such coverage. 

 

	12.	DAMAGE TO THE PREMISES 

 12.1 Landlord’s Right to Terminate. If a portion of
the Premises or the Building is substantially damaged by fire or other casualty, Landlord may terminate this Lease as of the date of such damage by giving Tenant written notice of such termination within sixty (60) days of such fire or
casualty. 

  
 - 14 - 

 12.2 Landlord’s Obligation to Repair. In the event that Landlord elects not to
terminate this Lease as aforesaid, then this Lease shall continue in full force and effect and Landlord shall promptly repair the damage and restore the Premises, excluding Tenant’s personal property, fixtures, furniture, equipment and floor
coverings, to substantially the condition thereof immediately prior to such damage. Landlord’s obligation to repair such damage and restore the Premises shall be limited to the extent of the insurance proceeds made available to Landlord and
allocated for the Premises. Landlord shall not be liable for any inconvenience or annoyance to Tenant or injury to the business of Tenant resulting from delays in repairing such damage. 

12.3 Rent Abatement. For so long as such damage renders the Premises or a portion thereof unsuitable for Tenant’s use thereof
immediately prior to the occurrence of such fire or casualty, a just and proportionate abatement of Fixed Rent shall be made, provided that such damage is not due to the fault or neglect of Tenant or Tenant’s Agents. 

12.4 Tenant’s Option to Terminate. If damage to the Premises or to the Building renders the Premises substantially unsuitable for
Tenant’s use thereof immediately prior to the occurrence of such fire or casualty, and provided that the damage was not due to the fault or neglect of Tenant or Tenant’s Agents, then Tenant may elect to terminate this Lease prior to the
time such damage is repaired if and only if either: 
 a. Landlord fails to give written notice within sixty (60) days
of said fire or casualty of its intention to restore the Premises; or 
 b. Landlord fails to restore the Premises to a
condition suitable for the Permitted Use within one hundred eighty (180) days of said fire or casualty, provided such failure is not due to the action or inaction of Tenant, Tenant’s Agents, or causes beyond the reasonable control of
Landlord. 
 Tenant shall exercise its option to terminate by giving written notice to Landlord within thirty days after Landlord’s
failure to notify or failure to restore, as specified above. 
 12.5 Definitions. The term “substantial damage” as used
herein shall refer to damage of such character that the same cannot in the ordinary course be reasonably expected to be repaired, within one hundred twenty (120) days from the time that such work would commence. 

 

	13.	EMINENT DOMAIN 

 In the event that the whole of the Premises or Landlord’s Property
shall be lawfully condemned or taken in any manner for public or quasi-public use, this Lease shall forthwith terminate as of the date of divesting of Landlord’s title. 

In the event that only a part of the Premises or Landlord’s Property shall be so condemned or taken, then, if such condemnation or taking
is results in any of the following, either Landlord or Tenant may by delivery of notice in writing to the other within sixty (60) days following the date on which Landlord’s title has been divested by such authority, terminate this Lease:

  
 - 15 - 

 a. Results in the loss of reasonable access to the Premises, or renders the Premises
substantially unsuitable for Tenant’s use thereof immediately prior to the occurrence of such taking; 
 b. Results in the loss to
Tenant of twenty-five (25%) percent or more of the floor area of the Premises; or 
 c. Results in loss of facilities in the Building
that supply heat, air conditioning, water, drainage, plumbing, electricity or other utilities to Premises. 
 In the event that only a part
of the Premises or Landlord’s Property shall be so condemned or taken, then, if such condemnation or taking is substantial as hereinafter defined, Landlord may, in addition, by delivery of notice in writing within sixty (60) days following
the date on which Landlord’s title has been divested by such authority, terminate this Lease. “Substantial” shall mean any condemnation or taking which: 

a. Results in the loss of reasonable access to the Building, or renders the Building substantially unsuitable for its then uses; 

b. Results in the loss to Landlord of more than twenty-five (25%) percent of the floor area of the Building or more than fifteen
(15%) percent of the total area of the land; or 
 c. Results in loss of facilities in the Building that supply heat, air conditioning,
water, drainage, plumbing, electricity or other utilities to Building. 
 If this Lease is not terminated as aforesaid or if such
condemnation or taking is not substantial, then this Lease shall continue in full force and effect except that the Fixed Rent shall be equitably abated as of the date of divesting of title. Landlord shall, with reasonable diligence and at its
expense, restore the remaining portion of the Premises as nearly as practicable to the same condition as it was prior to such condemnation or taking. Landlord’s obligation to restore the remaining portion of the Premises shall be limited to the
extent of the condemnation proceeds made available therefor to Landlord. 
 In the event of any condemnation or taking, Landlord shall be
entitled to receive the entire award in the condemnation proceedings, including any award made for the value of the estate vested by this Lease in Tenant, and Tenant hereby expressly assigns to Landlord any and all right, title and interest of
Tenant now or hereafter arising in or to any such award or any part thereof. Notwithstanding the foregoing, Tenant shall have the right to bring a separate condemnation proceeding for relocation expenses and trade fixtures, or to bring other claims,
payable in the manner and extent as, and if, provided by law, provided such awards do not reduce the awards to Landlord on account of such condemnation or taking. 

  
 - 16 - 

	14.	Intentionally Deleted 

  

	15.	LANDLORD’S SERVICES 

 15.1 Electric Current. 

a. Landlord shall install and maintain at its cost separate electric meters for measuring electricity furnished to the
Premises. Tenant shall contract with the company supplying electrical current for the purchase and obtaining of electrical current directly from such company, which shall be billed directly to and paid for by Tenant. This shall include all current
used in the Premises, including but not limited to all electricity used for heating, air conditioning and ventilation, lighting, office equipment and machines. 

b. If Tenant shall require electrical current for use in the Premises in excess of the present capacities and if in
Landlord’s reasonable judgment, Landlord’s facilities are inadequate for such excess requirements or such excess requirements will result in an additional burden on the Building systems and additional cost to Landlord on account thereof,
then Landlord shall upon written request and at the sole cost and expense of Tenant, furnish and install such additional wires, conduits, feeders, switchboards and appurtenances as reasonably may be required to supply such additional requirements of
Tenant, provided current therefor is available to Landlord, and provided further that the same shall be permitted by applicable laws and insurance regulations and shall not cause permanent damage to the Building or the Premises, cause or create a
dangerous or hazardous condition, entail unreasonable alterations or repairs, or interfere with or disturb other tenants or occupants of the Building. Tenant shall reimburse Landlord on demand for all costs incurred by Landlord on account thereof.

 c. If requested by Tenant, Landlord, at Tenant’s expense, shall purchase and install all replacement lamps
(including, but not limited to, incandescent and fluorescent lights) used in the Premises. 
 d. Landlord shall not in any
way be liable or responsible to Tenant for any loss, damage or expense which Tenant may sustain or incur if the quantity, character or supply of electrical energy is changed or is no longer available or suitable for Tenant’s requirements. 

e. Except as may be disclosed in the Additional Plans (and thereby approved by Landlord), Tenant agrees that it shall not make
any material alteration or material addition to the electrical equipment or appliances in the Premises without obtaining the prior written consent of Landlord in each instance, which consent will not be unreasonably withheld, and Tenant shall
promptly advise Landlord of any other alteration or addition to such electrical equipment appliances. 
 15.2 Water. Landlord shall
furnish hot and cold water to the Premises or to a common area lavatory for ordinary office cleaning, toilet, lavatory and drinking purposes. If Tenant requires, uses or consumes water for any purpose other than for the aforementioned purposes,
Landlord may (a) assess a reasonable charge for the additional water used or consumed by Tenant; or (b) install a water meter and thereby measure Tenant’s water consumption for all 

  
 - 17 - 

 
purposes. In the latter event, Landlord shall pay the cost of the meter and the cost of installation thereof and shall keep said meter and installation equipment in good working order and repair.
Tenant agrees to pay for water consumed, as shown on said meter, together with the sewer use charge based on said meter charges as and when bills are rendered. On default in making such payment, Landlord may pay such charges and collect the same
from Tenant as additional rent hereunder. 
 15.3 Elevators, Heat. Landlord shall: (a) provide elevator facilities (which may be
manually or automatically operated, either or both, as Landlord may from time to time elect) during Business Hours and have one elevator in operation available for Tenant’s use, non-exclusively together
with others having business in the Building, at all other times that the Building is open; and (b) furnish heat (in amounts as are customarily provided by buildings of the same age, condition and character as the Building) to the Premises and
to Common Areas of the Building during Business Hours during the normal heating season, Landlord shall provide heat the Premises at times in addition to Business Hours, at Tenant’s Expense (as Special Services hereunder), provided Tenant gives
Landlord reasonable prior notice (as shall be established by Landlord) of its need for such after-hours heat. As of the date hereof, such notice must be given no later than 12:00 noon for after-hours heat in the evenings and no later than 12:00 noon
on Fridays for weekend heat. 
 15.4 Interruption or Curtailment of Services. Landlord reserves the right to interrupt, curtail, stop
or suspend (a) the furnishing of elevator and other services, and (b) the operation of the plumbing and electric systems whenever necessary for repairs, alterations, replacements or improvements desirable or necessary to be made in the
reasonable judgment of Landlord or whenever necessary due to accident or emergency, difficulty or inability in securing supplies or labor strikes, or any other cause beyond the reasonable control of Landlord, whether such other cause is similar or
dissimilar to those hereinabove specified, until said cause has been removed. Except when caused by the gross negligence of Landlord, there shall be no diminution or abatement of rent or other compensation due from Tenant to Landlord hereunder, nor
shall this Lease be affected or any of Tenant’s obligations hereunder reduced, and Landlord shall have no responsibility or liability for any such interruption, curtailment, stoppage or suspension of services or systems, except that Landlord
shall exercise all due diligence to eliminate the cause of same. 
 15.5 Energy Conservation. Notwithstanding anything to the
contrary contained in this Lease, Landlord may institute such reasonable policies, programs or measures as may be necessary, required or expedient for the conservation and/or preservation of energy or energy services, provided either the majority of
similar buildings in Boston, Massachusetts are subject to similar policies, programs or measures, or such are necessary or required to comply with applicable governmental codes, rules, regulations or standards. 

15.6 Tenant Directory. Landlord agrees to maintain a tenant directory in the lobby of the Building in which a reasonable number of
listings will be placed identifying Tenant and the location of the Premises in the Building. Landlord reserves the right to charge Tenant a reasonable fee for each such listing; however, Landlord shall provide Tenant with two (2) listings at no
cost to Tenant. 

  
 - 18 - 

	16.	ACCESS  

 The Building shall remain open during all Business Hours, except as provided
herein, and Tenant’s servants, employees, agents and business invitees shall have the free and uninterrupted right of access in common with others entitled thereto to the Premises during Business Hours. Subject to reasonable security measures,
Tenant and its employees and, if escorted by employees, guests and business invitees, shall have access to the Premises at all other times. 
  

	17.	SUBLEASE AND ASSIGNMENT 

 17.1 Generally. Tenant shall not voluntarily,
involuntarily or by operation of law assign, transfer, mortgage or otherwise encumber the Lease or any interest of Tenant therein, in whole or in part of the Premises or permit the Premises or any part thereof to be used or occupied by others,
without the prior written consent of Landlord. A transfer of a majority of Tenant’s stock or a transfer or change of control of Tenant (if Tenant is a corporation), or a change in the composition of persons or entities owning any interest in
Tenant (if Tenant is not a corporation), or any transfer of Tenant’s interest in the Lease by operation of law or by merger or consolidation of Tenant with or into any other entity, firm or corporation, shall be deemed an assignment for
purposes of this Article 17. Any subletting or assignment pursuant to this Article shall be subject to and conditioned upon the following: 

(a) at the time of any proposed subletting or assignment, Tenant shall not be in default under any of the terms, covenants or
conditions of this Lease; 
 (b) the sublessee or assignee shall occupy only the Premises and conduct its business in
accordance with the Permitted Use; 
 (c) prior to occupancy, Tenant and its assignee or sublessee shall execute, acknowledge
and deliver to Landlord a fully executed counterpart of a written assignment of lease or a written sublease, as the case may be, by the terms of which: 

(1) in case of an assignment, Tenant shall assign to such assignee Tenant’s entire interest in this Lease, together with
all prepaid rents hereunder, and the assignee shall accept said assignment and assume and agree to perform directly for the benefit of Landlord all of the terms, covenants and conditions of this Lease on Tenant’s part to be performed; or 

(2) in case of a subletting, the sublessee thereunder shall agree to be bound by and to perform all of the terms, covenants and
conditions of this Lease on the Tenant’s part to be performed, except the payments of rents, charges and other sums reserved hereunder, which Tenant shall continue to be obligated to pay and shall pay to Landlord; 

(d) Tenant shall pay to Landlord monthly one-half of the excess of the rents and other
charges received by Tenant pursuant to the assignment or sublease over the rents and other charges reserved to Landlord under this Lease attributable to the space assigned or sublet, less Tenant’s reasonable costs of such assignment or sublet,
excluding any buildout or fit-up costs; 

  
 - 19 - 

 (e) Tenant shall acknowledge that, notwithstanding such assignment or sublease
and consent of Landlord thereto, Tenant shall not be released or discharged from any liability whatsoever under this Lease and will continue to be liable (jointly and severally with the assignee) with the same force and effect as though no
assignment or sublease had been made; and 
 (f) Tenant shall pay to Landlord the sum of One Thousand ($1,000) Dollars to
cover Landlord’s administrative costs, overhead and attorneys’ fees in connection with each such assignment or subletting. 
 17.2
Landlord’s Consent. Landlord shall not unreasonably withhold its consent to a proposed transfer, sublease or assignment pursuant to the preceding Section 17.1. Landlord’s failure to consent shall be deemed unreasonable if the
conditions set forth in Subsections 17.1(a) - 17.1(f) are met and if: 
 a. The proposed assignment or subletting is to be
made to a parent, subsidiary or successor corporation in connection with the reorganization of Tenant or to a partnership of which Tenant is a general partner, provided the net worth of such successor is at least equal to the greater of the net
worth of Tenant as of the Term Commencement Date or the net worth of the Tenant as of the date of the proposed transfer and provided the successor has a good reputation in the community; or 

b. The proposed assignee or subtenant has a good credit rating, which shall be at least equal to that of Tenant as of the Term
Commencement Date, and demonstrable ability to comply with the terms and conditions of this Lease, a good reputation in the community and the proposed use by such subtenant or assignee (even though Permitted Use) could not in Landlord’s
reasonable opinion be expected to detract from the character of the Building at the time of the proposed assignment or sublease. 
 Landlord may withhold
its consent if said transfer, sublease or assignment is not approved by the holder of any mortgage on Landlord’s Property. 
 17.3
No Waiver. The consent by Landlord to an assignment or subletting shall not in any way be construed to relieve Tenant from obtaining the express consent of Landlord to any further assignment or subletting for the use of all or any part of the
Premises, nor shall the collection of rent by Landlord from any assignee, sublessee or other occupant after default by Tenant be deemed a waiver of this covenant or the acceptance of such assignee, sublessee or occupant as tenant or a release of
Tenant from the further performance by Tenant of the obligations in this Lease on Tenant’s part to be performed. 
  

	18.	SUBORDINATION 

 This Lease is subject and subordinate to any ground leases and real
estate mortgages to any lender prior to or subsequent to the date of execution and delivery of this Lease and to all renewals, modifications, consolidations, replacements or extensions thereof, provided that, with respect to ground leases and real
estate mortgages subsequent to the date of execution and delivery of this Lease, each such ground lessor or mortgagee enters into an agreement, in customary form, recognizing Tenant under this Lease and providing that, in the event of

  
 - 20 - 

 
foreclosure or termination of a ground lease, Tenant shall remain undisturbed under this Lease if Tenant is not in default under any of the terms and conditions of the Lease. In confirmation of
the foregoing, Tenant shall, upon the request of Landlord, promptly execute and deliver all such instruments as may be appropriate to subordinate this Lease to any mortgages securing notes issued by Landlord and to all advances made thereunder and
to the interest thereon and all renewals, replacements and extensions thereof, provided that (with respect to a subsequent mortgage or ground lease) such nondisturbance is granted by such mortgagee or ground lessee. At the request of Landlord,
Tenant shall join in a subordination agreement requested by any mortgagee who desires to subordinate its mortgage to this Lease, provided, however, that the provisions of said mortgage relating to the receipt and application of insurance proceeds
and condemnation awards shall in no event be subordinated to this Lease. Landlord represents that, as of this date, the only mortgagee of Landlord’s Property is Sun Life Insurance Company. 

 

	19.	ESTOPPEL CERTIFICATE  

 Tenant shall, at any time during the Term, within ten
(10) days after Landlord’s request therefor, deliver a duly executed and acknowledged written instrument to Landlord or to a person or entity specified by Landlord in customary form certifying: 

(a) That the Lease is unmodified and in full force and effect or, if there has been any modification, that the same is in full force and
effect, as modified and stating any such modification; 
 (b) Whether or not there are any existing setoffs or defenses against the
enforcement of any of the terms, agreements, covenants and conditions of this Lease and any modifications thereof on the part of Tenant to be performed or complied with, and if so, specifying the same; and 

(c) The date to which Fixed Rent and all additional rent and other charges have been paid. 

Upon Tenant’s failure to deliver timely the estoppel certificate, Landlord may give Tenant an additional written notice; and the failure
by Tenant to deliver the estoppel certificate within ten (10) days after such additional written notice shall constitute as to any person entitled to rely upon such statements an acknowledgment that this Lease is unmodified and in full force
and effect and a waiver of any defaults which may exist prior to the date of such notice. 
  

	20.	MORTGAGEE’S RIGHTS 

 In the event any mortgagee succeeds to the interest of Landlord
under the Lease: 
 (a) the mortgagee shall not be liable for any act or omission of any prior landlord (including Landlord); 

(b) the mortgagee shall not be liable for the return of any security deposit unless the same has been received by mortgagee from Landlord and
mortgagee acknowledges receipt in writing of said deposit; 

  
 - 21 - 

 (c) the mortgagee shall not be bound by any rent or additional rent which Tenant might have
prepaid for more than the then current month under the Lease; 
 (d) the mortgagee shall not be bound by any amendments or modifications of
the Lease made after the date Tenant receives notice of the name and address of such mortgagee, without the consent of mortgagee; and 
 (e)
the mortgagee shall not be subject to any offsets or defenses which Tenant might have against any prior landlord (including Landlord). 
  

	21.	NOTICE TO MORTGAGEE AND GROUND LESSOR 

 After receiving notice from any person, firm or
other entity that it holds a mortgage which includes the Premises as part of the mortgaged premises, or that it is the ground lessor under a lease with Landlord as ground lessee, which includes the Premises as a part of the demised premises, no
notice from Tenant to Landlord with respect to any default or claimed default of Landlord hereunder shall be effective unless and until a copy of the same is given to such holder or ground lessor at the address as specified in said notice (as it may
from time to time be changed), and the curing of any of Landlord’s defaults by such holder or ground lessor within no more than thirty (30) days from the date of said notice shall be treated as performance by Landlord. If such default by
Landlord by its nature cannot be cured within thirty (30) days, such holder or ground lessor shall be given such additional time as is reasonably necessary, provided such holder or ground lessor has commenced diligently to correct such default
and thereafter diligently pursues such correction to completion, For the purposes of this Article 21, the term “mortgage” includes a mortgage on a leasehold interest of Landlord ( but not one on Tenant’s leasehold interest). 

 

	22.	Intentionally Deleted 

  

	23.	TENANT’S COVENANTS  

 Tenant covenants and agrees as follows: 

A. Tenant shall perform promptly all of the obligations of Tenant set forth in this Lease, and shall pay when due all Fixed Rent, additional
rent, and all charges which by the terms of this Lease are to be paid by Tenant. 
 B. Tenant shall use the Premises only for the Permitted
Use, and shall comply with any and all present or future reasonable rules and regulations established by Landlord, provided such rules and regulations are enforced against similarly situated tenants in a nondiscriminatory manner. 

C. Tenant shall pay all costs (to the extent not reimbursed by insurance proceeds) on demand for all loss or damage suffered or incurred by
Landlord caused by any nuisance or neglect suffered on the Premises or Landlord’s Property due to Tenant or Tenant’s Agents. 
 D.
Intentionally Deleted. 

  
 - 22 - 

 E. Tenant shall permit Landlord and its agents to examine the Premises at reasonable times and
upon reasonable notice (which notice may be given orally) to Tenant and to show the Premises to prospective tenants commencing one year prior to the expiration of this Lease. 

F. Tenant shall pay all costs for utilities that are not supplied by Landlord that are charged directly to Tenant by any utility company. 

G. Except only for items which are expressly the Landlord’s responsibility hereunder, Tenant shall comply with all laws applicable to the
Premises and Tenant’s use thereof, including, without limitation, all applicable statutes, ordinances, constitutional provisions, codes, by-laws, regulations, rulings, decisions, rules, order,
determinations and requirements of any federal, state, county, local or other legislative, executive, judicial or other governmental body or authority (hereinafter “Applicable Law”). Tenant shall obtain all required licenses and permits
relating to the Premises or Tenant’s use thereof, except only for the building permit for the Initial Tenant Improvements and the certificate of occupancy upon the completion of such work, which shall be Landlord’s responsibility. Tenant
shall make all changes and alterations in the Premises required by any Applicable Law if the same are necessitated by Tenant’s special or unusual use of the Premises but not if the same are required for general office use. Except for
Tenant’s Additional Improvements and any other Alterations, Tenant shall not be required to render the Premises in compliance with Applicable Law at the Term Commencement Date or upon any subsequent change in law, unless related to
Tenant’s use thereof. 
 H. Tenant shall comply with the requirements of all policies of public liability, fire and casualty and other
insurance at any time in force with respect to the Premises, the Building and Landlord’s Property. 
 I. Tenant shall cause any
furniture, equipment or supplies to be moved in or out of the Building only upon the elevator designated by Landlord for that purpose and then only during such hours as may be established by Landlord. 

J. Tenant shall not injure, overload, deface or otherwise harm the Premises or Landlord’s Property, commit any nuisance, permit the
emission of any objectionable odor or noise from the Premises, store or dispose of trash or refuse on or otherwise obstruct the driveways, walks, halls, parking areas or other common areas. 

K. Tenant shall not suffer or permit strip or waste. 

L. Tenant shall not permit any use that may create a public or private nuisance. 

M. Tenant shall not place or maintain any merchandise, vending machines or other articles for the sale of goods or services on any sidewalk or
ways adjacent to the Premises, or elsewhere on the exterior or in the interior of the Premises. 

  
 - 23 - 

 N. Tenant shall not conduct any auction, fire, bankruptcy or going-out-of business sale, nor use or permit the use of any sound apparatus for reproduction or transmission of music or sound that is audible beyond the physical interior of the Premises. 

O. Tenant shall not install any window air conditioning unit in or upon the Premises. 

P. At the expiration of the term or earlier termination of this Lease, Tenant shall surrender all keys to the Premises, remove all of its
trade fixtures and personal property in the Premises and all Tenant’s signs wherever located, repair all damage caused by such removal and yield up the Premises (including all Alterations made by Tenant, except for such Alterations as Landlord
shall request Tenant to remove) subject to Article 9 of this Lease, broom-clean and in the same good order and repair in which Tenant is obliged to keep and maintain the Premises by the provisions of the Lease. Any property not so removed shall be
deemed abandoned and may be removed and disposed of by Landlord in such manner as Landlord shall determine and Tenant shall pay Landlord the entire cost and expense incurred by it for such removal and disposition and in making any incidental repairs
and replacements to the Premises. Tenant shall also pay for the use and occupancy of the Premises during performance of its obligations under this Article. Tenant shall further indemnify Landlord against all loss, cost and damage resulting from
Tenant’s failure and delay in surrendering the Premises as above provided. 
 Q. Tenant shall not place a load upon any floor of the
Premises or Building exceeding the floor load per square foot area which such floor was designed to carry and which is allowed by law. Business machines and mechanical equipment shall be placed and maintained by Tenant at Tenant’s expense in
settings sufficient to absorb and prevent vibration, noise and annoyance. Any moving of such equipment shall be at the sole risk and hazard of Tenant and Tenant shall indemnify and save Landlord harmless against and from any liability, loss, injury,
claim or suit resulting directly or indirectly from such moving. 
 R. Tenant shall not place any signs or other forms of advertising on or
about the exterior of the Premises or the Building, upon any sidewalks or ways adjacent to the Building or within the interior of the Premises that are visible from the exterior of the Building; and no signs shall be affixed in any manner to the
windows of the Premises. Notwithstanding the foregoing, but subject to the prior written approval of Landlord, which approval shall not be unreasonably withheld, Tenant may place signs indicating the name of Tenant’s business at the locations
where signs currently exist for the previous tenant of the Premises. 
  

	24.	EVENTS OF DEFAULT 

 The following shall be deemed to be defaults hereunder: 

A. Tenant’s failure to pay the Fixed Rent, Operating Expenses or Real Estate Taxes when due hereunder and such failure continues for more
than ten days after written notice thereof from Landlord, or if Tenant fails to pay any other charges provided for hereunder and such failure continues for more than ten (10) days after written notice from Landlord designating such failure; or

  
 - 24 - 

 B. Tenant’s failure to comply with any other obligation or covenant hereunder and such
failure continues for more than thirty (30) days after written notice from Landlord to Tenant specifying such failure. Notwithstanding the foregoing, if such failure by its nature cannot be cured within 30 days, Tenant shall be given such
additional time as is reasonably necessary, provided Tenant has commenced diligently to correct said failure and thereafter diligently pursues such correction to completion; or 

C. An assignment is made by Tenant or any guarantor of this Lease for the benefit of creditors; or 

D. Tenant’s leasehold interest is taken on execution; or 

E. A lien or other involuntary encumbrance is filed against Tenant’s leasehold interest or Tenant’s other. property, which is not
discharged or bonded against within forty-five (45) days thereafter; or 
 F. A petition is filed by or against Tenant or any guarantor
of the Lease for adjudication as a bankrupt, or for reorganization or an arrangement under any provision of the Federal Bankruptcy Code as then in force and effect; or 

G. A receiver is appointed for any part of Tenant’s property; or 

H. Tenant’s failure to remain a corporation in good standing and qualified to do business in Massachusetts. 

 

	25.	RIGHTS OF LANDLORD UPON TENANT’S DEFAULT 

 25.1 Landlord’s Remedies. In
the event any default shall continue beyond any applicable notice or grace period hereunder (notwithstanding any waiver, license or indulgence granted by Landlord with respect to the same or any other default in any former instance), Landlord shall
have the right, then or at any time thereafter, at its sole election either 
 (a) to terminate this Lease by written notice to Tenant,
which termination shall take effect on the date of Landlord’s dispatch of said notice or on any later date (on or prior to the expiration of the current portion of the Term) specified in Landlord’s termination notice; or 

(b) to enter upon and take possession of the Premises (or any part thereof in the name of the whole) without demand or notice, and repossess
the same as of the Landlord’s former estate, expelling Tenant and those claiming under Tenant, forcibly if necessary, without being deemed guilty of any manner of trespass and without prejudice to any other remedy for any default hereunder.

 Landlord’s repossession of the Premises under this Article shall not be construed to effect a termination of the Lease, unless
Landlord sends Tenant a written notice of termination as required hereunder. 
 25.2 Reletting. Landlord shall have the right (at its
sole election and whether or not this Lease shall be terminated under Section 25.1) to relet the Premises or any part thereof for 

  
 - 25 - 

 
such period or periods (which may extend beyond the Term) and at such rent or rents and upon such other terms and conditions as Landlord may reasonably deem advisable, and in connection with any
such reletting, Landlord may make or cause to be made such additions, alterations and improvements to the Premises as Landlord may deem advisable. In the event that this Lease is terminated, Landlord agrees to use reasonable efforts to relet the
Premises; however, reasonable efforts shall not require Landlord to give any special priority to the reletting of the Premises or give the Premises any preference over the letting of any other space in the Building. 

25.3 Removal of Goods. If Landlord shall terminate this Lease or take possession of the Premises by reason of a default, Tenant, and
those claiming under Tenant, shall forthwith remove their goods and effects from the Premises. If Tenant or any such claimant shall fail so to remove forthwith, Landlord, without liability to Tenant or to those claiming under Tenant, may remove such
goods and effects and may store the same for the account of Tenant or of the owner thereof in any place selected by Landlord or, at Landlord’s sole election, Landlord may sell the same at public auction or at private sale on such terms and
conditions as to price, payment and otherwise as Landlord, in its sole judgment, may deem advisable. Tenant shall be responsible for all costs of removal, storage and sale, and Landlord shall have the right to reimburse itself from the proceeds of
any such sale for all such costs paid or incurred by Landlord. If any surplus sale proceeds shall remain after such reimbursement, Landlord may deduct from such surplus any other sum due to Landlord hereunder and shall pay over to Tenant the
remaining balance of such surplus sale proceeds, if any. 
 25.4 Current Damages. No termination or repossession provided for in
Section 25.1 shall relieve Tenant of its liabilities and obligations hereunder (or under its instrument of guarantee), all of which shall survive such termination or repossession. In the event of any such termination or repossession, Tenant
shall pay Landlord, in advance, on the first day of each month (and pro rata for the fraction of any month) for what would have been the entire balance of the original Term or of the current extension period,
one-twelfth of the Annual Rental for the Premises, as defined in Section 25.5 hereof, less the proceeds (if any) of any reletting of the Premises which remain after deducting Landlord’s reasonable
expenses in connection with such reletting. Such expenses shall include, without limitation, removal, storage and remodeling costs, the cost of painting and refurbishing the Premises and attorneys’ and brokers’ fees. 

25.5 Annual Rental. The Annual Rental for the Premises shall be the total of the Fixed Rent, Tenant’s Share of Real Estate Taxes
and Operating Expenses, and all other charges payable by Tenant (whether or not to Landlord) for the lease year ending next prior to such termination or repossession. 

25.6 Intentionally Deleted. 

25.7 Remedies Cumulative. Any and all rights and remedies which Landlord may have under this Lease and at law and equity shall be
cumulative and shall not be deemed inconsistent with each other, and any two or more of all such rights and remedies may be exercised at the same time insofar as permitted by law. 

25.8 Landlord’s Right to Cure Defaults. Landlord shall have the right but not the obligation, to cure at any time upon ten
(10) days written notice, and in the event of an 

  
 - 26 - 

 
emergency without notice, any default by Tenant under the Lease. Whenever Landlord so elects, all costs and expenses incurred by Landlord, including reasonable attorney’s fees, in curing a
default shall be paid by Tenant to Landlord on demand, as additional rent hereunder, together with interest thereon from the date of payment by Landlord to the date of payment Tenant at the rate of twelve (12%) percent per annum. 

25.9 Costs of Enforcement. Landlord and Tenant shall each pay all reasonable costs and expenses (including without limitation
reasonable attorneys’ fees) incurred by the other party in enforcing its obligations or the other party’s rights under this Lease, provided that the other party shall prevail. 

 

	26.	NO WAIVER; NO ACCORD AND SATISFACTION 

 26.1 No Waiver. Any consent or permission
by Landlord or Tenant to any act or omission which otherwise would be a default hereunder or any waiver by Landlord or Tenant of the terms, covenants or conditions herein, shall not in any way be held or construed to operate so as to impair the
continuing obligation of any term, covenant or condition herein, or to permit any similar acts or omissions. The failure of Landlord to seek redress for a violation of, or to insist upon the strict performance of, any covenant, condition or
obligation of this Lease shall not be deemed a waiver of such violation nor prevent a subsequent act, which would have originally constituted a violation, from having all the force and effect of an original violation. The receipt by Landlord of any
rent with knowledge of any default hereunder shall not be deemed to have been a waiver of such default, unless such waiver is in writing signed by the Landlord. 

26.2 No Accord and Satisfaction. No acceptance by Landlord of a lesser sum than any sum due under any provision of this Lease shall be
deemed to be other than on account of the earliest installment of such sum due, nor shall any endorsement or statement on any check or letter accompanying any check or payment be deemed an accord and satisfaction, and Landlord may accept such check
or payment without prejudice to any rights to recover the balance of such installment or pursue any other remedy in this Lease provided. 
  

	27.	RECORDING 

 Landlord and Tenant agree not to record this Lease or any portion thereof;
however, Landlord and Tenant each agree upon request of the other to execute and deliver to the other a notice of lease or short form of lease suitable for recording and setting forth the name of the Landlord and the Tenant, the term of the Lease
and an appropriate description of the Premises. 
  

	28.	LIABILITY 

 In no event shall Landlord be liable for any default hereunder unless the
same occurs during and within the period of time that it is the owner of and in possession of Landlord’s Property. In no event and under no circumstances shall Landlord be liable to Tenant for any consequential damages in connection with any
act of Landlord, its agents or servants. The placement by Tenant of any goods, wares and merchandise in the Premises or any areas within Landlord’s Property shall be at the sole risk and hazard of Tenant. Neither Landlord nor any agent or
employee of Landlord shall be liable for any damage to the person or property of Tenant or Tenant’s Agents, including but not limited to damage resulting from the following, unless 

  
 - 27 - 

 
solely due to the gross negligence or willful misconduct of Landlord: (a) steam, gas, electricity, water, rain or snow, leaks from pipes, appliances or plumbing, falling plaster or other
building components, dampness or any other cause; (b) any hidden defect on the Premises, the Building or Landlord’s Property; and/or (c) acts or omissions of persons occupying adjacent premises or other parts of the Building or
otherwise entitled to use Landlord’s Property. 
 Notwithstanding anything to the contrary contained in this Lease, it is specifically
understood and agreed that the monetary liability of Landlord hereunder shall be limited to its equity in the Premises in the event of a default under this Lease by Landlord. In furtherance of the foregoing, Tenant hereby agrees that any judgment it
may obtain against Landlord as a result of a breach of any of the terms, covenants or conditions hereof shall be enforceable solely against Landlord’s fee interest in the Premises. Nothing in this Lease shall be construed in any event
whatsoever to impose any personal liability upon-any trustee, beneficiary, shareholder or officer of Landlord. 

Except as hereafter provided, Tenant be not be liable to Landlord for consequential damages in connection with any act of Tenant; provided,
however, the foregoing shall not be limit in any way the damages to which Landlord shall be entitled (which shall include all direct, indirect and consequential damages resulting therefrom) in the event of: (1) the failure of Tenant to vacate
the Premises as and when required under the terms of this Lease, including without limitation damages pursuant to Tenant’s indemnification contained in Section 22P hereof; (ii) the failure of Tenant to comply with the provisions of
Article 35 hereof; (iii) any indemnifications of Landlord contained in this Lease; or (iv) any liability relating to or arising from Tenant’s particular use of the Premises (as opposed to general office use). 

 

	29.	FORCE MAJEURE 

 In any case where either party is required to do any act, the time for
the performance thereof shall be extended by a period equal to any delay caused by or resulting from Act of God, war, civil commotion, fire or other casualty, labor difficulties, shortages of labor, materials or equipment, governmental regulations,
or other causes beyond such party’s reasonable control, whether such times are designated by a fixed time or a “reasonable time”. This clause shall not be applicable to any payment of rent or other charges due from Tenant to Landlord.

  

	30.	MECHANICS LIENS  

 Tenant shall not permit any mechanics’ or materialmen’s or
other liens to stand against the Premises, the Building or Landlord’s Property for any labor or materials furnished Tenant in connection with work of any character performed on the Premises by, for, or at the direction of Tenant. Any such lien
shall be discharged by payment in full within thirty (30) days thereafter or by filing the bond required by law. If Tenant fails to discharge any such lien, Landlord may do so at Tenant’s expense and Tenant shall reimburse Landlord for any
expense or cost incurred by Landlord in connection therewith, within fifteen (15) days of receipt of Landlord’s bill therefor. 
  

	31.	DEFINITIONS  

 The words “Landlord” and “Tenant” as used herein shall
include their respective heirs, executors, administrators, successors, representatives, assigns, invitees, agents, and servants. 

  
 - 28 - 

 
The words “it”, “he” and “him” where applicable apply to the Landlord or Tenant regardless of gender, number, corporate entity, trust or other body. If more than one
party signs this Lease as Tenant, the covenants, conditions and agreements of Tenant shall be joint and several obligations of each party. 
  

	32.	SEVERABILITY CLAUSE 

 If any term, covenant, condition or provision of this Lease or the
application thereof to any person or circumstance is declared invalid or unenforceable by the final ruling of a court of competent jurisdiction having final review, the remaining terms, covenants, conditions and provisions of this Lease and their
application to persons or circumstances will not be affected thereby and will continue to be enforced and recognized as valid agreements of the parties; in the place of such invalid or unenforceable provision, there will be substituted a like, but
valid and enforceable provision which comports to the findings of the aforesaid court and most nearly accomplishes the original intention of the parties. 

This Lease may be executed in any number of counterparts and each fully executed counterpart shall be deemed an original. 

 

	33.	NOTICES 

 Any notices required under this lease shall be in writing and delivered by hand
or mailed by registered or certified mail to Tenant c/o Director of Real Property Services, 4th Floor, Ballou Hall, Tufts University, Medford, Massachusetts 02155, or to Landlord care of its Management Agent, Whittier Partners, 155 Federal Street,
Boston, Massachusetts 02110. Landlord or Tenant may by proper notice to the other as provided herein, change its notice address. 
  

	34.	HOLDING OVER 

 If for any reason Tenant retains possession of the Premises or any part
thereof after the termination of the Term or any extension thereof, such holding over shall constitute a tenancy from month to month, terminable by either party upon thirty (30) days prior written notice to the other party, and Tenant shall pay
Landlord monthly rental during the month to month tenancy computed as the rent (including Fixed Rent and all additional rent) payable hereunder for the final month of the last year of the Term prior to such holding over plus one hundred
(100%) percent of said rent. The month to month tenancy shall otherwise be on the same terms and conditions as set forth in the Lease, as far as applicable. 
  

	35.	ENVIRONMENTAL HAZARDS  

 Except for small amounts of materials customarily associated
with office use (provided same is stored, used and disposed of in compliance with all Environmental Requirements), Tenant and Tenant’s Agents, shall not use, maintain, generate, allow or bring on the Premises or Landlord’s Property or
transport or dispose of, on or from the Premises or Landlord’s Property (whether into the ground, into any sewer or septic system, into the air, by removal off-site or otherwise) any Hazardous Matter (as
hereinafter defined). 

  
 - 29 - 

 Tenant shall promptly deliver to Landlord copies of any notices, orders or other communications
received from any governmental agency or official affecting the Premises and concerning alleged violations of the Environmental Requirements (hereinafter defined). 

Tenant shall save Landlord (together with its officers, directors, stockholders, partners, beneficial owners, trustees, employees, agents,
contractors, attorneys, and mortgagees) harmless and indemnified from and against any and all Environmental Damages (hereinafter defined) which may be asserted by Tenant, any other person or entity, or government agency or which the indemnified
parties may sustain or be put to on account of: (1) the presence or release of any Hazardous Matter upon, in or from the Premises during the Term and during any period when the Tenant, or Tenant’s Agents are occupying the Premises or any
part thereof, unless solely caused by the actions of third parties not under the control or supervision of Tenant or Tenant’s Agents; (2) the activities or other action or inaction of Tenant or Tenant’s Agents in violation of
Environmental Requirements; and (3)the breach of any of Tenant’s obligations under this Article 35 during the Term hereof and any period in which Tenant or Tenant’s Agents occupy the Premises. 

The provisions of this Article 35 shall be in addition to any other obligations and liabilities Tenant may have to Landlord under this Lease
or otherwise at law or in equity, and in the case of conflict between this Article 35 and any other provision of this Lease, the provision imposing the most stringent requirement on Tenant shall control. The obligations of Tenant under this Article
35 shall survive the expiration or termination of this Lease and the transfer of title to Landlord’s Property. 
 The following terms
as used herein shall have the meanings set forth below: 
 “Hazardous Matter” shall mean any substance: (i) which is
or becomes defined as Hazardous Substance, Hazardous Waste, Hazardous Material or Oil under The Comprehensive Environmental Response, Compensation and Liability Act, 42 U.S.C. Section 9601 et seq., M.G.L. Chapter 21C, M.G.L. Chapter 21D
or M.G.L. Chapter 21E, and the regulations promulgated thereunder, as same may be amended from time to time; or (ii) which is toxic, explosive, corrosive, flammable, infectious, radioactive, carcinogenic, mutagenic or otherwise hazardous to
health or the environment and which is or becomes regulated and the presence of which requires investigation or remediation pursuant to any Applicable Law. 

“Environmental Requirements” shall mean all Applicable Law, the provisions of any and all Approvals, and the terms and
conditions of this lease insofar as same relate to the release, maintenance, use, keeping in place, transportation, disposal or generation of Hazardous Matter, including without limitation those pertaining to reporting, licensing, permitting, health
and safety of persons, investigation, containment, remediation, and disposal. 
 “Environmental Damages” shall mean all
liabilities, injuries, losses, claims, damages (whether special, consequential or otherwise), settlements, attorneys’ and consultants’ fees, fines and penalties, interest and expenses, and costs of environmental site investigations,
reports and cleanup, including without limitation costs incurred in connection with: any investigation or assessment of site conditions or of health of persons using the Building or Landlord’s Property, to the extent required or prudent due to
the presence or suspected presence of Hazardous Matter; 

  
 - 30 - 

 
risk assessment and monitoring; any cleanup, remedial, removal or restoration work required by any governmental agency or recommended by Landlord’s environmental consultant; any decrease in
value of Landlord’s Property; any damage caused by loss or restriction of rentable or usable space in Landlord’s Property; or any damage caused by adverse impact on marketing or financing of Landlord’s Property. 

 

	36.	GOVERNING LAW  

 This Lease shall be governed exclusively by the provisions hereof and by
the laws of the Commonwealth of Massachusetts, as the same may from time to time exist. 
  

	37.	BROKERAGE  

 Tenant and Landlord each warrant and represent that neither has dealt with
any broker in connection with the consummation of this Lease, except for Whittier Partners, and in the event any brokerage claim is made against either party predicated upon prior dealings with the other party, except by Whittier Partners, such
party shall defend the claim against the other party and save harmless and indemnify the other party on account of loss, cost or damage which may arise by reason of such claim. 

 

	38.	WAIVER OF COUNTERCLAIMS  

 In the event Landlord commences any proceedings for non-payment of rent (Fixed Rent or additional rent) or for recovering possession of the Premises, Tenant shall not interpose any counterclaim of whatever nature or description in any such proceeding except for
compulsory counterclaims. This shall not, however, be construed as a waiver of the Tenant’s right to assert such claims in any separate action or actions brought by Tenant. 

 

	39.	INTENTIONALLY DELETED. 

  

	40.	ENTIRE AGREEMENT 

 The parties acknowledge that in the course of negotiating this Lease
their respective representative have gradually reached preliminary agreement on the several terms set forth in this instrument. The parties acknowledge and agree that at all times they have intended that none of such preliminary agreements (either
singly or in combination) shall be binding on either party, and that they shall be bound to each other only by a single, formal, comprehensive document containing all of the agreements of the parties, in final form, which has been executed by
Landlord or a duly authorized representative of Landlord and by Tenant. The parties acknowledge that none of the prior oral and written agreements between them (and none of the representations on which either of them has relied) relating to the
subject matter of this Lease shall have any force or effect whatever, except as and to the extent that such agreements and representations have been incorporated in this Lease. 

 

	41.	TENANT’S OPTION TO EXTEND THE TERM 

 41.1 Exercise and Effect of Option.
Tenant shall have the option to extend the Term of this Lease for one (1) additional five (5) year term (the “extension period”), provided that: (i)

  
 - 31 - 

 
Tenant is not in default after any notice and cure periods hereunder under any of the terms and conditions of this lease at the time it exercises such option to extend or at the commencement of
such extension; and (ii) Tenant has given Landlord written notice of its election to extend the Term no later than nine (9) months prior to the expiration date of the original Term. If Tenant fails to give such notice to Landlord by such
date, Tenant’s rights under this Article 41 shall be deemed waived and of no further force and effect. In the event that Tenant shall extend the Term as aforesaid, such extension shall be upon the same terms and conditions as set forth herein,
except that: 
 (a) After the extension period, there shall be no further option to extend the Term; and 

(b) The annual Fixed Rent hereunder shall be adjusted as provided in this Article. 

41.2 Fixed Rent During Extension Period. The annual Fixed Rent hereunder during the extension period shall be determined and adjusted
as follows: 
 During such extension period, commencing on the first day of the sixth lease year, the annual Fixed Rent payable hereunder
shall be in the amount of the Fair Market Rent, as hereinafter determined, but in no event shall such annual Fixed Rent be less than $150,880 per year. 

The “Fair Market Rent” shall be the market rate for the rental of the Premises, based upon the average current market rate of space
leased in the Building and the terms of this Lease, as of the date of the expiration of the Term, but in no event shall the Fair Market Rent be less than- $150,880 per year, and the Fair Market Rent shall be
determined as follows: 
 (i) After the exercise by Tenant of its option to extend the Term, Landlord shall, not later than 60 days prior to
the expiration of the Term, advise Tenant in writing its determination of the Fair Market Rent for the Premises for the extension period. Tenant shall be deemed to have accepted the Fair Market Rent contained in Landlord’s notice, and such
rental rate shall be conclusively deemed to be the Fair Market Rent of the Premises for the extension Term, unless Tenant notifies Landlord in writing, within 10 days after Landlord’s notice, that Tenant disputes the aforementioned
determination by Landlord. 
 (ii) In the event that Tenant disputes the determination of the Fair Market Rent by Landlord (as provided
above), and the Landlord and Tenant are unable to agree on the Fair Market Rent for the Premises at least 30 days prior to the expiration of the Term, the same shall be determined by arbitration as follows: 

1. Landlord and Tenant shall each promptly designate and notify the other party of the name and address of an appraiser selected by such
party. Such two appraisers shall, within twenty (20) days after the designation of the second of the appraisers, make their determinations of the Fair Market Rent in writing and give notice thereof to each other and to Landlord and Tenant. Such
two (2) appraisers shall have twenty (20) days after the receipt of notice of each other’s determination to confer with each other and to attempt to reach agreement as to the determination of the Fair Market Rent. If such appraisers:
shall concur in such determination, 

  
 - 32 - 

 
they shall give notice thereof to Landlord and Tenant and such concurrence shall be final and binding upon Landlord and Tenant. If such appraisers shall fail to concur as to such determination
within said twenty (20) day period, they shall give notice thereto to Landlord and Tenant and shall immediately designate a third appraiser. If the two appraisers shall fail to agree upon the designation of such third appraiser within five
(5) days after said twenty (20) day period, then they or either of them shall give notice of such failure to agree to Landlord and Tenant and if Landlord and Tenant fail to agree upon the selection of such third appraiser within five
(5) days after the appraiser(s) appointed by the parties give notice as aforesaid, then either party on behalf of both may apply to the American Arbitration Association or any successor thereto, or on his or her failure, refusal or inability
to, act, to a court of competent jurisdiction, for the designation of such third appraiser. The third appraiser shall conduct such hearings and investigations as he or she may deem appropriate and shall, within ten (10) days after the date of
his or her designation, make an independent determination of the Fair Market Rent, which shall be final and binding upon Landlord and Tenant. 

2. All appraisers shall be real estate appraisers or consultants who shall have had at least seven (7) years continuous experience in the
business of appraising real estate in the downtown Boston real estate leasing market. 
 3. The determination of the appraisers, as provided
above, shall be conclusive upon the parties and shall have the same force and effect as a judgment made in a court of competent jurisdiction. 

4. Each party shall pay fees, costs and expenses of the appraiser selected by it and its own counsel fees and
one-half (1/2) of all other expenses and fees of any such appraisal. 
 If the parties are
unable to agree on the Fixed Rent (or the arbitration has not concluded) prior to the first day of an extension period, Tenant shall make monthly payments on account of Fixed Rent (in addition to all other rent and other payments hereunder) in the
amount of 125% of the Fixed Rent payable during the preceding lease year of the Term, until such annual Fixed Rent amount has been established as herein provided, at which time an appropriate retroactive rent adjustment payment or credit shall be
made, if necessary. 
 41.3 Additional Rent during Extension Period. In addition to Fixed Rent (as determined and adjusted as
provided in this Article), during the extension period Tenant shall continue to pay all other rent as provided in this lease, including Tenant’s share of Operating Expenses and Real Estate Taxes and all other charges hereunder. 

IN WITNESS WHEREOF, the parties hereunto set their hands and seals as of November 10, 1993. 

 

							
	TENANT:				TRUSTEES OF TUFTS COLLEGE
				
					By:		 /s/ Steven S. Manos

							Its Vice President & Treasurer

  
 - 33 - 

							
	LANDLORD:						
			
					KING REAL ESTATE CORPORATION,
					Trustee of Kneeland Street Real Estate Trust
				
					By:		 /s/ Karl Greenman

							Its Vice President & Treasurer

  
 - 34 - 

  
 

 

  
 - 35 - 

 EXHIBIT B 

Initial Tenant Improvements 

  
 - 36 - 

 AMENDMENT TO LEASE 

75 KNEELAND STREET, BOSTON, MASSACHUSETTS 

(Trustees of Tufts College - 6th Floor) 

This Amendment to Lease (“Amendment”), entered into as of March 31, 1998, is by and between KING REAL ESTATE CORPORATION, AS TRUSTEE OF
KNEELAND STREET REAL ESTATE TRUST (“Landlord”), and TRUSTEES OF TUFTS COLLEGE (“Tenant”). 
 Landlord and Tenant entered into a lease,
dated November 10, 1993 (the “Lease”), for certain premises consisting of the entire 6th floor of the building located at 75 Kneeland Street, Boston, Massachusetts, as more particularly described in the Original Lease (the
“Premises”). Terms used in this Amendment which are defined in the Lease and which are not specifically defined herein shall have the meaning given to them in the Lease. 

Landlord and Tenant desire to extend the term of the Lease and amend certain other provisions of the Lease. 

Now, therefore, for good and valuable consideration, the receipt and sufficiency of which are hereby acknowledged, Landlord and Tenant agree as follows: 

 

	1.	TERM. 

 (a) The Term of the Lease (which currently expires on December 31, 1998) is
extended for a period of five (5) years, commencing January 1, 1999, and ending on December 31, 2003 (the “Extension Term”). 

(b) Article 41 of the Lease (Tenant’s Option to Extend the Term), is hereby deleted. 

 

	2.	FIXED RENT. 

 (a) Prior to the commencement of the Extension Term, the annual Fixed Rent shall
continue to be due and payable in the amounts provided for in Section 4 of the Lease. 
 (b) Commencing on the first day of the
Extension Term and for the entire Extension Term, the Fixed Rent due and payable by the Tenant shall be as follows: 
  

									
	 Lease Year
	  	Annual Fixed Rent	 	  	Monthly Installments	 
			
	 1, 2 and 3 (1/1/99- 12/31/01)
	  	$	233,864.00	  	  	$	19,488.70	  
			
	 4 and 5 (1/1/02 - 12/31/03)
	  	$	271,584.00	  	  	$	22,632.00	  

	3.	OPERATING EXPENSES AND REAL ESTATE TAXES. 

 (a) Prior to the commencement of the Extension Term,
additional rent payments on account of Operating Expenses and Real Estate Taxes shall continue to be due and payable in the amounts provided for in Section 6 of the Lease. 

(b) Commencing on the first day of the Extension Term and for the entire Extension Term, the Operating Expenses Base, as provided in
Section 6.1 of the Lease, shall be the Operating Expenses for calendar year 1998, and Tenant shall pay, as additional rent as provided in the Lease, 7.143% of any Operating Expenses in excess of the Operating Expenses Base. 

(c) Commencing on the first day of the Extension Term and for the entire Extension Term, the Tax Base as provided in Section 6.3 of the
Lease shall be the Real Estate Taxes for Fiscal Year 1999 (July 1, 1998 to June 30, 1999), and Tenant shall pay, as additional rent as provided in the Lease, 7.143% of any Real Estate Taxes in excess of the Tax Base. 

 

	4.	NOTICES 

 Landlord’s address for notices and for the payment of rent, as provided in Sections 5 and 33 of
the Lease, shall be as follows: 
 c/o King Associates LLP 

21 Elkins Street 
 South Boston,
MA 02127 
  

	5.	RATIFICATION. 

 In all other respects, the Lease shall remain unmodified and in full force and effect. 

 

	6.	CERTIFICATION 

 Tenant hereby certifies that the Lease is in full force and effect, that there have been no
other modifications or amendments thereto, that Landlord has fulfilled all of its obligations under the Lease, and Landlord is not in default under any of the terms and conditions of the Lease. The Lease, as amended by this Amendment, is hereby
ratified and confirmed by Landlord and Tenant. 
  

	7.	BINDING 

 This agreement shall be binding upon and inure to the benefit of the parties hereto, their heirs,
executors administrators, successors, in interest and assigns. 

  
 - 2 - 

 Executed as a sealed instrument as of the day and year first above written. 

LANDLORD: 
  

			
	 KING REAL ESTATE CORPORATION,
 AS
TRUSTEE OF KNEELAND STREET REAL ESTATE TRUST

	By King Associates LLP, as Managing Agents
		
	By:		 /s/ Steven S. Manos

			Name: Steven S. Manos
			Title: Executive Vice President
	
	TENANT:
	
	TRUSTEES OF TUFTS COLLEGE
		
	By:		 /s/ Alden I. Gifford

			Name: Alden I. Gifford
			Title: Partner

  
 - 3 - 

 THIRD AMENDMENT TO LEASE 

75 KNEELAND STREET, BOSTON, MASSACHUSETTS 

(Paratek Pharmaceuticals, Inc. – 6 Floor) 

This Third Amendment to Lease (“Third Amendment”), entered into as of January 28, 2002, by and between KING REAL ESTATE CORPORATION, AS TRUSTEE
OF KNEELAND STREET REAL ESTATE TRUST (“Landlord”), and PARATEK PHARMACEUTICALS, INC. (“Tenant”). 
 Landlord and the Trustees of Tufts
College entered into a Lease dated November 10, 1993, as amended by Amendment to Lease dated March 31, 1998, which lease was assigned to Tenant and further amended by Assignment, Assumption, Amendment and Consent dated September 1,
2001 (together, the “Lease”), for certain premises consisting of the entire 6th floor (the “Premises”) of the building located at 75 Kneeland Street, Boston, Massachusetts (the “Building”), as more particularly
described in the Lease. Terms used in this Third Amendment which are defined in the Lease and which are not specifically defined herein shall have the meaning given to them in the Lease. 

Landlord and Tenant desire to extend the term of the Lease and amend certain other provisions of the Lease. 

Now, therefore, for good and valuable consideration, the receipt and sufficiency of which are hereby acknowledged, Landlord and Tenant agree as follows: 

 

	1.	TERM. 

 (a) The Term of the Lease (which currently expires on December, 31, 2003) is extended
for a period of 13 years, and shall now expire on December 31, 2016 (the period commencing January 1, 2004, and ending on December 31, 2016 is referred to herein as the “Extended Term”). 

(b) Section 41 of the Lease (containing an option to extend the Term), is hereby deleted and of no further force and effect. 

(c) Section 8.C. of the Lease (containing a right to terminate the Lease) is hereby deleted and of no further force and effect. 

 

	2.	RENT. 

 (a) Prior to the commencement of the Extended Term, the annual Fixed Rent shall continue
to be due and payable in the amounts provided for in the Lease. 

 (b) Commencing on the first day of the Extended Term, and thereafter through the end of the
Extended Term, the Fixed Rent due and payable by the Tenant under the Lease shall be as follows: 
  

									
	 Lease Year
	  	Annual Fixed Rent	 	  	Monthly Installments	 
			
	 1, 2 and 3 (1/10/04 – 12/31/04)
	  	$	467,728.00	  	  	$	38,977.33	  
			
	 2, 3 and 4 (1/1/05 – 12/31/07
	  	$	512,992.00	  	  	$	42,749.33	  
		
	 5 through 13 (1/1/08 – 12/31/16)
	  	 
 	Fair Market Rent, payable in
equal monthly installments	  
  

 (c) With respect the 5th through 13th Lease Years (January 1, 2008 through December 31, 2016), the Fixed
Rent payable during such period shall be “Fair Market Rent”, i.e., the greater of (i) the Fixed Rent payable during the 4th Lease Year or (ii) the “Net Effective Rent” for the rental of the Premises, as of the
first day of the 5th Lease Year. For purposes hereof, “Net Effective Rent” shall mean the rent (e.g., rents generally offered for leases which by their term provide for a base rent only with a separate rental payment for Tenant’s
allocable share of the operating expenses and real estate taxes of the Building, excluding therefrom any market concessions such as work performed by landlord, tenant improvements allowances or leasing commissions or other costs and expenses for the
lease transaction because Landlord is not incurring those costs upon a renewal), generally in effect for comparable space on comparable floors with comparable views in comparable office buildings of age similar to the Building located in the Boston
commercial office market with tenants of comparable financial credit for leases commencing on or about the date for which the “Net Effective Rent” is to be determined. “Fair Market Rent” shall be determined as follows: 

(1) Landlord shall advise Tenant in writing (“Landlord’s Notice”) of its determination of the Fair Market Rent not more than 180
days and not less than 120 days prior to the beginning of the 5th Lease Year (if Landlord shall fail to send Landlord’s Notice by such date, Tenant shall send a written reminder notice to Landlord, and Landlord shall send Landlord’s Notice
within 15 days after receipt of said reminder notice). Tenant shall be deemed to have accepted the rental rate contained in Landlord’s notice, and such rental rate shall be conclusively deemed to be the Fair Market Rent unless Tenant notifies
Landlord in writing, within 15 days after Tenant received Landlord’s Notice, that Tenant disputes Landlord’s determination. 
 (2)
If Tenant disputes the determination of the Fair Market Rent by Landlord (as provided above), and Landlord and Tenant are unable to agree on the Fair Market Rent for the Premises within thirty (30) days, the same shall be determined as follows:

 Landlord and Tenant shall, within thirty (30) days following the expiration of said thirty (30) day period provided in
subsection (2) above, each appoint a licensed real estate broker who has been actively engaged in the leasing of office space in 

  
 - 2 - 

 
comparable office buildings in the Boston real estate market for not less than ten (10) years immediately preceding the date of appointment and shall not be a sole practitioner and shall not
have represented such party in the prior 5 years (each an “Appraiser” and collectively, the “Appraisers”). Within thirty (30) days after being retained, the Appraisers shall each make an independent determination of Fair
Market Rent. If the difference between the Appraisers’ values is equal to or less than five percent (5%), then the Fair Market Rent shall be the average of the sum of the Appraisers’ values. If the difference between the Appraisers’
values is greater than five percent (5%), then the Appraisers shall jointly and promptly choose a third real estate broker, having the same qualifications as those set forth above for Appraisers (the “Arbiter”) to whom the Appraisers shall
submit in writing their respective determinations of the Fair Market Rent. Within thirty (30) days after being retained, the Arbiter shall offer the Arbiter’s determination of Fair Market Rent. If the Fair Market Rent determined by the
Arbiter lies between the Appraisers’ values, then Fair Market Rent shall be the average of the sum of (A) the Arbiter’s value and (B) the Appraiser’s value nearest to the Arbiter’s value. If the Arbiter’s
determination of Fair Market Rent is either higher or lower than both of the Appraisers’ values, then Fair Market Rent shall be the average of the sum of the two nearest values. 

If the Appraisers cannot agree on an Arbiter within ten (10) business days after the expiration of the Appraisal Period, then either party
may apply to the American Arbitration Association office in Boston, Massachusetts in charge of real estate valuation arbitrations for appointment of the Arbiter. 

If neither the Appraisers nor the Arbiter have finally determined Fair Market Rent prior to the date on which Fixed Rent based upon such Fair
Market Rent is to go into effect pursuant to Section 2(b) herein, Tenant shall pay Fixed Rent based upon Landlord’s Notice (the “Interim Rent”), subject to adjustment upon final determination of the Fair Market Rent. In the event
the Fair Market Rent, as finally determined by the above procedure, is (i) in excess of the Interim Rent, Tenant, within thirty (30) days following such final determination, shall pay over to Landlord all such accumulated excess, or
(ii) less than the Interim Rent, Landlord, within thirty (30) days following such final determination, shall pay over to Tenant all such accumulated excess or shall allow Tenant a credit equal to such excess against Fixed Rent next coming
due hereunder. 
  

	3.	OPERATING EXPENSES AND REAL ESTATE TAXES 

 (a) Prior to the commencement of the Extended Term,
additional rent on account of Operating Expenses and Real Estate Taxes shall continue to be due and payable as provided in the Lease. 
 (b)
Commencing on The first day of the Extended Term and thereafter through the end of the Extended Term, the “Operating Expenses Base” shall be defined as the Operating Expenses (as defined in the Lease) for calendar year 2003, and Tenant
shall pay, as additional rent, Tenant’s Proportionate Share of any Operating Expenses in excess of the Operating Expenses Base. For purposes of this Section 3(b) and (c), “Tenant’s Proportionate Share” during the Extended
Term shall be defined as 7.145%. 

  
 - 3 - 

 (c) Commencing on the first day of the Extended Term and thereafter through the end of the
Extended Term, the “Tax Base” shall be defined as the Real Estate Taxes (as defined in the Lease) for fiscal year 2004 (July 1, 2003 to June 30, 2004), and Tenant shall pay, as additional rent, Tenant’s Proportionate Share of any
Real Estate Taxes in excess of the Tax Base. 
 (d) On the first day of each month throughout the Term (including prior to the commencement
of the Extended Term and during the Extended Term), Tenant shall pay to Landlord, on account towards Tenant’s share of anticipated increases in Operating Expenses and Taxes above the Operating Expenses Base or the Tax Base, respectively, one-twelfth of the total amount reasonably estimated by Landlord to be Tenant’s share thereof for such Operating Year or Tax Year. 
  

	4.	SHAFTWAY 

 From and after the execution date hereof, Tenant shall have, as appurtenant to the Premises, the
right and easement to install, maintain and use utility lines and ventilation ducts within the shaftway for the lobby manual passenger elevator. Tenant shall be responsible, at its sole cost and expense, for the dismantling of the existing elevator
in such shaftway, for properly securing the elevator doors on each floor of the Building, and for any installations, all of which work shall be performed in accordance with all Applicable Law and shall subject to the provisions of the Lease
regarding Alterations. 
  

	5.	RIGHT TO PURCHASE THE PROPERTY 

 (a) Provided (i) this Lease is then in full force and
effect, and (ii) Tenant is not in default hereunder beyond any applicable notice, grace or cure periods, and (iii) Tenant has a lease or leases in effect for and is occupying at least 3 full floors of the Building, then, commencing as of
the first day of the Extension Term, and not before, in the event that Landlord shall desire to sell the Property, prior to marketing the Property to the general public, Landlord shall notify Tenant in writing of its desire to sell the Property and,
for a period of 30 days following such notice, Tenant shall have the exclusive right to negotiate with Landlord regarding the purchase of the Property by Tenant; provided by granting Tenant such exclusive right to negotiate, Landlord shall not
thereby be obligated in any way to sell the Property to Tenant. 
 (b) The foregoing rights shall not apply with respect to (i) any
sale or transfer of the Property to or among the beneficiaries of Landlord, or the partners of any beneficiaries of Landlord, or any family members, or to any sale or transfer for nominal consideration (provided in the case of such a sale or
transfer, the provisions of this section shall survive and remain in force and effect with respect to any subsequent sale) or (ii) a sale in connection with, or a deed in lieu of, a foreclosure, or a sale by operation of law (provided in the
case of such a sale or transfer, the right of Tenant hereunder shall terminate and be of no further force and effect), and Tenants rights hereunder shall specifically be subordinate to the rights of all mortgagees. 

(c) Tenant’s rights under this Section shall in any event terminate and be void and of no further force and effect upon the earlier of:
(i) the end of the 12th Lease Year (December 31, 

  
 - 4 - 

 
2015) or (ii) the date of the sale of the Property by Landlord following the notice and exclusive negotiation period provided for above. Tenant’s rights under this Section shall be
available only to the named Tenant, Paratek Pharmaceuticals, Inc., or its nominee to take title on its behalf, if any, and upon any assignment of this Lease by the named Tenant (except for an assignment to an entity referred to in
Section 17.2(a) of the Lease), the rights granted under this Section shall be void and of no further force and effect. 
 (d)
Notwithstanding anything else to the contrary, this Section 5 shall be of no force and effect, and shall be deemed void ab initio, if, prior to the first day of the Extended Term: (i) the Property shall have been sold by Landlord (except
for a sale or transfer of the Property to or among the beneficiaries of Landlord, or the partners of any beneficiaries of Landlord, or any family members, or for a sale or transfer for nominal consideration, which sale or transfer shall be subject
to the rights of the Tenant hereunder); or (ii) the Property shall be under a written agreement of sale with a prospective purchaser, and subsequent to the first day of the Extended Term the Property shall be sold to such purchaser, or its
nominee or assignee. 
  

	6.	RATIFICATION. 

 In all other respects, the Lease shall remain unmodified and in full force and effect. The
Lease, as amended by this Third Amendment, is hereby ratified and confirmed by Landlord and Tenant. 
  

	7.	CERTIFICATION 

 Tenant hereby certifies that the Lease is in full force and effect, that there have been no
other modifications or amendments thereto, that Landlord has fulfilled all of its obligations under the Lease, and Landlord is not in default under any of the terms and conditions of the Lease. 

 

	8.	BINDING 

 This agreement shall be binding upon and inure to the benefit of the parties hereto, their heirs,
executors, administrators, successors, in interest and assigns. 
 Executed as a sealed instrument as of the day and year first above written. 

 

									
	LANDLORD:				TENANT:
			
	 KING REAL ESTATE CORPORATION,
 AS
TRUSTEE OF KNEELAND STREET REAL
 ESTATE TRUST
 By its Managing
Agents
 KING ASSOCIATES LLP
				PARATEK PHARMACEUTICALS, INC.
					
	By:		 /s/ Alden I. Gifford Jr.
				By:		 /s/ George C. Hillman

			Name: Alden I. Gifford Jr.						Name: George C. Hillman
			Title: Partner						Title: Executive Vice President

  
 - 5 -EX-10.16

 Exhibit 10.16 
 Execution Copy 
 COLLABORATIVE RESEARCH AND LICENSE AGREEMENT

 between 
 WARNER CHILCOTT COMPANY, INC. 
 and 

PARATEK PHARMACEUTICALS, INC. 
 July 2, 2007 
 Portions of this Exhibit, indicated by the mark “[***],” were
omitted and have been filed separately with the Secretary of the Commission pursuant to the Registrant’s application requesting confidential treatment pursuant to Rule 406 of the Securities Act of 1933, as amended. 

 TABLE OF CONTENTS 

 

							
	 ARTICLE 1:
	 	DEFINITIONS	  	 	1	  
			
	 ARTICLE 2:
	 	ARTICLE 2: GOVERNANCE	  	 	12	  
			
	 ARTICLE 3:
	 	DEVELOPMENT; BACKUP COMPOUND RESEARCH PROGRAM	  	 	15	  
			
	 ARTICLE 4:
	 	COMMERCIALIZATION OF PRODUCTS	  	 	20	  
			
	 ARTICLE 5:
	 	CONSIDERATION AND FUNDING	  	 	21	  
			
	 ARTICLE 6:
	 	TREATMENT OF CONFIDENTIAL INFORMATION; PUBLICITY; NON-SOLICITATION	  	 	23	  
			
	 ARTICLE 7:
	 	EXCLUSIVITY; LICENSE GRANTS; ROYALTIES	  	 	24	  
			
	 ARTICLE 8:
	 	INTELLECTUAL PROPERTY RIGHTS	  	 	29	  
			
	 ARTICLE 9:
	 	ARTICLE 9: FILING, PROSECUTION AND MAINTENANCE OF PATENT RIGHTS	  	 	30	  
			
	 ARTICLE 10:
	 	TERMINATION	  	 	34	  
			
	 ARTICLE 11:
	 	REPRESENTATIONS AND WARRANTIES	  	 	40	  
			
	 ARTICLE 12:
	 	INDEMNIFICATION	  	 	41	  

 List of Exhibits and Schedules 
  

			
	 Exhibit A
	 	Development Plan
	 Exhibit B
	 	Tufts License Agreement
		
	 Schedule 1
	 	Lead Candidate List
	 Schedule 2
	 	Backup Compound List
	 Schedule 3
	 	Joint Press Release

  
 i 

Portions of this Exhibit, indicated by the mark “[***],” were omitted and have been filed separately with the Secretary of the Commission
pursuant to the Registrant’s application requesting confidential treatment pursuant to Rule 406 of the Securities Act of 1933, as amended. 

 COLLABORATIVE RESEARCH AND LICENSE AGREEMENT 

This Collaborative Research and License Agreement (this “Agreement”) is made and entered into as of July 2, 2007 (the
“Effective Date”) between Paratek Pharmaceuticals, Inc., a Delaware corporation with offices at 75 Kneeland Street, Boston, MA 02111 (“Paratek”), and Warner Chilcott Company, Inc., a corporation organized and existing under the
laws of Puerto Rico with offices at Union Street, Road 195 Km 1.1, Fajardo, PR 00738 (“WCCI”). Each of WCCI and Paratek is sometimes referred to individually herein as a “Party” and WCCI and Paratek are sometimes collectively
referred to herein as the “Parties.” 
 WITNESSETH: 

WHEREAS, Paratek has developed expertise in the design, synthesis and characterization of novel and improved classes of tetracycline
derived compounds for use as human pharmaceuticals and owns or otherwise controls certain technology related thereto; 

WHEREAS, WCCI has developed expertise in the development and commercialization of human pharmaceuticals and is engaged in the development
and commercialization of pharmaceutical compounds for the treatment, prevention, and diagnosis of acne vulgaris and rosacea; and 
 WHEREAS, both Parties desire to enter into a development program with the objective of having WCCI develop and commercialize tetracycline derived compounds for the treatment of acne vulgaris and rosacea.

 NOW, THEREFORE, in consideration of the mutual covenants contained herein, and for other good and valuable consideration, the
Parties hereto, intending to be legally bound, hereby agree as follows: 
 ARTICLE 1: DEFINITIONS 

Whenever used in this Agreement with an initial capital letter, the terms defined in this Article 1 shall have the meanings specified.

 1.1 “Adverse Event” means any serious untoward medical occurrence in a patient or subject who is
administered a Lead Candidate or Product, but only if and to the extent that such serious untoward medical occurrence is required under Applicable Law, rules or regulations to be reported to the FDA or any other Regulatory Authority. 

1.2 “Affiliate” means any corporation, firm, partnership or other entity, which directly or indirectly controls
or is controlled by or is under common control with a Party to this Agreement. For purposes of this definition, “control” means ownership, directly or through one or more Affiliates, of (a) fifty percent (50%) or more of the
shares of stock entitled to vote for the election of directors, in the case of a corporation, or (b) fifty percent (50%) or more of the equity interests in the case of any other type of legal entity or status as a general partner in any
partnership, or (c) any other arrangement whereby a Party controls or has the right to control the Board of Directors or equivalent governing body of a corporation or other entity. 

  
 Portions of this Exhibit,
indicated by the mark “[***],” were omitted and have been filed separately with the Secretary of the Commission pursuant to the Registrant’s application requesting confidential treatment pursuant to Rule 406 of the Securities Act of
1933, as amended. 

 1.3 “Alliance Manager” means the person appointed by each Party to
serve as such Party’s principal coordinator and liaison for the conduct of the Backup Compound Research Programs and the Development of Lead Candidates and Products. The Alliance Manager appointed by WCCI is referred to as the “WCCI
Alliance Manager,” and the Alliance Manager appointed by Paratek is referred to as the “Paratek Alliance Manager.” 
 1.4 “Annual Net Sales” means the aggregate Net Sales during a particular Calendar Year. 
 1.5 “Applicable Law” means all Federal, state, local national and supra-national laws, statutes, rules and regulations, including any rules, regulations, guidelines or requirements
of Regulatory Authorities, national securities exchanges or securities listing organizations that may be in effect from time to time during the term and applicable to a particular activity hereunder. 

1.6 “Backup Compounds” means the Paratek Compounds that are listed on the Backup Compound List attached hereto as
Schedule 2, as amended from time to time. 
 1.7 “Backup Compound Research Plan” means the
written plan describing the research activities to be carried out by each Party during each Contract Year during the Backup Compound Research Program Term in conducting the Backup Compound Research Program pursuant to this Agreement, as such written
plan may be amended, modified or updated. Each Backup Compound Research Plan shall be prepared by, or at the direction of, the Alliance Managers and approved by the JSC as soon as practicable after WCCI determines to conduct research on, or to
identify, any Backup Compound pursuant to Section 3.5 and shall be attached to the minutes of the meeting of the JSC at which such plan was approved by the JSC. 
 1.8 “Backup Compound Research Program” means the collaborative research program conducted by Paratek and WCCI for the purpose of identifying or further researching or developing
Backup Compounds pursuant to Article 3 of this Agreement and reflected in the Backup Compound Research Plans. 
 1.9
“Backup Compound Research Program Term” means the date of approval by the JSC of a Backup Compound Research Plan and shall continue for such period as the Parties shall mutually agree in the Backup Compound Research Plan,
subject to earlier termination upon termination or expiration of this Agreement pursuant to Article 10 hereof. 
 1.10
“Calendar Quarter” means the period beginning on the Effective Date and ending on the last day of the calendar quarter in which the Effective Date falls, and thereafter each successive period of three (3) consecutive
calendar months ending on March 31, June 30, September 30 or December 31. 
 1.11
“Calendar Year” means each successive period of twelve (12) months commencing on January 1 and ending on December 31. 
 1.12 “Clinical Trials” means, collectively, any Phase I Clinical Trial, Phase II Clinical Trial, and/or Phase III Clinical Trial. 

  
 2 

Portions of this Exhibit, indicated by the mark “[***],” were omitted and have been filed separately with the Secretary of the Commission
pursuant to the Registrant’s application requesting confidential treatment pursuant to Rule 406 of the Securities Act of 1933, as amended. 

 1.13 “Clinical Trial Data” means all data, results and information
produced in the conduct by or on behalf of WCCI of any Clinical Trials. 
 1.14 “Commercialization” or
“Commercialize” means, with respect to a Product, any and all activities directed to the pre-marketing, marketing, detailing, promotion, distribution and sale of such Product after the
date of filing of an NDA with respect to such Product. When used as a verb, “Commercializing” means to engage in Commercialization and “Commercialized” shall have a corresponding meaning. 

1.15 “Commercially Reasonable Efforts” or “Commercially Reasonable” means the efforts and
resources comparable to those undertaken by [***], as applicable, [***] of similar products that are not subject to this Agreement, taking into account the [***]. 
 1.16 “Commercially Reasonable Justification” means, with respect to WCCI’s obligations to use Commercially Reasonable Efforts, the [***]or [***]of (a) [***] (such as a
[***], or [***], by [***]) that could be [***] to [***] and [***] and/or [***]; (b) [***]; (c) [***]; (d) [***] with respect to the [***] (including, without limitation, a [***]) that is [***]; or (e) [***] with respect to [***].

 1.17 “Commercialization Regulatory Approval” means, with respect to any Product, the Regulatory
Approval required by Applicable Laws in the Territory to sell such Product for use in the Field in such Territory. “Commercialization Regulatory Approval” shall include, without limitation, the approval of any NDA, sNDA or other Drug
Approval Application. 
 1.18 “Confidential Information” means (a) with respect to Paratek, all
tangible embodiments of Paratek Technology, (b) with respect to WCCI, all tangible embodiments of WCCI Technology and (c) with respect to each Party, (i) all tangible embodiments of Joint Technology and (ii) with respect to a
Party (the “receiving Party”), all information and Technology which are disclosed by the other Party or any of its Affiliates (the “disclosing Party”) to the receiving Party hereunder or to any of its employees, consultants,
Affiliates or sublicensees, whether orally, visually, in writing or by way of any other media, that if disclosed in tangible form is marked “confidential,” or if disclosure is not in tangible form, the disclosing Party has notified the
receiving Party at the time of disclosure that such disclosure is confidential and summarized such disclosure in writing, marking the summary “confidential” and submitting it to the receiving Party (or, if applicable, to such of the
receiving Party’s Affiliates or sublicensees to whom disclosure has been made) within thirty (30) days of the disclosure; provided, however, that the term “Confidential Information” shall not mean or include any such Technology
or information, or any portion thereof, that (A) as of the date of productions development or disclosure is known to the receiving Party, its Affiliates or sublicensees, as demonstrated by credible written documentation, other than by virtue of
a prior confidential disclosure by the disclosing Party to such receiving Party or any of its Affiliates or sublicensees; (B) as of the date disclosure is in, or subsequently enters, the public domain, through no fault or omission of the
receiving Party or any of its Affiliates or sublicensees; (C) is obtained from a Third Party having a lawful right to make such disclosure free from any obligation of confidentiality to the disclosing Party; or (D) is independently
developed by or for the receiving 

  
 3 

Portions of this Exhibit, indicated by the mark “[***],” were omitted and have been filed separately with the Secretary of the Commission
pursuant to the Registrant’s application requesting confidential treatment pursuant to Rule 406 of the Securities Act of 1933, as amended. 

 
Party, its Affiliates or its sublicensees without reference to or reliance upon any Confidential Information of the disclosing Party as demonstrated by credible written documentation. For
purposes of clarity, any technical or financial information of a disclosing Party disclosed at any meeting of the JSC, or disclosed through an audit report shalt constitute Confidential Information of such disclosing Party. 

1.19 “Contract Year” means the period beginning on the Effective Date and ending on the first anniversary
thereof, and each succeeding twelve (12) month period thereafter. 
 1.20 “Control” or
“Controlled” means (a) with respect to Technology (other than Proprietary Materials) and/or Patent Rights, the possession by a Party or any of its Affiliates of the ability to grant a license or sublicense of such
Technology and/or Patent Rights as provided herein without violating the terms of any legally binding agreement between such Party or any of its Affiliates and, any Third Party, and (h) with respect to Proprietary Materials, the possession by a
Party or any of its Affiliates of the ability to supply such Proprietary Materials to the other Party as provided herein without violating the terms of any legally binding agreement between such Party or any of its Affiliates and, any Third Party.

 1.21 “Derived” means obtained, developed, created, synthesized, designed, derived or resulting from,
based upon, containing, incorporating or otherwise generated from (whether directly or indirectly, or in whole or in part). 

1.22 “Development” or “Develop” means, with respect to a Lead Candidate and/or Product,
all clinical and other activities set forth in the applicable Development Plan undertaken to obtain Regulatory Approval of such Lead Candidate and/or Product in the Territory in accordance with this Agreement. When used as a verb,
“Developing” means to engage in Development and “Developed” shall have a corresponding meaning. 
 1.23
“Development Plan” means the written plan describing the Development activities to be carried out during each Contract Year with respect to the Lead Candidates as such written plan may be amended, modified or updated. The
initial Development Plan, which will describe the Development activities to be carried out during the first Contract Year is attached hereto as Exhibit A. Each amendment and/or update to the Development Plan shall be set forth in a written
document prepared by, or at the direction of, the Alliance Managers and approved by the JSC, shall specifically state that it is an amendment, modification or update to the Development Plan and shall be attached to the minutes of the meeting of the
JSC at which such amendment, modification or update was approved by the JSC. Without limiting the nature or frequency of any other amendments, modifications or updates of the Development Plan that may be approved by the JSC, the Development Plan
shall be updated at least once prior to the end of each Contract Year to describe the Development activities to be carried out during the next Contract Year in conducting the Development pursuant to this Agreement. 

1.24 “Development Timelines” means the written schedule of the Development activities to be performed and the
Development milestones to be achieved, for each Lead Candidate by WCCI during each Contract Year during the Term. The initial Development Timelines applicable to the Lead Candidates until an IND is filed with respect to a Product shall

  
 4 

Portions of this Exhibit, indicated by the mark “[***],” were omitted and have been filed separately with the Secretary of the Commission
pursuant to the Registrant’s application requesting confidential treatment pursuant to Rule 406 of the Securities Act of 1933, as amended. 

 
be included as part of the initial Development Plan to be attached hereto as Exhibit A. Any amendment and/or update to the Development Timelines shall be set forth in a written document
prepared by, or at the direction of, the Alliance Managers and approved by the JSC and shall be attached to the minutes of the meeting of the JSC at which such amendment, modification or update is approved by the JSC. For purposes of clarity, the
term Development Timelines shall include, collectively, the Phase II Development Timelines, the NDA Development. Timelines and the Launch Development Timelines. 
 1.25 “Drug Approval Application” means any application for Regulatory Approval required before commercial sale or use of a Product as a drug or to treat a particular indication in
a regulatory jurisdiction in the Territory, including without limitation: (a) an NDA and any counterpart of an NDA in the Territory; and (b) all supplements and amendments that may be filed-with respect to the foregoing. 

1.26 “Effective Date” means the date set forth in the preamble of this Agreement. 

1.27 “Excluded Indications” means any self-limited or other infectious conditions other than acne vulgaris and
rosacea, including without limitation impetigo, uncomplicated and complicated skin and skin structure infections and other non-infectious inflammatory skin conditions. 

1.28 “Executive Officers” means the Chief Executive Officer of WCCI (or an executive officer of WCCI. designated
by such Chief Executive Officer) and the Chief Executive Officer of Paratek (or an executive officer of Paratek designated by such Chief Executive Officer). 
 1.29 “External Preclinical Activity Costs” means the costs or expenditures incurred by Paratek (or for its account by an Affiliate) in connection with the engagement by Paratek or
such Affiliate of any Third Party Laboratory to conduct any Development activities. 
 1.30 “FDA” means
the United States Food and Drug Administration or any successor regulatory agency. 
 1.31 “FDCA” means
the United States Federal Food, Drug and Cosmetic Act, as amended. 
 1.32 “Field” means the treatment
of acne vulgaris and rosacea. For purposes of clarity, the Field shall not include any Excluded Indications. 
 1.33
“First Commercial Sale” means, with respect to any given Product, the date of the first commercial transfer or disposition for value to a Third Party of such Product by WCCI, an Affiliate of WCCI or a Sublicensee. 

1.34 “Force Majeure” means any occurrence beyond the reasonable control of a Party that (a) prevents or
substantially interferes with the performance by such Party or such Party’s Affiliates of any of its obligations hereunder, and (b) occurs by reason of any act of God, flood, fire, explosion, earthquake, strike, lockout, labor dispute,
casualty or accident, or war, revolution, 

  
 5 

Portions of this Exhibit, indicated by the mark “[***],” were omitted and have been filed separately with the Secretary of the Commission
pursuant to the Registrant’s application requesting confidential treatment pursuant to Rule 406 of the Securities Act of 1933, as amended. 

 
civil commotion, act of terrorism, blockage or embargo, or any injunction, law, order, proclamation, regulation, ordinance, demand or requirement of any government or of any subdivision,
authority or representative of any such government. 
 1.35 “Full-Time Equivalent” or
“FTE” means the equivalent of the work of a full-time scientist based upon a total of 1,880 hours per year of scientific work. For purposes of clarity, the portion of an FTE year devoted by a scientist to Development
activities shall be determined by dividing: (a) the number of hours during any twelve-month period devoted by such employee to the Development activities by (b) 1,880. 

1.36 “FTE Rate” means [***] US Dollars (US $[***]) per year, subject to increase no more than once annually by
the percentage increase, if any, in the Consumer Price Index for all Urban Consumers, as published by the U.S. Department of Labor, Bureau of Statistics. 
 1.37 “GLP” means current good laboratory practice standards promulgated or endorsed by the FDA, including those procedures expressed or implied in the Regulatory Filings made with
respect to a Product with the FDA. 
 1.38 “GIVIP” means current good manufacturing practices under
Title 21 of the United States Code of Federal Regulations, as amended from time to time. 
 1.39 “ICH
Guidelines” means the applicable guidelines of the International Conference on Harmonization of Technical Requirements for the Registration of Pharmaceuticals for Human Use. 

1.40 “IND” means an Investigational New Drug Application (as defined in the FDA, and the regulations promulgated
thereunder) that is required to be filed with the FDA before beginning clinical testing of a Product in human subjects, or any successor application or procedure. 
 1.41 “Initiation” means, with respect to any clinical trial, the first date that a human subject is dosed in such clinical trial. 

1.42 “Joint Patent Rights” means Patent Rights that contain one or more claims that cover Joint Technology.

 1.43 “Joint Technology” means any Program Invention that is (a) conceived or first reduced to
practice jointly by or on behalf of both WCCI (or any of its Affiliates) and Paratek (or any of its Affiliates) or (b) conceived or first reduced to practice by or on behalf of one Party or any of its Affiliates as a result of its use in any
material respect of the Technology of the other Party or any of its Affiliates. 
 1.44 “Lead Candidate”
means up to ten (10) Paratek Compounds that are listed on the Lead Candidate List attached hereto as Schedule 1, as amended from time to time. 
 1.45 “Licensed Patent Rights” means any Paratek Patent Rights or Joint Patent Rights that (a) contain one or more claims that cover any Backup Compound, Lead Candidate or
Product or (b) are necessary or useful for WCCI to exercise the licenses granted to it pursuant to Sections 7.2.1. 

  
 6 

Portions of this Exhibit, indicated by the mark “[***],” were omitted and have been filed separately with the Secretary of the Commission
pursuant to the Registrant’s application requesting confidential treatment pursuant to Rule 406 of the Securities Act of 1933, as amended. 

 1.46 “Licensed Technology” means any Paratek Technology that
(a) relates to any Backup Compound, Lead Candidate or Product and (b) is necessary or useful for WCCI to exercise the licenses granted to it pursuant to Sections 7.2.1. 

1.47 “NDA” means a New Drug Application, as defined in the FDCA and applicable regulations promulgated
thereunder. 
 1.48 “Net Sales” means the gross amount billed by WCCI or its Affiliates or Sublicensees
to Third Parties in the Territory for sales of each Product during the period in which royalties are payable hereunder less the following deductions from such gross amounts to the extent actually applied or taken: (a) [***]; (b) [***];
(c) [***]; (d) [***]; (e) [***] and (f) [***]. In addition, Net Sales hereunder are subject to the following: 
 (a) In the case of any sale or other disposal of a Product by WCCI or any of its Affiliates to any WCCI Affiliate or Sublicensee for resale, the Net Sales shall be calculated as above on the value charged
or invoiced on the first arm’s length sale to a Third Party who is not an Affiliate or Sublicensee. For purposes of clarification, amounts received by WCCI and its Affiliates for the sale of Products among WCCI and its Affiliates and
Sublicensees for resale shall not be included in the computation of Net Sales hereunder. 
 (b) In the event of a sublicense as
to any Products, Net Sales will be calculated with respect to sales of Products by the Sublicensee, except for sales by a Sublicensee to another Sublicensee for resale. For purposes of clarification, amounts received by WCCI and its Affiliates and
Sublicensees for the sale of Products among WCCI and its Affiliates and Sublicensees for resale shall not be included in the computation of Net. Sales hereunder. 
 (c) Use of Products in clinical or pre-clinical trials or other research or development activities or disposal of Products for purposes of a commercially reasonable
sampling program shall not give rise to any deemed sale for purposes of this definition. 
 (d) In the event that a Product is
sold as a component of a combination or bundled product that consists of Product together with another therapeutically active product for the same indication, then Net Sales shall be determined by multiplying the Net Sales of the combination or
bundled product by the fraction A/(A+B) where A equals the average selling price of such Product sold separately in finished form and B equals the aggregate average selling price of the relevant other product(s) sold separately in finished form, in
each case during the same royalty reporting period and in similar volumes. In the event that no separate sale of either Product or the relevant other product is made during the applicable royalty reporting period in similar volumes and in the
relevant country in which the sale of the combination or bundled product was made, then Net Sales shall be determined by multiplying the Net Sales of the combination or bundled product by a fraction (C/(C+D)), where C equals the fair market value of
Product and D equals the fair market value of the relevant other product(s), in each case determined by good faith negotiation of the Parties. If the Parties cannot agree on such fair 

  
 7 

Portions of this Exhibit, indicated by the mark “[***],” were omitted and have been filed separately with the Secretary of the Commission
pursuant to the Registrant’s application requesting confidential treatment pursuant to Rule 406 of the Securities Act of 1933, as amended. 

 
market value, the matter will be resolved in accordance with Article 13. If the relevant other product is sold separately in finished form and Product is not, then Net Sales shall be determined
by multiplying the Net Sales of the combination or bundled product by the fraction (E – B)/E, where E equals the average selling price of the combination or bundled product in the Territory. 

(e) If WCCI or its Affiliates or Sublicensees effect a sale or other disposal of a Product to a customer in the Territory other than in
an arm’s length transaction (except as may be otherwise set forth in clauses (a) through (d) above), the Net Sales of that Product shall be deemed to be “the fair market value” of such Product (i.e., the value that would
have been derived had said Product been sold as a separate product to a similar customer in the Territory in an arm’s length transaction at the time of such transaction). 
 1.49 “Paratek Background Technology” means any Technology that is useful in the Field and that is Controlled by Paratek as of the Effective Date and/or during the Term, including
any such Technology that is conceived or first reduced to practice during the Term by employees of, or consultants to, Paratek without the use in any material respect of any WCCI Technology, WCCI Program Technology or Joint Technology. 

1.50 “Paratek Competitive Compound” means any Paratek Compound (including any Abandoned Compound) (a) that
Paratek develops or commercializes itself for use in the Field and/or (b) to which Paratek grants any Third Party the right to develop or commercialize for use in the Field. For purposes of clarity, any Paratek Compound that is developed or
commercialized by Paratek or any Third Party for rosacea pursuant to Section 3.7 shall not be deemed to be a Paratek Competitive Compound for purposes of this Agreement. 
 1.51 “Paratek Compound” means any Tetracycline Compound that is Controlled by Paratek or any of its Affiliates at any time during the Term. 

1.52 “Paratek Internal Costs” means the aggregate costs incurred by Paratek in connection with its performance of
(a) its tasks and obligations set forth in the Backup Compound Research Plan and/or (b) any Development activities. For purposes of clarity, Paratek Internal Costs (a) shall be determined by Paratek on an FTE basis and (b) shall
not include any External Preclinical Activity Costs. 
 1.53 “Paratek Patent Rights” means any Patent
Rights that contain one or more claims that cover Paratek Technology. 
 1.54 “Paratek Program
Technology” means any Program Invention conceived or first reduced to practice by employees, contractors or consultants of Paratek or any of its Affiliates, alone or jointly with Third Parties, without the use in any material respect of
any WCCI Technology or Joint Technology. 
 1.55 “Paratek Technology” means, collectively, Paratek
Background Technology and Paratek Program Technology. 
 1.56 “Paratek Total Cost” means the sum of the
External Preclinical Activity Costs and the Paratek Internal Costs. 

  
 8 

Portions of this Exhibit, indicated by the mark “[***],” were omitted and have been filed separately with the Secretary of the Commission
pursuant to the Registrant’s application requesting confidential treatment pursuant to Rule 406 of the Securities Act of 1933, as amended. 

 1.57 “Party” means Paratek or WCCI. 

1.58 “Patent Rights” means the rights and interests in and to issued patents and pending patent applications
(which for purposes of this Agreement shall be deemed to include certificates of invention, applications for certificates of invention and priority rights) in the Territory, including all provisional applications, substitutions, continuations, continuations-in-part, divisions, and renewals, all letters patent granted thereon, and all reissues, reexaminations and extensions thereof. 

1.59 “Phase I Clinical Trial” means a human clinical trial in any country which provides for the introduction
into humans of a Lead Candidate or Product with the purpose of determining human toxicity, metabolism, absorption, elimination and other pharmacological action as more fully defined in 21 C.F.R. 312.21(a). 

1.60 “Phase II Clinical Trial” means a human clinical trial in any country that is intended to initially evaluate
the effectiveness of a Lead Candidate or Product for a particular indication or indications in patients with the disease or indication under study, as more fully defined in 21 C.F.R. 312.21(b), and to establish an appropriate dose for use in a Phase
III Clinical Trial. 
 1.61 “Phase III Clinical Trial” means a pivotal human clinical trial in the
Territory the results of which could be used to establish safety and efficacy of a Lead Candidate or Product as a basis for an NDA submitted to an applicable Regulatory Authority, as more fully defined in 21 C.F.R. 312.21(c). 

1.62 “Product” means any pharmaceutical composition, compound or product that consists of, incorporates, is
comprised of, or is otherwise Derived from, a Lead Candidate for use in the Field, including different salts, formulations, combinations, other presentations or Pharmaceutical Alternatives (as defined in the 22nd edition of Approved Drug Products
with Therapeutic Equivalence Evaluations issued by the United States Department of Health and Human Services). For purposes of clarity, the term “Derived from” for purposes of this definition shall not refer to any compound that
(a) is generated from any Tetracycline Compound that is not a Lead Candidate; (b) is being developed for any use outside of the Field; and/or (c) constitutes a new compound with a different chemical structure. 

1.63 “Product Trademark” means any trademark and trade name, whether or not registered, and any trademark
application, renewal, extension or modification thereto used for Products in the Territory, together with all goodwill associated therewith. 
 1.64 “Program Invention” means any Technology (including, without limitation, any new and useful process, method of manufacture or composition of matter) that is conceived or first
reduced to practice (actively or constructively) in the conduct of the Backup Compound Research Program or in connection with the Development of any Lead Candidate or Product. 
 1.65 “Proprietary Materials” means any tangible chemical, biological or physical research materials (including, without limitation, molecules, compounds and other chemical

  
 9 

Portions of this Exhibit, indicated by the mark “[***],” were omitted and have been filed separately with the Secretary of the Commission
pursuant to the Registrant’s application requesting confidential treatment pursuant to Rule 406 of the Securities Act of 1933, as amended. 

 
compositions) that are furnished by or on behalf of one Party or any of such Party’s Affiliates to the other Party or any of such other Party’s Affiliates in connection with this
Agreement, regardless of whether such materials are specifically designated as proprietary by the transferring Party. 
 1.66
“Regulatory Approval” means any approval, product and establishment license, registration or authorization of any Regulatory Authority necessary for the manufacture, use, importation, export, reimbursement, marketing,
promotion and sale by WCCI of a Product in the Territory. “Regulatory Approval” shall include, without limitation, approval of any NDA or any other Drug Approval Application. 

1.67 “Regulatory Authority” means the FDA or any counterpart of the FDA outside the United States, or other
national, supra-national, regional, state or local regulatory agency, department, bureau, commission, council or other governmental entity in the Territory with authority over the distribution, importation, exportation, manufacture, production, use,
storage, transport, reimbursement, or clinical testing and/or sale of a Product. 
 1.68 “Regulatory
Filings” means, collectively, any and all INDs, establishment license applications and drug master files, Drug Approval Applications, applications for designation of a Product as an “Orphan Product(s)” under the Orphan Drug
Act or any other similar filings (including any comparable foreign filings), and all data contained therein, as may be required by any Regulatory Authority for the Development, manufacture or Commercialization of a Product. 

1.69 “Sublicensee” means any Third Party to which WCCI, any WCCI Affiliate or any other Third Party grants a
sublicense of some or all of the rights granted to WCCI under Section 7.2.1 hereof in accordance with Section 7.2.2 hereof. 
 1.70 “Technology” means and includes all inventions, discoveries, improvements, trade secrets, works of authorship, and proprietary methods and materials (including, without
limitation, Proprietary Materials), whether or not patentable or otherwise protectable under copyright, trade secrecy of similar laws, including but not limited to (a) samples of, methods of production or use of, and structural and functional
information pertaining to, chemical compounds, proteins or other biological substances and (b) data, designs, formulations, techniques and know-how (including any negative results). 

1.71 “Territory” means the United States and its territories and possessions. 

1.72 “Tetracycline Compound” means a [***] or [***] that consists of, incorporates, is comprised of, or is
otherwise derived from any [***] (such as, but not limited to, [***] and [***]), including (a) [***]; (b) [***] in which one or several [***] have been replaced by [***], such as (but not limited to) [***], and [***] or any [***] of such
[***]; (c) [***] in which one or several [***] have been chemically opened and/or removed producing [***], or [***] with or without functional or reactive chemical groups; and (d) [***] or structures in which one or several suitable [***]
have been used to [***], which can be either [***] to the [***] to form a [***], or directly attached to the [***] via a [***]. For purposes of this definition, a [***] or 

  
 10 

Portions of this Exhibit, indicated by the mark “[***],” were omitted and have been filed separately with the Secretary of the Commission
pursuant to the Registrant’s application requesting confidential treatment pursuant to Rule 406 of the Securities Act of 1933, as amended. 

 
[***] shall be deemed to be derived from a [***] if (i) the person deriving such [***] or [***] has actual knowledge that such [***] or [***] has been derived from a [***] or (ii) an
analysis of the [***] of such [***] or [***] by any person that is reasonably skilled in the art would lead such person to conclude that such [***],[***] or [***] has been derived from a [***] or [***] or [***] ([***] to [***]). 

1.73 “Third Party” means any person or entity other than WCCI and Paratek and their respective Affiliates.

 1.74 “Third Party Laboratory” means any Third Party contract research organization and/or laboratory
engaged by a Party to provide Development activities. 
 1.75 “Tufts IP Infringement” means an
Infringement of Patent Rights in the Field of Use as the terms “Patent Rights” and “Field of Use” are defined in the Tufts License Agreement. 
 1.76 “Tufts License Agreement” means the license agreement dated as of February 7, 1997, as amended, by and between Paratek and the Trustees of Tufts, a copy of which is
attached hereto as Exhibit B, as the same may be amended from time to time in accordance with the provisions of Section 7.4. 
 1.77 “Valid Claim” means a claim in an issued, unexpired patent within the Paratek Patent Rights or Joint Patent Rights that (a) has not been finally cancelled, withdrawn,
abandoned or rejected by any administrative agency or other body of competent jurisdiction, (b) has not been revoked, held invalid, or declared unpatentable or unenforceable in a decision of a court or other body of competent jurisdiction that
is unappealable or unappealed within the time allowed for appeal, (c) has not been rendered unenforceable through disclaimer or otherwise, and (d) is not lost through an interference proceeding. 

1.78 “WCCI Background Technology” means any Technology that is useful in the Field and that is Controlled by WCCI
as of the Effective Date and/or during the Term, including any such Technology that is conceived or first reduced to practice during the Term by employees of, or consultants to, WCCI without the use in any material respect of any Paratek Technology,
Licensed Technology or Joint Technology. 
 1.79 “WCCI Patent Rights” means any Patent Rights that
contain one or more claims that cover WCCI Technology. 
 1.80 “WCCI Program Technology” means
(a) any Program Invention conceived or first reduced to practice by employees, contractors or consultants of WCCI or any of its Affiliates, alone or jointly with Third Parties, without the use in any material respect of any Paratek Technology
or Joint Technology and (b) any Clinical Trial Data. 
 1.81 “WCCI Technology” means, collectively,
WCCI Background Technology and WCCI Program Technology. 

  
 11 

Portions of this Exhibit, indicated by the mark “[***],” were omitted and have been filed separately with the Secretary of the Commission
pursuant to the Registrant’s application requesting confidential treatment pursuant to Rule 406 of the Securities Act of 1933, as amended. 

 Additional Definitions. In addition, each of the following definitions shall
have the respective meanings set forth in the section of this Agreement indicated below: 
  

			
	 Definition
	  	Section
		
	 AAA
	  	13.1.2
	 Abandoned Compound
	  	3.6.1
	 Acquiror
	  	14.9
	 Additional Compound
	  	3.6.2
	 Additional Compound Notification
	  	3.6.2
	 Chair
	  	2.2
	 Code
	  	7.2.4
	 Diligence Failure Notice
	  	3.9.3(a)
	 Discontinued Product
	  	5.3.1
	 Filing Party
	  	9.1.2
	 Generic Product
	  	7.5.3
	 Infringement
	  	9.2.1(a)
	 Infringement Notice
	  	9.2.1(a)
	 Indemnified Party
	  	12.3
	 Indemnifying Party
	  	12.3
	 IND Milestone Date
	  	2.2
	 JSC
	  	2.1
	 Launch Development Timelines
	  	2.2
	 Licensed Product
	  	12.8.1
	 Losses
	  	12.1
	 NDA Development Timelines
	  	2.2
	 Paratek Diligence Obligation
	  	3.9.1
	 Paratek Indemnities
	  	12.2
		
	 Definition
	  	Section
		
	 Patent Coordinator(s)
	  	8.3
	 Phase II Development Timelines
	  	2.2
	 Recipient Party
	  	3.11
	 Rosacea Option Notice
	  	3.7
	 Royalty Term
	  	7.5.3
	 Term
	  	10.1
	 Termination Event
	  	10.2.2
	 Transferring Party
	  	3.11
	 Tufts
	  	7.3
	 WCCI Diligence Failure
	  	3.9.3(a)
	 WCCI Indemnities
	  	12.1

 ARTICLE 2: GOVERNANCE 
 2.1 Establishment and Function of JSC. Paratek and WCCI shall establish a Joint Steering Committee (the “JSC”) to plan, administer and monitor the Backup Compound Research Program
and the Development. The JSC shall approve all Backup Compound Research 

  
 12 

Portions of this Exhibit, indicated by the mark “[***],” were omitted and have been filed separately with the Secretary of the Commission
pursuant to the Registrant’s application requesting confidential treatment pursuant to Rule 406 of the Securities Act of 1933, as amended. 

 
Plans and Development Plans, review and monitor the progress of the Backup Compound Research Program and the Development, and recommend necessary adjustments to the Backup Compound Research
Program and the Development as the research and/or Development activities thereunder take place. 
 2.2 Composition;
Responsibilities. The JSC will be comprised of three (3) representatives of Paratek and three (3) representatives of WCCI and will continue in effect throughout the Term. Each Party will designate its JSC representatives within
thirty (30) days of the Effective Date and shall have the right to replace any of its JSC representatives from time to time by giving prior notice of such replacement to the other Party. The JSC will be chaired by one of the WCCI designated
representatives during the Term (the “Chair”). During the period commencing on the Effective Date and continuing until the payment by WCCI of the milestone payment associated with the filing of an IND with respect to a Product pursuant to
Section 5.3.1 (the “IND Milestone Date”), the JSC will (a) meet at least four (4) times per Calendar Year and (b) be responsible for (i) reviewing the efforts of the Parties in the conduct of the Backup Compound
Research Program, if any, and the Development activities, (ii) reviewing and approving the Backup Compound Research Plans, if any, the Development Plan and/or any amendments, modifications and updates to any such Backup Compound Research Plan
and Development Plan, (iii) addressing such other matters as either Party may bring before the JSC, (iv) determining the Development Timelines applicable to the Development of any Lead Candidate during the period from (A) the IND
Milestone Date with respect to such Lead Candidate or Product to the completion of Phase II Clinical Trials with respect to such Lead Candidate or Product (the “Phase II Development Timelines”), (B) the Initiation of Phase III
Clinical Trials with respect to such Lead Candidate or Product to the filing of an NDA with respect to such Lead Candidate or Product (the “NDA Development Timelines”) and (C) the filing of an NDA with respect to such Lead Candidate
or Product to the First Commercial Sale of a Product Derived from such Lead Candidate or Product (the “Launch Development Timelines”) and (v) performing such other tasks and undertaking such other responsibilities as may be set forth
in this Agreement, including, without limitation, the responsibilities set forth in Article 3 hereof. The JSC shall determine the Phase II Development Timelines, the NDA Development Timelines and the Launch Development Timelines promptly upon the
substantial completion of the material Development activity specified in the immediately preceding Development Timeline. Following the IND Milestone Date (a) at Paratek’s request, which shall not be made more frequently than twice per
Calendar Year, the JSC will meet for the sole purpose of serving as a forum for WCCI to update Paratek as to clinical Development and Commercialization progress with respect to Lead Candidates and Products, (b) each Party may continue to
exercise its right under this Section 2.2 to replace its JSC representatives from time to time by giving prior notice of such replacement to the other Party and (c) each Party may continue to exercise its right under Section 2.3.2
hereof to have representatives of such Party or of its Affiliates who are not members of the JSC attend JSC meetings as observers at the invitation of such Party with the approval of the other Party, which shall not be unreasonably withheld. At each
such meeting of the JSC after the IND Milestone Date, the representatives of WCCI on the JSC shall provide an update to the JSC as to WCCI’s general strategy for the Development and Commercialization of each Product in the Field, including,
without limitation, to the extent applicable, (i) an update to each Development Plan concerning the applicable Development Timelines for the Development of each Lead Candidate and Product and Regulatory Filings with respect thereto in

  
 13 

Portions of this Exhibit, indicated by the mark “[***],” were omitted and have been filed separately with the Secretary of the Commission
pursuant to the Registrant’s application requesting confidential treatment pursuant to Rule 406 of the Securities Act of 1933, as amended. 

 
the Field in the Territory, (ii) an update concerning the anticipated timelines on a region-by region basis for the commercial launch of each Product
and (iii) sales forecast guidance for each Product in the Field in the Territory. If there is a material change in such timelines or guidance after any such meeting, WCCI will promptly notify Paratek thereof. 

2.3 Meetings. 
 2.3.1 Schedule of Meetings. Within sixty (60) days of the Effective Date, the JSC shall meet and shall establish a schedule of times for meetings, taking into account, without
limitation, the planning needs of the Development and the obligations of the JSC to consult and/or render decisions on matters before it. Meetings shall also be convened upon the determination of any JSC representative, by written notice thereof to
the remaining representatives of the JSC, that a meeting of the JSC is required to discuss and/or resolve any matter or matters with respect to the Backup Compound Research Program and/or the Development. In any event, prior to the IND Milestone
Date, any Paratek representative to the JSC may call a meeting of the JSC not more than once each Calendar Quarter and after the IND Milestone Date, may call a meeting not more than twice per Calendar Year. Meetings shall be held at the offices of
WCCI or another mutually agreed upon location; provided, however, that the Parties may mutually agree to meet by teleconference or video conference or may act by a written memorandum signed by each JSC representative or its designee. 

2.3.2 Quorum; Voting; Decisions. At each JSC meeting, at least two (2) members designated by each Party shall
constitute a quorum. Each JSC member shall have one vote on all matters before the JSC; provided, that, the member or members of each Party present at a JSC meeting shall have the authority to cast the votes of any of such Party’s members on
the JSC who are absent from the meeting. Except as otherwise provided in Section 2.4 hereof, all decisions of the JSC shall be made by majority vote of the members. Whenever any action by the JSC is called for hereunder during a time period in
which the JSC is not scheduled to meet, the Chair shall cause the JSC to take the action in the requested time period by calling a special meeting or by action without a formal meeting by written memorandum signed by the Chair and one of the other
Party’s members. Representatives of each Party or of its Affiliates who are not members of the JSC may attend JSC meetings as non-voting observers at the invitation of either Party with the approval of
the other Party, which shall not be unreasonably withheld. 
 2.3.3 Minutes. The JSC shall keep accurate minutes
of its deliberations, which record all proposed decisions and all actions recommended or taken. Drafts of the minutes shall be delivered to the members of the JSC within a reasonable time not to exceed ten (10) days after the meeting. The Chair
shall be responsible for the preparation and circulation of the draft minutes. Draft minutes shall be edited by the Chair and shall be issued in final form within a reasonable time not to exceed twenty (20) days after the meeting only with the
approval of both Alliance Managers, as evidenced by their signatures on the minutes. 
 2.3.4 Expenses. Paratek
and WCCI shall each bear all expenses of their respective JSC members related to their participation on the JSC and attendance at JSC meetings. 

  
 14 

Portions of this Exhibit, indicated by the mark “[***],” were omitted and have been filed separately with the Secretary of the Commission
pursuant to the Registrant’s application requesting confidential treatment pursuant to Rule 406 of the Securities Act of 1933, as amended. 

 2.4 JSC Decisions. The JSC members shall use reasonable efforts to reach
agreement on any and all matters. In the event that, despite such reasonable efforts, agreement on a particular matter cannot be reached by the JSC, then, subject to the remainder of this Section 2.4, the Chair of the JSC shall have the right
to make the final decision on such matter, but shall only exercise such right in good faith after full consideration of the positions of both Parties. Notwithstanding the foregoing, the unanimous approval of all JSC members shall be required for any
of the following matters: (a) any change to the Development Plan or any Backup Compound Research Plan that would require Paratek to incur material additional costs and expenses to perform research or hire additional personnel or develop
capabilities that Paratek does not have at such time; (b) the adoption of, or change to, any patent strategy with respect to Joint Technology; (c) the determination of the Phase II Development Timelines, NDA Development Timelines and the
Launch Development Timelines and (d) any change to any such Development Timelines that would result in such Development Timeline being delayed in excess of six (6) months. If the JSC fails to reach unanimous agreement on any of the matters
set forth above in the foregoing sentence, then the matter shall be referred by any member thereof to the Executive Officers for resolution by good faith negotiations within thirty (30) days after notice thereof is received. 

ARTICLE 3: DEVELOPMENT; BACKUP COMPOUND RESEARCH PROGRAM 
 3.1 Development. Each Party shall be primarily responsible for those tasks and obligations in connection with the Development that are assigned to it pursuant to this Article 3 and the
Development Plan. The initial Development Plan shall be attached hereto as Exhibit A. 
 3.2 Management of
Development. Paratek and WCCI will each appoint an Alliance Manager on the Effective Date. Each Party will have the right, upon written notice to the other Party, to designate a different Alliance Manager. The Alliance Managers will be
members of the JSC, will jointly oversee the conduct of the Development until the later of the IND Milestone Date and the expiration of the Backup Compound Research Program Term. Following such date, the Alliance Managers will continue to meet
either in person or telephonically for the purpose of serving as a forum for WCCI to update Paratek as to Development and Commercialization progress with respect to Lead Candidates and/or Products. In connection therewith, WCCI shall provide the
Paratek Alliance Manager with the updates described in Section 3.3.2; provided, that, in providing each such update, WCCI shall be entitled to omit discussion of Confidential Information of WCCI that WCCI reasonably determines to be materially
sensitive. If there is a material change in such timelines or guidance in between such updates, WCCI will endeavor to notify Paratek thereof through the Alliance Managers. The role and responsibilities of the Paratek Alliance Manager and the WCCI
Alliance Manager shall terminate on the later of the termination of the Term and the date on which no Lead Candidate or Product is being Developed. 
 3.3 Records; Reports. 
 3.3.1 Record Keeping. Paratek
and WCCI shall each maintain records in sufficient detail and in accordance with GLP and as will properly reflect all work performed and results achieved in the performance of their respective activities in connection with the

  
 15 

Portions of this Exhibit, indicated by the mark “[***],” were omitted and have been filed separately with the Secretary of the Commission
pursuant to the Registrant’s application requesting confidential treatment pursuant to Rule 406 of the Securities Act of 1933, as amended. 

 
Development of Lead Candidates and the conduct of the Backup Compound Research Program (including all data in the form required under any applicable governmental regulations) in a manner
appropriate for purposes of supporting the filing of potential patent applications. Paratek and WCCI shall each provide the other the right to inspect and copy such records to the extent reasonably required for the exercise of its rights or the
performance of its obligations under this Agreement; provided, that, such records shall be Confidential Information of the disclosing Party and subject to Article 6 hereof. 
 3.3.2 Development Updates. WCCI shall keep the Paratek Alliance Manager regularly informed of the progress of the conduct of Development activities under this Agreement. Without limiting the
generality of the foregoing, WCCI shall, at least once per Calendar Quarter (a) provide updates to the Paratek Alliance Manager in reasonable detail regarding the status of the conduct of all Development activities and shall present to the
Paratek Alliance Manager all data and results generated in connection with such activities, and (b) provide the Paratek Alliance Manager with such additional information regarding the conduct of such Development activities that it has in its
possession as may be reasonably requested from time to time by the Paratek Alliance Manager. 
 3.4 Information
Exchange. Scientists at Paratek and WCCI shall cooperate in the performance of the Development and, subject to any confidentiality obligations to Third Parties, shall exchange information and materials as necessary to carry out the
Development. The Parties expect that such exchange of information and materials may involve short-term on-site visits by scientists of one Party to the facilities of the other Party. 

3.5 Paratek Development Activities. If WCCI wishes Paratek to conduct research as part of the Backup Compound Research
Program or any Paratek Development activities as part of the Development, other than the research or Development activities specified in the Development Plan, it shall provide Paratek with written notice, which notice shall describe in reasonable
detail the research or Development activities it wishes Paratek to conduct and the estimated budget and timeframe applicable thereto. Upon receipt of such notice, Paratek will determine in good faith whether it has the resources available, and
whether in its sole discretion it wishes, to conduct the Backup Compound Research Program and/or the Development activities. To the extent Paratek agrees to conduct the Backup Compound Research Program and/or the Development activities, it shall
provide WCCI with written notice of same, which notice shall include an estimate of the Paratek Total Cost applicable thereto and the Alliance Managers will prepare and execute a Backup Compound Research Plan and/or an amendment to the Development
Plan to reflect the research or Development activities, as the case may be, and such estimated Paratek Total Cost applicable thereto. All such research and/or Development activities will be conducted at WCCI’s sole cost and expense. 

3.6 Abandoned Compounds; Additional Compounds. 
 3.6.1 Abandoned Compounds. If, at any time and from time to time during the Term, the JSC determines in good faith that further Development and/or Commercialization, as the case may be, of
any Backup Compound, Lead Candidate or Product in accordance with the provisions of this Agreement has ceased to be scientifically, technically or commercially viable, 

  
 16 

Portions of this Exhibit, indicated by the mark “[***],” were omitted and have been filed separately with the Secretary of the Commission
pursuant to the Registrant’s application requesting confidential treatment pursuant to Rule 406 of the Securities Act of 1933, as amended. 

 
it will promptly provide written notice thereof to Paratek (each, an .”Abandoned Compound”). Following an Abandoned Compound designation or at any time a Lead Candidate or Product
otherwise becomes an Abandoned Compound pursuant to any of the other provisions of this Agreement (a) Paratek or any of its Affiliates may thereafter proceed with development and commercialization of such Abandoned Compound for any and all uses
outside of the Field, either alone or in conjunction with Third Parties; (b) all licenses granted by Paratek to WCCI with respect to such Abandoned Compound shall immediately terminate; provided, that, any. abandonment by WCCI pursuant to this
Section 3.6.1 shall not constitute a breach of this Agreement; and (c) WCCI may, in its discretion, designate a Backup Compound to replace such Lead Candidate (which shall be reflected in an amendment to Schedule 1 hereto) in the
Development, whereupon the JSC shall promptly direct the Alliance Managers to prepare an amendment to the Development Plan to describe the activities to be conducted, and the applicable Development Timelines, with respect to such Lead Candidates.

 3.6.2 Additional Compounds. If, at any time during the Term, Paratek reasonably determines in good faith that a
Paratek Compound is potentially more suitable for Development and Commercialization than the then specified Lead Candidates (such compound, an “Additional Compound”), Paratek shall promptly inform WCCI (the “Additional Compound
Notification”) of such determination and WCCI shall have the right to designate such Additional Compound as a Lead Candidate hereunder (which shall be reflected in an amendment to Schedule 1 hereto), it being understood that WCCI must
notify Paratek in writing of such designation within forty-five (45) days of receipt of the Additional Compound Notification in order to exercise its rights under this Section 3.6.2. For the avoidance of doubt, Paratek shall have no
obligation under this Section 3.6.2 to engage in research activities it would not otherwise conduct in the ordinary course of its research and development with respect to Paratek Compounds. 

3.7 Rosacea Development Option. If at any time during the period commencing on the Effective Date and continuing until the
Initiation of a Phase III Clinical Trial with respect to a Product, WCCI determines in good faith that it intends to use Commercially Reasonable Efforts to Develop one or more Lead Candidates for rosacea, WCCI shall give written notice to the JSC
specifying such Lead Candidate (the “Rosacea Option Notice”). On or before ninety (90) days from the date of receipt of the Rosacea Option Notice, WCCI shall prepare, for approval by the JSC pursuant to Section 2.2, a Development
Plan covering the Development of such Lead Candidate for rosacea. Notwithstanding the foregoing, if WCCI fails to provide the Rosacea Option Notice within the period described in this Section 3.7 or the JSC fails to approve a Development Plan
for such Lead Candidate for rosacea in accordance with Section 2.2, the grant to WCCI of the right to Develop and Commercialize Products for rosacea under this Agreement shall convert to a non-exclusive
right and Paratek shall thereafter have the unencumbered right to grant one or more Third Parties the non-exclusive right to develop and commercialize any Paratek Compound that is not a Backup Compound, Lead
Candidate or Product for rosacea. 
 3.8 Exclusive Periods. 

3.8.1 Development of Lead Candidates. During the period commencing on the Effective Date and continuing for so long as WCCI is
Developing at least one Lead Candidate in 

  
 17 

Portions of this Exhibit, indicated by the mark “[***],” were omitted and have been filed separately with the Secretary of the Commission
pursuant to the Registrant’s application requesting confidential treatment pursuant to Rule 406 of the Securities Act of 1933, as amended. 

 
accordance with its obligations under Section 3.9.2, (i) Paratek and its Affiliates shall not grant any rights (whether by license or otherwise) to any Third Party to any Backup
Compound or Lead Candidate in the Territory that has not become an Abandoned Compound, and (ii) Paratek and its Affiliates shall not research, develop or commercialize any Backup Compound or Lead Candidate in the Territory that has not become
an Abandoned Compound in collaboration with, at the request of, or for the benefit (in whole or in part) of any Third Party (other than pursuant to non-commercial collaborations in accordance with
Section 7.1.3 hereof). 
 3.8.2 Commercialization of Products. During the period commencing on the Effective Date
and continuing for so long as WCCI is Commercializing a Product in accordance with its obligations under Section 3.9.2, (i) Paratek and its Affiliates shall not grant any rights (whether by license or otherwise) to any Third Party to such
Product in the Territory (including, without limitation, any rights to the Lead Candidate from which such Product is Derived) and (ii) Paratek and its Affiliates shall not research, develop or commercialize such Product in the Territory
(including, without limitation, any rights to the Lead Candidate from which such Product is Derived) in collaboration with, at the request of, or for the benefit (in whole or in part) of any Third Party. 

3.9 Due Diligence. 
 3.9.1 Paratek Obligations. Paratek agrees that it will (a) undertake the responsibilities assigned to it, as set forth in this Article 3 and in the Development Plan and any Backup Compound
Research Plan, if any; including, but not limited to, the dedication of resources to such efforts as set forth in the Development Plan and such Backup Compound Research Plan; and (b) use Commercially Reasonable Efforts to perform the activities
assigned to Paratek in this Article 3 and in the Development Plan and such Backup Compound Research., Plan in a professional and timely manner (collectively, the “Paratek Diligence Obligation”). Paratek may satisfy its obligations under
this Section 3.9.1 either itself or through Paratek Affiliates and/or Third Party Laboratories. 
 3.9.2 WCCI Obligations.
WCCI agrees that it will (a) use Commercially Reasonable Efforts to undertake those responsibilities assigned to it, as set forth in this Article 3 and in the Development Plan in a professional and timely manner; (b) use Commercially
Reasonable Efforts to Develop Lead Candidates for Commercialization as a Product in the Field in the Territory in accordance with the Development Timelines; and (c) use Commercially Reasonable Efforts to Develop and Commercialize at least one
Product in the Field in the Territory. WCCI may satisfy its obligations under this Section 3.9.2 either itself or through WCCI Affiliates, Sublicensees and/or contract research organizations. For the avoidance of doubt, WCCI shall be deemed to
have satisfied its obligations under this Section 3.9.2 if it uses Commercially Reasonable Efforts to Develop and Commercialize a Product solely with respect to an acne indication until such time as the JSC approves a Development Plan with
respect to rosacea in accordance with Section 3.7. 

  
 18 

Portions of this Exhibit, indicated by the mark “[***],” were omitted and have been filed separately with the Secretary of the Commission
pursuant to the Registrant’s application requesting confidential treatment pursuant to Rule 406 of the Securities Act of 1933, as amended. 

 3.9.3 Breach of WCCI Diligence Obligation. 

(a) Paratek may provide WCCI with written notice of any material breach by WCCI of its covenants set forth in Section 3.9.2 hereof
that is not caused by Paratek’s failure to meet a Paratek Diligence Obligation pursuant to Section 3.9.1 above (a “WCCI Diligence Failure”), at any time Paratek reasonably believes a WCCI Diligence Failure has taken place. Such
written notice (a “Diligence Failure Notice”) shall set forth in reasonable detail the nature of the alleged failure and shall request written justification, in the form of detailed reasons, that would support the proposition that WCCI is
meeting such diligence obligations. in such event, WCCI shall provide such written justification to Paratek within thirty (30) days after such Diligence Failure Notice is given and shall identify any Commercially Reasonable Justification
applicable thereto. If Paratek does not receive a Commercially Reasonable Justification from WCCI within such thirty (30) day period or if Paratek and WCCI are not able to resolve any disagreement with respect to a WCCI Diligence Failure within
sixty (60) days after WCCI’s receipt of the Diligence Failure Notice, then either Paratek or WCCI, acting alone, may at any time following WCCI’s receipt of such Diligence Failure Notice by delivery to the. other Party of a written
notice indicating such Party’s election to have the disagreement resolved by arbitration, cause the matter to be submitted to binding arbitration under Section 13.1.2 hereof; provided that (i) the arbitrators shall be entitled to
review and resolve only whether or not a WCCI Diligence Failure occurred during the applicable reporting period of time that is the subject of such disagreement, and (ii) the arbitrators shall be individuals who are knowledgeable in the field
of the development, manufacture, and sale of drugs and drug products, and shall have no current or prior business relationships with Paratek, WCCI or any of their respective Affiliates. 

(b) If the arbitrator determines that a WCCI Diligence Failure occurred, then Paratek’s sole and exclusive remedy shall be, on a Product-by-Product basis as to the Product with respect to which such WCCI Diligence Failure occurred to (i) terminate any or all of the licenses and rights granted under
Section 7.2.1 hereof and the restrictions of Sections 3.8 and 7.1.1, or (ii) convert the licenses and rights granted under any or all of Section 7.2.1 from exclusive licenses to non-exclusive
licenses and terminate the restrictions of Sections 3.8 and 7.1.1, in either case only as such licenses and rights apply to such Product, which termination and/or conversion, as the case may be, shall be at the discretion of Paratek and he effective
sixty (60) days after Paratek gives written notice to WCCI specifying the remedy that Paratek is electing to exercise under this Section 3.9.3. 
 (c) The Parties agree that Paratek’s sole and exclusive remedy, with respect to a WCCI Diligence Failure shall be as set forth in this Section 3.9.3, and Paratek shall not bring, commence,
continue or prosecute any claim, legal action or proceeding under, in relation to, arising out of or in connection with a WCCI Diligence Failure except as set forth in this Section 3.9.3. 

3.10 Compliance with Laws. Each Party agrees to carry out all work assigned to such Party in the Backup Compound Research
Plan and the Development Plan as well as all Development and Commercialization obligations hereunder in compliance with all Applicable Laws. For the avoidance of doubt, each activity performed by a Party under the Development Plan or Backup Compound
Research Plan that will or would reasonably be expected to be submitted to a Regulatory Authority in support of a Regulatory Filing or Drug Approval 

  
 19 

Portions of this Exhibit, indicated by the mark “[***],” were omitted and have been filed separately with the Secretary of the Commission
pursuant to the Registrant’s application requesting confidential treatment pursuant to Rule 406 of the Securities Act of 1933, as amended. 

 
Application, shall comply in all material respect with ICH Guidelines (or other comparable regulation and guidance of any Regulatory Authority in the Territory), and, if and as applicable, the
regulations and guidance of the FDA that constitute GLP and GMP. 
 3.11 Supply of Proprietary Materials. From
time to time during the Term, either Party (the “Transferring Party”) may supply the other Party (the “Recipient Party”) with Proprietary Materials of the Transferring Party for use in the Development and/or the Backup Compound
Research Program. In connection therewith, the Recipient Party hereby agrees that (a) it and its Affiliates shall not use such Proprietary Materials for any purpose other than exercising any rights granted to it or reserved by it hereunder or
for performing its obligations hereunder; (b) it and its Affiliates shall use such Proprietary Materials only in compliance with all Applicable Law; (c) it and its Affiliates shall not transfer any such Proprietary Materials to any Third
Party without the prior written consent of the Transferring Party, except as expressly permitted hereby and except in connection with the exercise of any rights granted to the Recipient Party or reserved by it hereunder; (d) as between the
Transferring Party and the Receiving Party, the Transferring Party shall retain full ownership of all such Proprietary Materials, subject to any licenses granted by the Transferring Party to the Recipient Party pursuant to this Agreement; and
(e) upon the expiration or termination of this Agreement, the Recipient Party shall, at the instruction of the Transferring Party, either destroy or return any such Proprietary Materials which are not the subject of the grant of a continuing
license hereunder. In addition, each of Paratek and WCCI agrees that, during the Term, neither Party nor any of their respective Affiliates shall transfer to any Third Party, without the approval of the other Party, any Proprietary Materials that
constitute or are part of Joint Technology. 
 ARTICLE 4: COMMERCIALIZATION OF PRODUCTS 

4.1 Commercialization of Products. Subject to the remainder of this Article 4, WCCI shall have the sole right and
responsibility for all aspects of Commercializing Products in the Territory. 
 4.2 Compliance. WCCI shall perform
its obligations described in Section 4.1 in good scientific manner and in compliance with all Applicable Laws. 
 4.3
Information; Updates. WCCI shall keep Paratek regularly informed of the progress of its efforts to Commercialize Products in the Field in the Territory, by providing periodic updates which shall summarize WCCI’s efforts to
Commercialize Lead Candidates and Products in the Field and identify the Regulatory Filings and Drug Approval Applications with respect to such Lead Candidates and Products that WCCI or any of its Affiliates or Sublicensees have filed; provided,
that, in providing each such update, WCCI shall be entitled to omit discussion of Confidential Information of WCCI that WCCI reasonably determines to be materially sensitive. 
 4.4 Product Recalls. In the event that any Regulatory Authority issues or requests a recall or takes similar action in connection with a Product, or in the event WCCI reasonably believes
that an event, incident or circumstance has occurred that may result in the need for a recall, market withdrawal or other corrective action regarding a Product, WCCI shall promptly 

  
 20 

Portions of this Exhibit, indicated by the mark “[***],” were omitted and have been filed separately with the Secretary of the Commission
pursuant to the Registrant’s application requesting confidential treatment pursuant to Rule 406 of the Securities Act of 1933, as amended. 

 
advise Paratek thereof by telephone or facsimile. Following such notification, WCCI shall decide and have control of whether to conduct a recall or market withdrawal (except in the event of a
recall or market withdrawal mandated by a Regulatory Authority, in which case it shall be required) or to take other corrective action in the Territory and the manner in which any such recall, market withdrawal or corrective action shall be
conducted; provided, that, WCCI shall keep Paratek regularly informed regarding any such recall, market withdrawal of corrective action. WCCI shall bear all expenses of any such recall, market withdrawal or corrective action (including, without
limitation, expenses for notification, destruction and return of the affected Product and any refund to customers of amounts paid for such Product). 
 4.5 Adverse Event Information. WCCI shall provide notice to Paratek of any Adverse. Events that occur during the Term, including without limitation, all filings made with Regulatory
Authorities with respect to Adverse Events promptly after making such filings. WCCI shall make available to Paratek for review and copy at Paratek’s expense, upon reasonable request, all Adverse Event information and product complaint
information relating to Lead Candidates and Products as compiled, prepared and filed by WCCI with the FDA or similar Regulatory Authorities in the normal course of business in connection with the Development, Commercialization or sale of any Lead
Candidates or Products. Paratek acknowledges and agrees that such information shall be the Confidential Information of WCCI and subject to the provisions of Article 6 hereof. 
 4.6 Manufacture of Products for Commercial Sale. Unless otherwise agreed to by the Parties, WCCI shall have the sole obligation and responsibility for the manufacture of all Products
(including without limitation the active pharmaceutical ingredient in any Product) for commercial sale. 
 ARTICLE 5:
CONSIDERATION AND FUNDING 
 5.1 Upfront Fee. As reimbursement for research conducted by Paratek, WCCI hereby
agrees to pay Paratek a non-refundable, non-creditable fee in the amount of Four Million U.S. Dollars (US $4,000,000) payable in immediately available funds on the
Effective Date. 
 5.2 R&D Reimbursement. In consideration of the conduct by Paratek of (a) any
activities under the Backup Compound Research Program agreed to by Paratek and/or (b) any Development activities under the Development agreed to by Paratek, WCCI shall reimburse Paratek for one hundred percent (100%) of the Paratek Total
Cost incurred by Paratek as part of such activities. Paratek shall invoice WCCI on a quarterly basis with respect to such Paratek Total Cost within fifteen (15) days of end of each Calendar Quarter and WCCI shall pay all such invoices within
thirty (30) days of receipt of each such invoice. 

  
 21 

Portions of this Exhibit, indicated by the mark “[***],” were omitted and have been filed separately with the Secretary of the Commission
pursuant to the Registrant’s application requesting confidential treatment pursuant to Rule 406 of the Securities Act of 1933, as amended. 

 5.3 Development Milestone Payments. 

5.3.1 Milestones. In further consideration of the grant of the rights and licenses by Paratek hereunder, WCCI will make the
following nonrefundable, non-creditable (other than as provided in this Section 5.3.1) milestone payments to Paratek within [***] ([***])[***] after the achievement by WCCI and/or WCCI’s Affiliates
and Sublicensees of each such milestone event for each Product: 
  

					
	 Milestone Event
	  	Milestone Payment	 
	 Filing of IND with respect to a Product
	  	$	1 million	  
	 Initiation of Phase II Clinical Trials with respect to a Product
	  	$	2.5 million	  
	 Initiation of Phase III Clinical Trials with respect to a product
	  	$	4 million	  
	 Acceptance of NDA in the Territory for a Product
	  	$	5 million	  
	 [***]
	  	$	[***	] 

 For the avoidance of doubt, WCCI shall only be obligated to make each milestone payment set forth in this
Section 5.3.1 upon the first occurrence of the milestone event relating to such payment for a given Product and shall have no obligation to make any milestone payment as a result of any subsequent filing, clinical trial initiation, NDA filing
or Regulatory Approval with respect to an alteration of the dosage, formulation or any other variation of such Product, so long as such Product continues to be Derived from the same Lead Candidate. In addition, if the JSC determines to discontinue
Development of a Product (the “Discontinued Product”), then WCCI shall he entitled to deduct the amount of all milestone payments made with respect to the Discontinued Product from any milestone payments that become due hereunder with
respect to the next Product that is Developed by WCCI that achieves the applicable milestones. 
 5.3.2 Determination That
Payments Are Due. WCCI shall provide Paratek with prompt written notice upon its achievement of each of the milestones set forth in Section 5.3.1 of this Agreement. In the event that, notwithstanding the fact that WCCI has not given any
such notice, Paratek believes any such milestone payment is due, it shall so notify WCCI in writing, and shall provide to WCCI the data and information demonstrating that the conditions for payment have been achieved. Within thirty (30) days of
its receipt of such notice, WCCI shall review the data and information and shall certify in writing whether or not the conditions for payment have been achieved. Any negative determination shall be accompanied by a detailed explanation of the
reasons therefor. Any dispute under this Section 5.3.2 that relates to whether or not a milestone has been achieved shall be submitted to arbitration under Article 13 of this Agreement. 

5.4 Payments. All payments made by WCCI to Paratek hereunder shall be made by wire transfer to the account specified below,
or such other account as specified in writing by Paratek from time to time: 
  

			
	Bank Name:	  	[***]
	Bank Address:	  	Boston, MA
	Account Name:	  	Paratek Pharmaceuticals, Inc.
	Account Number:	  	[***]

  
 22 

Portions of this Exhibit, indicated by the mark “[***],” were omitted and have been filed separately with the Secretary of the Commission
pursuant to the Registrant’s application requesting confidential treatment pursuant to Rule 406 of the Securities Act of 1933, as amended. 

 ARTICLE 6: TREATMENT OF CONFIDENTIAL INFORMATION; PUBLICITY; NON-SOLICITATION 
 6.1 Confidentiality 

6.1.1 Confidentiality Obligations. Paratek and WCCI each recognize that the other Party’s Confidential Information
constitute highly valuable and proprietary confidential information and materials. Paratek and WCCI each agrees that during the Term and for an additional five (5) years thereafter, it will keep confidential, and will cause its employees,
consultants, Affiliates and Sublicensees to keep confidential, all Confidential Information of the other Party, and to limit the use of the Confidential Information of the other Party to those purposes permitted under this Agreement. Each receiving
Party shall take such action, and shall cause its Affiliates and Sublicensees to take such action, to preserve the confidentiality of the disclosing Party’s Confidential Information as it would customarily take to preserve the confidentiality
of its own Confidential Information, using a level of care that shall not under any circumstances be less than reasonable care. Each receiving Party, upon the request of the disclosing Party, will return all the Confidential Information and
Proprietary Materials disclosed or transferred to it by the disclosing Party pursuant to this Agreement, including all copies and extracts of documents and all manifestations in whatever form, within sixty (60) days of such request or, if
earlier, the termination or expiration of this Agreement; provided, however, that the receiving Party may retain Confidential Information of the disclosing Party relating to any license which survives such termination and one copy of all other
Confidential Information may be retained in inactive archives solely for the purpose of establishing the contents thereof. 

6.1.2 Limited Disclosure. Paratek and WCCI each agree that any disclosure of the disclosing Party’s Confidential
Information to any officer, employee, consultant, agent, Affiliate or sublicensee of a receiving Party, as the case may be, shall be made only if and to the extent necessary to carry out its rights and responsibilities under this Agreement, shall be
limited to the maximum extent possible consistent with such rights and responsibilities and shall only be made to persons who are bound by written confidentiality obligations (including such provision as contained in employment agreements) to
maintain the confidentiality thereof and not to use such Confidential Information except as expressly permitted by this Agreement. Paratek and WCCI each further agree not to disclose or transfer the disclosing Party’s Confidential Information
to any Third Party under any circumstance without the prior written approval from the disclosing Party, except as otherwise expressly permitted by this Agreement. Notwithstanding, the foregoing, each receiving Party may disclose information to the
extent such disclosure is reasonably necessary to (a) file and prosecute Patent Rights which are filed or prosecuted in accordance with the provisions of this Agreement, (b) file, prosecute or defend litigation in accordance with the
provisions of this Agreement or (c) comply with Applicable Law, regulations or court orders; provided, however, that if a receiving Party is required to make any such disclosure of a disclosing Party’s Confidential Information in
connection with any of the foregoing, it will give reasonable advance notice to the disclosing Party of such disclosure requirement and will use reasonable efforts to assist such disclosing Party in efforts to secure confidential treatment of such
information required to be disclosed. The Parties hereby agree that a copy of this Agreement may be provided by Paratek to Tufts pursuant to Paratek’s obligations under the Tufts License Agreement. 

  
 23 

Portions of this Exhibit, indicated by the mark “[***],” were omitted and have been filed separately with the Secretary of the Commission
pursuant to the Registrant’s application requesting confidential treatment pursuant to Rule 406 of the Securities Act of 1933, as amended. 

 6.1.3 Employees and Consultants. Paratek and WCCI each hereby represents that
all of its employees, and all of the employees of its Affiliates, and any consultants to such Party or its Affiliates, in any case that participate in the activities of the Backup Compound Research Program and/or the Development and
Commercialization and who shall have access to Confidential Information of the other Party or any of its Affiliates shall be bound by written obligations (including such provision as contained in employment agreements) to maintain such information
in confidence and not to use such information except as expressly permitted herein. Each Party agrees to enforce confidentiality obligations to which its employees and consultants (and those of its Affiliates) are obligated. 

6.2 Publicity. Neither Party nor any of its Affiliates may publicly disclose the existence or terms of this Agreement
without the prior written consent of the other Party; provided, however, that either Party may make such a disclosure (a) to the extent required by law or by the requirements of any nationally recognized securities exchange, quotation system or
over-the-counter market on which such Party has its securities listed or traded or (b) to any investors, prospective investors, lenders and other potential or
current financing sources who are obligated to keep such information confidential. In the event that such disclosure is required under clause (a) as aforesaid, the disclosing Party shall make reasonable efforts to provide the other Party with
notice beforehand and to endeavor to coordinate with the other Party with respect to the wording and timing of any such disclosure. The Parties, upon the execution of this Agreement, will publicly issue a joint press release, in the form of Schedule
3 attached hereto, with respect to this Agreement and the Parties relationship hereunder. Once such press release or any other written statement is approved for disclosure by both Parties, either Party or any of such Party’s Affiliates, may
make subsequent public disclosure of the contents of such statement without the further approval of the other Party. Additionally, from time to time, the Parties may make additional press releases with regard to events occurring under this
Agreement, including achievement of milestones, with the prior written consent of both Parties. 
 6.3 Prohibition on
Solicitation. Without the written consent of the other Party, neither Party nor its Affiliates shall, during the Term of this Agreement or for a period of one (1) year following the expiration or termination of the Term, whichever is
shorter, solicit any employee of such Party or its Affiliates who participated in the Backup Compound Research Program and/or the Development activities. This provision shall not restrict either Party or its Affiliates from advertising employment
opportunities in any manner that does not directly target the other Party or its Affiliates. 
 ARTICLE 7: EXCLUSIVITY;
LICENSE GRANTS; ROYALTIES 
 7.1. Exclusivity During the Term. 

7.1.1 Paratek Restrictions. During the Term, Paratek, for itself and its Affiliates, agrees not to directly or indirectly
(a) undertake any research, development, manufacturing, marketing, promotion, sale or other commercialization of any Tetracycline Compound for use in the Field and in the Territory or (b) grant any license or other rights to any Third
Party to research, develop, manufacture, market, sell, promote or otherwise commercialize any Tetracycline Compound for use in the Field and in the Territory. 

  
 24 

Portions of this Exhibit, indicated by the mark “[***],” were omitted and have been filed separately with the Secretary of the Commission
pursuant to the Registrant’s application requesting confidential treatment pursuant to Rule 406 of the Securities Act of 1933, as amended. 

 7.1.2 WCCI Restrictions. During the Term, WCCI agrees that, except pursuant to
and as permitted by this Agreement, neither WCCI nor its Affiliates shall, either itself or directly or indirectly with or through any WCCI Affiliate or any Third Party, undertake any research, development, manufacturing, marketing, promotion, sale
or other commercialization of any product containing a Paratek Compound for any use other than the Development and Commercialization of Products in the Field in accordance with this Agreement. 

7.1.3 Non-Commercial Collaboration. Notwithstanding the foregoing, with the prior
written consent of the other Party, each Party or any of such Party’s Affiliates may enter into agreements with academic, research, or other non-commercial institutions with the goal of advancing the
collaboration between the Parties hereunder; provided that the terms of such agreements provide that such academic, research or other non-commercial institutions do not acquire any exclusive intellectual
property rights out of or in connection with the work research and development activities performed under such agreements. 

7.2 Development and Commercialization Licenses. 
 7.2.1 License to WCCI in the Field. Subject to the terms of this Agreement, including, without limitation, Sections 3.7 and 3.9 hereof, Paratek hereby grants (and hereby agrees to cause any
of its Affiliates that Controls Licensed Technology, Licensed Patent Rights and/or any interest in Joint Technology or Joint Patent Rights to grant) to WCCI (a) an exclusive (even as to Paratek and its Affiliates, except as provided below, and
subject to Section 3.7) royalty-bearing license, including the right to grant sublicenses as provided in Section 7.2.2 below, under Licensed Technology and Licensed Patent Rights and Paratek’s interest in Joint Technology and Joint
Patent Rights, (i) to research, have researched, Develop, have Developed, manufacture and have manufactured Lead Candidates and Backup Compounds that are not Abandoned Compounds in the Field and in the Territory in accordance with this
Agreement; and (ii) to research, have researched, Develop, have Developed, manufacture, have manufactured, use, have used, sell, distribute for sale, have distributed for sale, offer for sale, have sold, import, have imported, otherwise
Commercialize and otherwise have Commercialized Products in the Field and in the Territory and (b) an exclusive (even as to Paratek and its Affiliates) royalty-free license, including the right to grant sublicences as provided in
Section 7.2.2 below, to research, have researched, develop, have developed, manufacture and have manufactured Paratek Competitive Compounds in the Field and in the Territory. For the avoidance of doubt, Paratek grants no right or license under
the Licensed Technology or Licensed Patent Rights or Paratek’s interest in Joint Technology and Joint Patent Rights to WCCI or its Affiliates to make derivatives of any Backup Compounds, or to commercialize such derivatives, unless any such
derivatives become Lead Candidates and/or unless any such derivative would be deemed to have been Derived from a Product for purposes of Section 1.62. WCCI hereby grants Paratek a non-exclusive,
worldwide, royalty-free license under the Licensed Technology and Licensed Patent Rights and Paratek’s interest in Joint Technology and Joint Patent Rights solely to perform its obligations under the Backup Compound Research Program, if any,
and/or to conduct the Paratek Development activities set forth in the Development Plan with respect to Lead Candidates, if any. 

  
 25 

Portions of this Exhibit, indicated by the mark “[***],” were omitted and have been filed separately with the Secretary of the Commission
pursuant to the Registrant’s application requesting confidential treatment pursuant to Rule 406 of the Securities Act of 1933, as amended. 

 7.2.2 Right to Sublicense. Subject to the provisions of Sections 7.2.1 and
2.3(e) of the Tufts License Agreement, if and to the extent applicable, WCCI shall have the right to (a) extend to its Affiliates, the rights and licenses granted to it under Section 7.2.1 and (ii) grant to Third Parties sublicenses
under the rights and licenses granted to it under Section 7.2.1; provided, that, (A) WCCI shall have obtained the prior written approval of Paratek, which approval shall not be unreasonably withheld, delayed or conditioned; (B) it
shall be a condition of any such extension or sublicense that such Affiliate or Third Party agrees to be bound by all of the applicable terms and conditions of this Agreement (including without limitation Article 6 hereof) and (C) WCCI shall
provide written notice to Paratek of any such extension or sublicense no more than thirty (30) days after such execution, and upon Paratek’s request, provide copies to Paratek of each such executed extension or sublicense. If WCCI, or a
Sublicensee, grants a sublicense to a Sublicensee or extends rights to its Affiliates, WCCI shall be deemed to have guaranteed that such Sublicensee or Affiliate will fulfill all of obligations under this Agreement applicable to such Affiliate or
Sublicensee; provided, however, that WCCI shall not be relieved of its obligations pursuant to this Agreement as a result of such sublicense or extension of rights. 
 7.2.3 License to Paratek Outside the Territory. Upon the request of Paratek, the Parties agree to enter into good faith negotiations with respect to the terms of a license agreement
containing royalty provisions and other customary terms, pursuant to which WCCI and its Affiliates would grant to Paratek an exclusive license (even as to WCCI and its Affiliates) (including the right to grant sublicenses, under WCCI Technology
(including, without limitation, all Clinical Trial Data) and WCCI Patent Rights and WCCI’s interest in Joint Technology and Joint Patent Rights, to research, have researched, Develop, have Developed, manufacture, have manufactured, use, have
used, sell, distribute for sale, have distributed for sale, offer for sale, have sold, import, have imported, otherwise Commercialize and otherwise have Commercialized Products, for any and all uses (including, without limitation any and all uses
within the Field) outside the Territory, it being understood that Paratek will covenant in any such license agreement to use Commercially Reasonable Efforts to prevent any such Products from being imported into the Territory for resale by any Third
Party without WCCI’s prior written consent. WCCI shall cause its Affiliates not to grant any rights (whether by license or otherwise) to any Third Party, or otherwise to take any other action, that would impair or adversely affect the ability
of such Affiliates to grant to Paratek a license in accordance with this Section 7.2.3. 
 7.2.4 Bankruptcy.
All the negative covenants set forth in Sections 3.8 and 7.1 hereof and the licenses and rights to licenses granted under or pursuant to Section 7.2 hereof by Paratek to WCCI or by WCCI to Paratek are, and shall otherwise be deemed to be, for
purposes of Section 365(n) of the United States Bankruptcy Code (the “Code”), and any such equivalent law in the United States, licenses of rights to “intellectual property” as defined under Section 101(35A) of the
Code. The Parties agree that WCCI or Paratek, as a covenantee and licensee of such rights under this Agreement, shall retain and may fully exercise all of its rights and elections under the Code, and any such equivalent law, and that upon
commencement of a bankruptcy proceeding by or against Paratek or WCCI, as the case may be, under the Code, WCCI or Paratek, as applicable, shall be entitled to a complete duplicate of or complete access to, any such intellectual property and all
embodiments of such intellectual property. Such intellectual property and all embodiments thereof shall be promptly delivered to WCCI (i) upon any such commencement of a bankruptcy proceeding upon written request therefor by WCCI,

  
 26 

Portions of this Exhibit, indicated by the mark “[***],” were omitted and have been filed separately with the Secretary of the Commission
pursuant to the Registrant’s application requesting confidential treatment pursuant to Rule 406 of the Securities Act of 1933, as amended. 

 
unless Paratek (or the bankruptcy trustee) elects to continue to perform all of its obligations under this Agreement or (ii) if not delivered under (i) above, upon the rejection of this
Agreement by or on behalf of WCCI upon written request therefor. The foregoing is without prejudice to any rights WCCI may have arising under the Code or other Applicable Law. 
 7.3 Tufts License Agreement. Paratek entered into the Tufts License Agreement with the Trustees of Tufts College (“Tufts”) that may cover intellectual property rights that are
inter alia claiming methods of synthesis for Lead Candidates. Paratek hereby grants to WCCI an exclusive royalty-free sublicense under the license granted to Paratek pursuant to the Tufts License Agreement solely to the extent such sublicense is
required by WCCI in order to exercise the license granted to WCCI pursuant to Section 7.2 of this Agreement, without infringing any of the patent rights licensed to Paratek by Tufts. Without limiting the generality of the foregoing, WCCI and
Paratek hereby acknowledge and agree that the provisions of Sections 3.8, 3.9, 3.10, 7.1, 8.1, 8.5 and 9.3 and Articles V, XI, and XII of the Tufts License Agreement shall be binding upon WCCI, as a sublicensee under the Tufts License Agreement and
such provisions shall be fully enforceable for all purposes related thereto both by Tufts and Paratek. Paratek shall be responsible for any and all payments and royalties due to Tufts under the Tufts License Agreement. Paratek shall perform all of
its obligations under the Tufts License Agreement in accordance with the terms therein, and shall not take any action that would cause or result in the termination of the Tufts License Agreement. Paratek shall not amend, modify, or enter into any
agreement contemplating the amendment or modification, of the Tufts License Agreement if such amendment or modification would adversely affect WCCI’s rights under this Agreement. Notwithstanding anything to the contrary in this Agreement, WCCI
agrees that it shall not use the name “Tufts University” or any variant thereof, or identify Tufts or any portion of Tufts as a beneficiary of this Agreement without the prior express written consent of Tufts, which may be withheld or
withdrawn by Tufts in its complete and uncontrolled discretion. 
 7.4 No Other Rights. WCCI shall receive no
rights to utilize Paratek Technology, or rights with respect to use of Paratek Technology, except as expressly set forth herein. Paratek shall receive no rights to utilize WCCI Technology, or rights with respect to use of WCCI Technology, except as
expressly set forth herein. 
 7.5 Payment of Royalties; Royalty Rates; Accounting and Records. 

7.5.1 Payment of Royalties on Products. In further consideration of the grant of the rights and licenses by Paratek
hereunder, WCCI shall pay Paratek a royalty based on aggregate Annual Net Sales of all Products sold by WCCI, its Affiliates and its Sublicensees, at the following incremental rates: 

 

					
	 Annual Net Sales
	  	Royalty Rate	 
	 Annual Net Sales up to $[***]
	  	 	[***	]% 
		
	 Portion of Annual Net Sales above $[***] and up to $[***]
	  	 	[***	]% 
		
	 Portion of Annual Net Sales above $[***]
	  	 	[***	]% 

  
 27 

Portions of this Exhibit, indicated by the mark “[***],” were omitted and have been filed separately with the Secretary of the Commission
pursuant to the Registrant’s application requesting confidential treatment pursuant to Rule 406 of the Securities Act of 1933, as amended. 

 7.5.2 Know-How Royalty Rates. If a
Product is not covered by a Valid Patent Claim in the Territory, WCCI shall pay Paratek royalties at [***] percent ([***]%) of the applicable rates specified in Section 7.5.1 until expiration of the Royalty Term applicable to such Product. The
Parties hereby acknowledge and agree that royalties that are payable for a Product during the Royalty Term for which no Patent Rights exist shall be in consideration of (a) Paratek’s expertise and
know-how concerning the research, manufacture and Development of Compounds in the Field, including development activities conducted prior to the Effective Date; (b) the disclosure by Paratek to WCCI of
results obtained in by Paratek in it performance of activities with respect to the Development; and (c) the licenses granted to WCCI hereunder with respect to Licensed Technology and Joint Technology that are not within the claims of any Patent
Rights Controlled by Paratek. 
 7.5.3 Royalty Term. WCCI shall pay royalties with respect to each Product on a Product-by-Product basis during the period (such period, the “Royalty Term”) commencing on the date of First Commercial Sale of such Product in the Territory and
continuing for so long as Products are sold in the Territory until the later of the date on which (a) there is no Valid Claim that is included in the Licensed Patent Rights or Joint Patent Rights that cover such Product in the Territory and
(b) sales of Generic Products by any Third Party in the Territory are equal to at least [***] percent ([***]%) of WCCI’s unit-based market share of the Product in the Territory (as measured by prescriptions or other similar information
available in the Territory). For purposes of this Section 7.5.3, a “Generic Product” means a pharmaceutical product that contains the same active ingredient as a Product and that is an AB Rated equivalent (as defined in the 22nd
edition of Approved Drug Products with Therapeutic Equivalence Evaluations issued by the United States Department of Health and Human Services) to the Product. 
 7.5.4 Payment Dates and Reports. The royalty payments shall be paid by WCCI within forty-five (45) days after the end of each Calendar Quarter in which such Net Sales are made and
royalties are owed hereunder. Each such payment shall be made in United States Dollars and shall be accompanied by a report showing the Net Sales of each Product sold by WCCI, any WCCI Affiliate or any Sublicensee, in the Territory, the applicable
royalty rate for such Product, and a calculation of the amount of royalty. 
 7.5.5 Records; Audit Rights. WCCI
and its Affiliates and Sublicensees shall keep for three (3) years from the date of each payment of royalties complete and accurate records of sales by WCCI and its Affiliates and Sublicensees of each Product, in sufficient detail to allow the
accruing royalties to be determined accurately. Paratek shall have the right for a period of three (3) years after receiving any such report or statement to appoint at its expense an independent certified public accountant (bound by written
confidentiality obligations no less protective than those set forth in Article 6 hereof) reasonably acceptable to WCCI to inspect the relevant records of WCCI and its Affiliates and Sublicensees to verify such report or statement. WCCI and its
Affiliates and Sublicensees shall each make its records available for inspection by such independent certified public accountant during their regular business hours at such place or places where such records are customarily kept, upon reasonable
notice from Paratek, solely to verify the accuracy of the reports and payments. Such inspection right shall not be exercised by Paratek more than once in any Calendar Year nor more than once with respect to sales of any Product in any given period.
Paratek agrees to hold in strict confidence, and in accordance with 

  
 28 

Portions of this Exhibit, indicated by the mark “[***],” were omitted and have been filed separately with the Secretary of the Commission
pursuant to the Registrant’s application requesting confidential treatment pursuant to Rule 406 of the Securities Act of 1933, as amended. 

 
Article 6 hereof, all information concerning such payments and reports, and all information learned in the course of any audit or inspection, except to the extent necessary for Paratek to reveal
such information in order to enforce its rights under this Agreement or if disclosure is required by law. The results of each inspection, if any, shall be binding on both Parties, absent manifest error. Paratek shall pay for such inspections, except
that in the event there is any upward adjustment in the aggregate royalties, payable for any Calendar Year shown by such inspection of more than five percent (5%) of the amount paid, WCCI shall pay for the reasonable costs of such inspection.

 7.5.6 Overdue Royalties. All royalties payments not paid within the time period set forth in this Article 7
shall bear interest at a rate of one percent (1%) per month from the due date until paid in full; provided, that, in no event shall such annual rate exceed the maximum interest rate permitted by law in regard to such payments. Such royalty or
milestone payment when made shall be accompanied by all interest so accrued. 
 7.5.7 Withholding Taxes. All
payments made or required to be made by WCCI hereunder shall be reduced by the amount of any taxes (including withholding taxes to the extent applicable), duties, levies, fees or charges imposed thereon, provided, that, WCCI complies with its
obligations set forth below in this Section 7.5.7 prior to making any payment to Paratek hereunder. WCCI shall make (or cause to be made) any applicable withholding payments due on behalf of Paratek and shall promptly provide (or cause to be
provided) Paratek with written documentation of any such payment sufficient to satisfy the requirements of the United States Internal Revenue Service relating to an application by Paratek for a foreign tax credit for such payment. 

ARTICLE 8: INTELLECTUAL PROPERTY RIGHTS 
 8.1 Disclosure of Program Inventions. Each Party shall promptly provide the other Party with written notice concerning all Program Inventions that are conceived, made or developed by
employees or consultants of either of them or their Affiliates, alone or jointly with employees or consultants of the other Party or its Affiliates. 
 8.2 Ownership. 
 8.2.1 Paratek Intellectual Property
Rights. Paratek shall have sole and exclusive ownership of all right, title and interest on a worldwide basis in and to any and all Paratek Technology and Paratek Patent Rights, with full rights to license or sublicense, subject to the
obligations and licenses to WCCI as set forth herein. Without limiting the foregoing and subject to the licenses and other rights granted to WCCI pursuant to this Agreement, Paratek shall be the sole owner of all Patent Rights, all trade secret
rights, all know-how and any other intellectual property rights in the Paratek Technology, including the sole and exclusive right to exclude others from making, using, selling, offering for sale or importing
the Paratek Technology or any products that consist of, or incorporate, any Paratek Technology. 
 8.2.2 WCCI Intellectual
Property Rights. WCCI shall have sole and exclusive ownership of all right, title and interest on a worldwide basis in and to any and all WCCI 

  
 29 

Portions of this Exhibit, indicated by the mark “[***],” were omitted and have been filed separately with the Secretary of the Commission
pursuant to the Registrant’s application requesting confidential treatment pursuant to Rule 406 of the Securities Act of 1933, as amended. 

 
Technology and WCCI Patent Rights, with full rights to license or sublicense, subject to the obligations and licenses to Paratek as set forth herein. Without limiting the foregoing, and subject
to the licenses and other rights granted to Paratek pursuant to this Agreement, WCCI shall be the sole owner of all Patent Rights, all trade secret rights, all know-how and any other intellectual property
rights in the WCCI Technology including the sole and exclusive right to exclude others from making, using, selling, offering for sale or importing the WCCI Technology or any products that consist of, or incorporate, any WCCI Program Technology.

 8.2.3 Joint Technology Rights. WCCI and Paratek shall jointly own all Joint Technology and Joint Patent Rights
and hereby agree that (a) subject to the rights of, and the licenses granted to, WCCI by Paratek under this Agreement (including, without limitation, under Section 7.2 hereof) and subject to the obligations of Paratek under this Agreement
(including, without limitation, Sections 3.8 and 7.1.1 hereof), Paratek may use or license or sublicense to any Affiliate or Third Party all such Joint Technology and Joint Patent Rights, and (ii) WCCI may use or license or sublicense to any
Affiliate or Third Party all such Joint Technology and Joint Patent Rights. 
 8.3 Patent Coordinators. Within
thirty (30) days of the Effective Date, Paratek and WCCI shall each appoint a patent coordinator (each, a “Patent Coordinator” and collectively, the “Patent Coordinators”), reasonably acceptable to the other Party, who shall
serve as such Party’s primary liaison with the other Party on matters relating to patent filing, prosecution, maintenance and enforcement. Each Party may replace its Patent Coordinator at any time by notice in writing to the other Party.

 8.4 Inventorship. In case of a dispute between Paratek and WCCI over inventorship, the Parties, with the advice
of the Patent Coordinators, shall make the determination of the inventor(s) by application of the standards contained in United States patent law. If the Parties cannot resolve the dispute, it shall be resolved by independent patent counsel, not
otherwise engaged by either of the Parties or any of their respective Affiliates, selected by the Patent Coordinators. Expenses of such independent patent counsel shall be shared equally by the Parties. 

ARTICLE 9: FILING, PROSECUTION AND MAINTENANCE OF PATENT RIGHTS 

9.1 Patent Filing, Prosecution and Maintenance. The JSC shall determine the jurisdictions within the Territory in which
patent applications will be filed with respect to Joint Patent Rights. Subject to the foregoing, the responsibility for filing, prosecution and maintaining Patent Rights shall be as follows: 

9.1.1 Patent Filing. During the Term and thereafter during any period of time during which WCCI shall have a license under
this Agreement to Paratek Patent Rights or to Joint Patent Rights, with respect to any Patent Rights arising hereunder: 
 (a)
Paratek, at its sole expense and acting through patent attorneys or agents of its choice, shall be responsible for the preparation, filing, prosecution and maintenance of all Patent Rights relating to the Paratek Technology. At Paratek’s
request, WCCI shall reasonably cooperate with and assist Paratek, at Paratek’s expense, in connection with such activities. 

  
 30 

Portions of this Exhibit, indicated by the mark “[***],” were omitted and have been filed separately with the Secretary of the Commission
pursuant to the Registrant’s application requesting confidential treatment pursuant to Rule 406 of the Securities Act of 1933, as amended. 

 (b) WCCI, at its sole expense and acting through patent attorneys or agents of its choice,
shall be responsible for the preparation, filing, prosecution and maintenance of all Patent Rights relating to the WCCI Technology. At WCCI’s request, Paratek shall reasonably cooperate with and assist WCCI, at WCCI’s expense, in
connection with such activities. 
 (c) Except as expressly provided in Article 11 hereof, neither Party makes any warranty
with respect to the validity, perfection or dominance of any patent or other proprietary right or with respect to the absence of rights in Third Parties which may be infringed by the manufacture or sale of any Product. Each Party agrees to bring to
the attention of the other Party any patent or patent application it discovers applicable to the subject matter of this Agreement, which relates to the rights of either Party under this Agreement. 

(d) Unless the Parties otherwise agree, (i) Paratek, acting through patent counsel or agents of its choice, shall be responsible
for the preparation, filing, prosecution and maintenance of Joint Patent Rights outside of the Territory; and (ii) WCCI, acting through patent counsel or agents of its choice, shall be responsible for the preparation, filing, prosecution and
maintenance of Joint Patent Rights within the Territory. The Parties shall share equally the control and the fees of counsel and the other costs and expenses related to patents and patent applications claiming inventions that are Joint Technology.
Should one Party desire not to share in the control, filing, prosecution or maintenance of any such patent or patent applications or shall fail to bear its share of the costs and expenses of filing, prosecuting or maintaining any such patent or
patent applications (and, in the case of such failure, if such failure is not cured within thirty (30) days after receipt of written notice of such failure from the participating Party), the
non-participating Party hereby assigns (or shall cause to be assigned) to the other Party all right, title and interest in and to such patent or patent application, and the Joint Technology claimed therein,
and the participating Party shall gain sole control of the filing, prosecution or maintenance of such patents or patent applications, which shall be deemed to be the Technology of such participating Party. 

9.1.2 Information and Cooperation. Each Party responsible for filing patents and any Patent Rights (other than with respect
to WCCI Technology) described in this Agreement (the “Filing Party”) shall keep the other Party regularly informed of the status of the Patent Rights for which it is responsible in accordance with this Article 9 (other than with respect to
WCCI Technology). The Filing Party shall provide the other Party with (a) copies of all filings and correspondence with the patent offices, administrative boards or courts which the Filing Party sends or receives in connection with filing,
prosecution, maintenance and defense of the Patent Rights for which it is responsible (other than with respect to WCCI Technology), and (b) copies of filings and correspondence referred to in the foregoing clause (a) sufficiently in
advance of the due date so as to give the other Party sufficient time to comment and shall give good faith consideration to the other Party’s comments. The Filing Party shall seek the advice of the other Party with respect to strategy for the
Patent Rights for which it is responsible (other than with respect to WCCI Technology) and shall give reasonable consideration to any suggestions or recommendations of the other Party concerning the preparation, filing, prosecution, maintenance and
defense of such Patent Rights. 

  
 31 

Portions of this Exhibit, indicated by the mark “[***],” were omitted and have been filed separately with the Secretary of the Commission
pursuant to the Registrant’s application requesting confidential treatment pursuant to Rule 406 of the Securities Act of 1933, as amended. 

 9.1.3 Abandonment. If Paratek decides to abandon or to allow to lapse any of
the Paratek Patent Rights in the Territory, Paratek shall inform WCCI of such decision promptly and, in any event, a reasonable amount of time prior to any applicable deadline that may be necessary to establish or preserve such Paratek Patent
Rights. WCCI shall have the right to assume responsibility for continuing the prosecution of such Paratek Patent Rights and paying any required fees to maintain such Paratek Patent Rights in the Territory or defending such Paratek Patent Rights, in
each case at WCCI’s sole expense and through patent counsel of its choice. WCCI shall not become an assignee of such Paratek Patent Rights as a result of its assumption of such responsibility under this Section 9.1.3 and such Paratek
Patent Rights shall remain subject to this Agreement. Upon transfer of Paratek’s responsibility for prosecuting, maintaining and defending any of the Paratek Patent Rights to WCCI under this Section 9.1.3, Paratek shall promptly deliver to
WCCI copies of all necessary files related to the Paratek Patent Rights with respect to which responsibility has been transferred and shall take all actions and execute all documents reasonably necessary for WCCI to assume such prosecution,
maintenance and defense. 
 9.2 Legal Action. 

9.2.1 Actual or Threatened Infringement. 
 (a) In the event either Party or any of such Party’s Affiliates becomes aware of any possible infringement or unauthorized possession, knowledge or use of any Technology that is the subject matter of
this Agreement, including any Joint Technology, in connection with the discovery, research, development, manufacture, use, sale import or commercialization of (i) a Paratek Compound in the Field, or (ii) a Lead Candidate or Product within
or outside of the Field (collectively, an “Infringement”), that Party shall promptly notify the other Party and provide it with full details (an “Infringement Notice”). 

(b) WCCI shall have the first right and option, but not the obligation, to prosecute or prevent an Infringement as WCCI will consider
appropriate. If WCCI does not commence an action to prosecute, or otherwise take steps to prevent or terminate the Infringement within one hundred eighty (180) days from any Infringement Notice, then, except with respect to WCCI Technology,
Paratek shall have the right and option to take such action as Paratek will consider appropriate to prosecute or prevent such Infringement unless (i) the Infringement is a Tufts IP Infringement, in which case Tufts shall have the right and
option to take such action as Tufts will consider appropriate to prosecute or prevent such Infringement or (ii) the provisions of Section 9.2.1(c) below shall not permit Paratek to prosecute or prevent such Infringement. Any and all
recoveries from any action for infringement shall be shared as follows: (1) if such Infringement is a Tufts IP Infringement and WCCI is prosecuting such action for Infringement, Tufts shall be paid [***] percent ([***]%) of any and all such
recoveries, net of costs incurred by WCCI for prosecuting the action, and WCCI shall retain the remaining balance and such remaining balance (net of costs incurred by WCCI for prosecuting the action) shall be treated as Net Sales, subject to the
payment of royalties to Paratek in accordance with this 

  
 32 

Portions of this Exhibit, indicated by the mark “[***],” were omitted and have been filed separately with the Secretary of the Commission
pursuant to the Registrant’s application requesting confidential treatment pursuant to Rule 406 of the Securities Act of 1933, as amended. 

 
Agreement; (2) if such Infringement is a Tufts IP Infringement and Paratek is prosecuting such action for Infringement, Tufts shall be paid [***] percent ([***]%) of any and all such
recoveries, net of costs incurred by Paratek for prosecuting the action, and the net balance remaining (net of costs incurred by Paratek for prosecuting the action) shall be retained by Paratek and [***] between Paratek and WCCI, respectively;
(3) if such Infringement is a Tufts IP Infringement and Tufts is prosecuting such action for Infringement, Tufts shall be entitled to retain from such recoveries an amount equal to the costs incurred by Tufts in prosecuting such action plus
[***] percent ([***]%) of the remaining balance, and the balance remaining after payment of all amounts due to Tufts shall be retained by WCCI and treated as Net Sales; (4) if such Infringement is not a Tufts IP Infringement and WCCI is
prosecuting such action for Infringement, such recoveries shall be allocated first, to reimburse WCCI and Paratek for their reasonable out-of-pocket expenses in making
such recovery (which amounts shall be allocated pro rata if insufficient to cover the totality of such expenses) and then WCCI shall treat and all such recoveries as Net Sales for purposes of this Agreement, subject to the payment of royalties to
Paratek in accordance with this Agreement; and (5) if such Infringement is not a Tufts IP Infringement and Paratek is prosecuting such action for Infringement, such recoveries shall be allocated first, to reimburse WCCI and Paratek for their
reasonable out-of-pocket expenses in making such recovery (which amounts shall be allocated pro rata if insufficient to cover the totality of such expenses) and the
balance shall be [***] between Paratek and WCCI, respectively. If either of WCCI or Paratek determines that it is necessary for the other Party or any of its Affiliates to join any such suit, action or proceeding, the necessary Party shall, upon
written notice from the prosecuting Party, execute (or cause to be executed) all papers and perform such other acts as may be reasonably required in the circumstances; provided, however, neither Party nor such Party’s Affiliates shall be
required to transfer any right, title or interest in or to any property to any other Party or any Third Party to confer standing on a Party hereunder. 
 (c) Notwithstanding anything in Section 9.2.1(b) express or implied to the contrary, but subject to the provisions of Section 10.2.5(b)(iii), in no event shall Paratek have the right to
prosecute or prevent the Infringement of or relating to (i) WCCI Patent Rights or WCCI Technology or (ii) Paratek Patent Rights, Joint Patent Rights, Paratek Technology or Joint Technology to the extent they pertain solely to Products,
Lead Candidates or rights that have been licensed exclusively to WCCI pursuant to Section 7.2.1. Nothing in this Section 9.2.1(c) is intended to limit the rights of Tufts under the Tufts License Agreement and WCCI hereby acknowledges that
Tufts may have the right under the Tufts License Agreement to prosecute or prevent an Infringement that Paratek does not have the right to prosecute or prevent by virtue of the provisions of this Section 9.2.1(c). 

(d) In any action under this Section 9.2.1, the Parties and their respective Affiliates shall fully cooperate with and assist each
other. No suit under this Section 9.2.1 may be settled without the approval of the JSC provided, however, any settlement by which Tufts would incur any obligation or liability, whether for the payment of money, the taking of any action, the
refraining from any action, or otherwise, shall require the advance written consent of Tufts, which may be withheld in the sole discretion of Tufts without relieving WCCI or Paratek, as the case may be, of any of its indemnification or other
obligations hereunder to Tufts. 

  
 33 

Portions of this Exhibit, indicated by the mark “[***],” were omitted and have been filed separately with the Secretary of the Commission
pursuant to the Registrant’s application requesting confidential treatment pursuant to Rule 406 of the Securities Act of 1933, as amended. 

 9.2.2 Defense of Claims. 

(a) In the event that any action, suit or proceeding is brought against Paratek or WCCI or any Affiliate or sublicensee of either Party
alleging the infringement of the Technology or intellectual property rights of a Third Party by reason of the discovery, development, manufacture, use, sale, importation or offer for sale of a Product or use of WCCI Technology, Paratek Technology or
Joint Technology in the discovery, Development, Commercialization, manufacture, use, sale, offer for sale, or importation of a Product, then WCCI shall have the sole right and obligation to defend itself and Paratek in such action, suit or
proceeding at its sole expense, unless such action, suit or proceeding alleges that the infringement arises from or otherwise pertains to the use of Paratek Technology by Paratek or WCCI to synthesize, generate, make and develop Paratek Compounds,
Lead Candidates or Products in which case WCCI shall have the right (but not the obligation) to defend Paratek in such action, suit or proceeding at its sole expense. Paratek shall have the right to separate counsel at its own expense in any action,
suit or proceeding being defended by WCCI pursuant to this Section 9.2.2(a). The Parties and their respective Affiliates shall cooperate with each other in the defense of any such suit, action or proceeding. The Parties will give each other
prompt written notice of the commencement of any such suit, action or proceeding or claim of infringement and will furnish each other a copy of each communication relating to the alleged infringement. Neither Party nor such Party’s Affiliates
shall compromise, settle or otherwise dispose of any such suit, action or proceeding which involves the other’s Technology or Patent Rights without the other Party’s advice and prior consent if such compromise, settlement or other
disposition would impair any rights retained by such other Party or any of its Affiliates to use such Technology or Patent Rights, provided that the Party not defending the suit shall not unreasonably withhold its consent to any settlement. If the
defending Party agrees that the other Party or any of its Affiliates should institute or join any suit, action or proceeding pursuant to this Section 9.2.2(a), the defending Party may at its expense, join the other Party or any of its
Affiliates as a party to the suit, action or proceeding, and the Party or Affiliate so joined shall execute all documents and take all other actions, including giving testimony, which may reasonably be required in connection with the prosecution of
such suit, action or proceeding. 
 (b) To the extent that the allegation of infringement is based principally on the use of
Joint Technology, such expenses shall be borne equally by the Parties. 
 (c) If as a consequence of such action, suit or
proceeding by a Third Party claiming that the discovery, development, manufacture, use or sale of a Product infringes such Third Party’s intellectual property rights, the Parties shall examine and discuss in good faith the consequences of such
prohibition or restriction or other conditions on this Agreement and on possible modifications thereto; provided, however, no action will be taken without the agreement of both Parties. 

ARTICLE 10: TERMINATION 
 10.1 Term. This Agreement shall commence on the Effective Date and shall continue until terminated in accordance with the provisions of this Article 10 (the “Term”). 

  
 34 

Portions of this Exhibit, indicated by the mark “[***],” were omitted and have been filed separately with the Secretary of the Commission
pursuant to the Registrant’s application requesting confidential treatment pursuant to Rule 406 of the Securities Act of 1933, as amended. 

 10.2 Termination. This Agreement may be terminated at any time by either Party
as follows: 
 10.2.1 Unilateral Right to Terminate During the Term. WCCI may terminate this Agreement for
convenience effective on the last day of each of the first and second Contract Year, provided that WCCI delivers written notice of termination to Paratek at least ninety (90) days prior to such effective date of termination. 

10.2.2 Unilateral Right to Terminate After the Term. If at any time on and after the date on which WCCI has commenced
Development of a Product (a) WCCI reasonably determines that (i) it would not be commercially viable to continue to Develop and Commercialize such Product and/or obtain Commercialization Regulatory Approval with respect to such Product and
(ii) WCCI is unlikely or unable to obtain Commercialization Regulatory Approval with respect to such Product (each, a “Termination Event”), (b) no Backup Compound is ready to be Developed by WCCI and (c) the Parties have not
agreed to extend the Development Plan to conduct Development activities with respect to such Backup Compound pursuant to Section 3.5, WCCI shall provide the JSC with written notice which shall describe the Termination Event in reasonable
detail. The JSC shall meet as soon as practicable thereafter to determine the additional actions, if any, to be undertaken by the Parties to fulfill the purposes of this Agreement. If the JSC fails to meet or the Parties are otherwise unable to
agree upon any such course of action within ninety (90) days of the date of WCCI’s Termination Event notice, then either Party shall have the right to terminate this Agreement by providing written notice of termination within ten
(10) days after the expiration of such 90-day period. 
 10.2.3 Termination
for Breach. In the event that either Party defaults or breaches any material term of this Agreement on its part to be performed or observed, the other Party shall have the right to terminate this Agreement (a) by giving thirty
(30) days’ written notice to the defaulting Party in the case of a breach of any payment term of this Agreement and (b) by giving sixty (60) days’ written notice to the defaulting Party in the case of any other breach;
provided, however, that in the case of a default or breach capable of being cured, if the said defaulting Party shall cure the said default or breach within such notice period after the said notice shall have been given, then the said notice shall
not be effective; and provided, further that the provisions of this Section 10.2.3 shall not apply to any material breach of this Agreement arising from a WCCI Diligence Failure (it being understood that Paratek’s sole and exclusive
remedies upon any material breach of this Agreement arising from a WCCI Diligence Failure are set forth in Sections 3.9.3). 

10.2.4 Termination for Insolvency. In the event that either Party files for protection under bankruptcy laws, makes an
assignment for the benefit of creditors, appoints or suffers appointment of a receiver or trustee over its property, files a petition under any bankruptcy or insolvency act of has any such petition filed against it which is not discharged within
sixty (60) days of the filing thereof, then the other Party may terminate this Agreement effective immediately upon written notice to such Party. 
 10.2.5 Consequences of Terminations Under Section 10.2.1. In the event of the termination of this Agreement by WCCI pursuant to Section 10.2.1: 

(a) all rights and licenses granted by one Party to the other hereunder shall immediately terminate; 

  
 35 

Portions of this Exhibit, indicated by the mark “[***],” were omitted and have been filed separately with the Secretary of the Commission
pursuant to the Registrant’s application requesting confidential treatment pursuant to Rule 406 of the Securities Act of 1933, as amended. 

 (b) each Party shall within thirty (30) days of the termination date, destroy, or at
the other Party’s request return, all of such other Party’s Confidential Information (other than with respect to maintaining one (1) archival copy of such Confidential Information related thereto for its legal files, for the sole
purpose of determining its obligations under this Agreement) and shall provide such Party with certification that all such Confidential Information have been destroyed or returned to such Party as appropriate; 

(c) the rights and obligations of the Parties and their respective Affiliates provided in Sections 3.11, 7.5.5, 10.2.5, 10.2.8, 12.1,
12.2, 12.3, 12.4, 12.5, 12.6, 12.7 and 14.2 and Articles 1 and 6 hereof shall survive such termination; and 
 (d) except as
expressly set forth in this Section 10.2.5 and Section 10.2.8 hereof, all other rights and obligations under this Agreement shall terminate. 
 10.2.6 Consequences of Terminations Under Sections 10.2.2. In the event of the termination of this Agreement by either Party pursuant to Sections 10.2.2: 

(a) The licenses granted to WCCI and its Affiliates pursuant to Section 7.2.1 and 7.2.2 hereof and the restrictions on Paratek and
its Affiliates pursuant to Sections 3.8 and 7.1.1 shall immediately terminate. 
 (b) WCCI shall be deemed to have granted to
Paratek, as of the date of termination, an exclusive (even as to WCCI), worldwide, royalty-free license, with the right to sublicense, in the Field under the WCCI Program Technology, the WCCI Patent Rights as they pertain to WCCI Program Technology,
WCCI’s interest in Joint Technology and Joint Patent Rights, and the Product Trademarks to develop, have developed, commercialize, make, have made, use, sell, have sold, offer for sale, distribute for sale, import and have imported those Lead
Candidates and Products being Developed or Commercialized by WCCI as of the date of termination. 
 (c) Each Party shall within
thirty (30) days of the termination date, destroy, or at the other Party’s request return, all of such other Party’s Confidential Information (other than with respect to maintaining one (1) archival copy of such Confidential
Information related thereto for its legal files, for the sole purpose of determining its obligations under this Agreement) and shall provide such other Party with certification that all such Confidential Information have been destroyed or returned
to such other Party as appropriate. 
 (d) WCCI shall, within thirty (30) days of the termination date, at the request of
Paratek, assign (if assignable under its terms) to Paratek for no additional consideration (other than Paratek’s assumption of WCCI’s obligations) all of WCCI’s rights and obligations under any then-existing agreement with any Third
Party that contains any sublicense to such Third Party of any of the rights licensed by Paratek to WCCI pursuant to this Agreement. Paratek shall indemnify and hold harmless WCCI against any and all Third Party claims, damages, losses, liabilities,
costs and expenses arising out of events occurring after the assignment incurred or suffered by WCCI in connection with any such agreement assigned to Paratek pursuant to this Section 10.2.6(d) or in connection with any dispute between such
Third Party and Paratek as a result of any action taken or not taken by Paratek. 

  
 36 

Portions of this Exhibit, indicated by the mark “[***],” were omitted and have been filed separately with the Secretary of the Commission
pursuant to the Registrant’s application requesting confidential treatment pursuant to Rule 406 of the Securities Act of 1933, as amended. 

 (e) If WCCI is manufacturing, or having manufactured, Lead Candidates or Products on the
date of termination, (1) WCCI shall supply, or have supplied, Paratek with those of such Lead Candidates or Products, as applicable, that Paratek may reasonably request until the earlier of (A) the date on which Paratek or its designee
validates a manufacturing process for such Lead Candidates or Products, it being understood that Paratek shall use Commercially Reasonable Efforts to complete such validation as promptly as practicable and (B) the date that is thirty six
(36) months following such termination, pursuant to a transition plan to be agreed upon by the Parties promptly following such termination, (2) Paratek shall pay WCCI [***], for the supply of Lead Candidate or Product, as applicable and
(3) WCCI shall provide to Paratek or its designee all information in its possession with respect to the manufacture of Lead Candidate or Product, as applicable. Any and all costs and expenses that WCCI shall incur to Third Party contract
manufacturers as a result of complying with the provisions of this Section 10.2.6(e) shall be paid by Paratek. WCCI shall have no liability or otherwise be responsible for any action taken or not taken by any Third Party contract manufacturer
of WCCI or for any Lead Candidate or Products supplied by a Third Party pursuant to this Section 10.2.6(e). Paratek shall indemnify and hold harmless WCCI against any and all Third Party claims, damages, losses, liabilities, costs and expenses
incurred or suffered by WCCI in connection with Lead Candidates or Products supplied pursuant to this Section 10.2.6(e) or any action taken or not taken by Paratek in connection with such Lead Candidates or Products. 

(f) Unless prohibited by any Regulatory Authority or under Applicable Laws, WCCI shall promptly (A) transfer to Paratek all of its
right, title and interest in all Regulatory Filings and Regulatory Approvals then in its name for all Lead Candidates and Products identified as of the date of termination and all material aspects of Confidential Information Controlled by it as of
the date of termination relating to such Regulatory Filings and Regulatory Approvals, (B) notify the appropriate Regulatory Authorities and take any other action reasonably necessary to effect such transfer of ownership, (C) deliver to
Paratek all correspondence between WCCI and such Regulatory Authorities relating to such Regulatory Filings and Regulatory Approvals and (D) transfer control to Paratek of all clinical trials being conducted as of the date of termination which
relate to the Products and continue to conduct such trials until the earlier of (Y) completion of the transfer and (Z) six (6) months from the termination effective date. Any and all costs and expenses that WCCI shall incur to third
parties as a result of complying with the provisions of this Section 10.2.6(b)(vii) shall be paid by Paratek, and any and all internal costs and expenses that WCCI incurs in complying with its obligations under Clause D of this
Section 10.2.6(e) shall be paid by Paratek. WCCI shall have no liability or otherwise be responsible for clinical trials that WCCI continues to conduct pursuant to this Section 10.2.6(e), and Paratek shall indemnify and hold harmless WCCI
against any and all Third Party claims, damages, losses, liabilities, costs and expenses (“Trial Claims”) incurred or suffered by WCCI in connection with such clinical trial except to such extent the Trial Claims are attributable to
WCCI’s gross negligence or willful misconduct. 

  
 37 

Portions of this Exhibit, indicated by the mark “[***],” were omitted and have been filed separately with the Secretary of the Commission
pursuant to the Registrant’s application requesting confidential treatment pursuant to Rule 406 of the Securities Act of 1933, as amended. 

 (g) the rights and obligations of the Parties and their respective Affiliates provided in
Sections 3.11, 7.5.5, 10.2.6, 10.2.8, 12.1, 12.2, 12.3, 12.4, 12.5, 12.6, 12.7 and 14.2 and Articles 1 and 6 hereof shall survive such termination. 
 (h) Except as expressly set forth in this Section 10.2.6 and Section 10.2.8 hereof, all other rights and obligations under this Agreement shall terminate. 

10.2.7 Consequences of Terminations Under Sections 10.2.3 or 10.2.4. In the event of the termination of this Agreement by
either Party pursuant to Sections 10.2.3 or 10.2.4: 
 (a) If WCCI is the Party giving notice of termination, the following
shall apply: 
 (i) WCCI and its Affiliates shall continue to have the licenses granted pursuant to Section 7.2.1 hereof,
subject to its continued payment of the applicable milestone and royalty payments with respect thereto as set forth in Sections 5.3.1 and 7.5.1 hereof, and the restrictions on Paratek and its Affiliates pursuant to Sections 3.8 and 7.1 shall remain
in effect in accordance with the respective terms thereof; provided that if such termination is a result of a breach by Paratek of its obligations under Sections 3.8 or 7.1.1 then Paratek shall be deemed to have granted to WCCI as of such
termination date an exclusive, fully paid up, perpetual, royalty-free license pursuant to Section 7.2.1 without further obligation to continue to make any milestone or royalty payments hereunder; 

(ii) all rights and licenses granted to Paratek and its Affiliates by WCCI and its Affiliates pursuant to this Agreement shall
immediately terminate; 
 (iii) Paratek shall within thirty (30) days of the termination date, destroy, or at WCCI’s
request return, all of WCCI’s Confidential Information (other than with respect to maintaining one (1) archival copy of such Confidential Information related thereto for its legal files, for the sole purpose of determining its obligations
under this Agreement) and any Proprietary Materials of WCCI, and shall provide WCCI with certification by an officer of Paratek that all such Confidential Information and Proprietary Materials have been destroyed or returned to WCCI, as appropriate;

 (iv) the rights and obligations of the Parties and their respective Affiliates provided in Sections 3.11, 7.5.5, 10.2.7,
10.2.8 12.1, 12.2, 12.3, 12.4, 12.5, 12.6, 12.7 and 14.2 and Articles 1 and 6 hereof shall survive such termination; and 
 (v)
except as expressly set forth in this Section 10.2.7(a) and Section 10.2.8 hereof, all other rights and obligations under this Agreement shall terminate. 
 (b) If Paratek is the Party giving notice of termination, then the following shall apply: 
 (i) The licenses granted to WCCI and its Affiliates pursuant to Sections 7.2.1 and 7.3.1 hereof and the restrictions on Paratek and its Affiliates pursuant to Sections 3.6.3 and 7.1.1 shall immediately
terminate. 

  
 38 

Portions of this Exhibit, indicated by the mark “[***],” were omitted and have been filed separately with the Secretary of the Commission
pursuant to the Registrant’s application requesting confidential treatment pursuant to Rule 406 of the Securities Act of 1933, as amended. 

 (ii) WCCI shall be deemed to have granted to Paratek, as of the date of termination, an
exclusive (even as to WCCI), worldwide, royalty-free license, with the right to sublicense, in the Field under the WCCI Program Technology, the WCCI Patent Rights as they pertain to WCCI Program Technology, WCCI’s interest in Joint Technology
and Joint Patent Rights, and the Product Trademarks to develop, have developed, commercialize, make, have made, use, sell, have sold, offer for sale, distribute for sale, import and have imported those Lead Candidates and Products being Developed or
Commercialized by WCCI as of the date of termination. 
 (iii) Each Party shall within thirty (30) days of the termination
date, destroy, or at the other Party’s request return, all of such other Party’s Confidential Information (other than with respect to maintaining one (1) archival copy of such Confidential Information related thereto for its legal
files, for the sole purpose of determining its obligations under this Agreement), and shall provide such other Party with certification that all such Confidential Information have been destroyed or returned to such other Party as appropriate.

 (iv) WCCI shall, within thirty (30) days of the termination date, at the request of Paratek, assign (if assignable
under its terms) to Paratek for no additional consideration (other than Paratek’s assumption of WCCI’s obligations) all of WCCI’s rights and obligations under any then-existing agreement with any Third Party that contains any
sublicense to such Third Party of any of the rights licensed by Paratek to WCCI pursuant to this Agreement. Paratek shall indemnify and hold harmless WCCI against any and all Third Party claims, damages, losses, liabilities, costs and expenses
arising out of events occurring after the assignment incurred or suffered by WCCI in connection with any such agreement assigned to Paratek pursuant to this Section 10.2.7(b)(iv) or in connection with any dispute between such Third Party and
Paratek as a result of any action taken or not taken by Paratek. 
 (v) If WCCI is manufacturing, or having manufactured, Lead
Candidates or Products on the date of termination, (1) WCCI shall supply, or have supplied, Paratek with those of such Lead Candidates or Products, as applicable, that Paratek may reasonably request until the earlier of (A) the date on
which Paratek or its designee validates a manufacturing process for such Lead Candidates or Products, it being understood that Paratek shall use Commercially Reasonable Efforts to complete such validation as promptly as practicable and (B) the
date that is thirty six (36) months following such termination, pursuant to a transition plan to be agreed upon by the Parties promptly following such termination, (2) Paratek shall pay WCCI [***], for the supply of Lead Candidate or
Product, as applicable and (3) WCCI shall provide to Paratek or its designee all information in its possession with respect to the manufacture of Lead Candidate or Product, as applicable. Any and all costs and expenses that WCCI shall incur to
Third Party contract manufacturers as a result of complying with the provisions of this Section 10.2.7(b)(v) shall be paid by Paratek. WCCI shall have no liability or otherwise be responsible for any action taken or not taken by any Third Party
contract manufacturer of WCCI or for any Lead Candidate or Products supplied by a Third Party pursuant to this Section 10.2.7(b)(v). Paratek shall indemnify and hold harmless WCCI against any and all Third Party claims, damages, losses,
liabilities, costs and expenses incurred or suffered by WCCI in connection with Lead Candidates or Products supplied pursuant to this Section 10.2.7(b)(v) or any action taken or not taken by Paratek in connection with such Lead Candidates or
Products. 

  
 39 

Portions of this Exhibit, indicated by the mark “[***],” were omitted and have been filed separately with the Secretary of the Commission
pursuant to the Registrant’s application requesting confidential treatment pursuant to Rule 406 of the Securities Act of 1933, as amended. 

 (vi) Unless prohibited by any Regulatory Authority or under Applicable Laws, WCCI shall
promptly (A) transfer to Paratek all of its right, title and interest in all Regulatory Filings and Regulatory Approvals then in its name for all Lead Candidates and Products identified as of the date of termination and all material aspects of
Confidential Information Controlled by it as of the date of termination relating to such Regulatory Filings and Regulatory Approvals, (B) notify the appropriate Regulatory Authorities and take any other action reasonably necessary to effect
such transfer of ownership, (C) deliver to Paratek all correspondence between WCCI and such Regulatory Authorities relating to such Regulatory Filings and Regulatory Approvals and (D) transfer control to Paratek of all clinical trials
being conducted as of the date of termination which relate to the Products and continue to conduct such trials until the earlier of (Y) completion of the transfer and (Z) six (6) months from the termination effective date. Any and all
costs and expenses that WCCI shall incur to third parties as a result of complying with the provisions of this Section 10.2.7(b)(vii) shall be paid by Paratek, and any and all internal costs and expenses that WCCI incurs in complying with its
obligations under Clause D of this Section 10.2.7(b)(vii) shall be paid by Paratek. WCCI shall have no liability or otherwise be responsible for clinical trials that WCCI continues to conduct pursuant to this Section 10.2.7(b)(vii), and
Paratek shall indemnify and hold harmless WCCI against any and all Trial Claims incurred or suffered by WCCI in connection with such clinical trial except to such extent the Trial Claims are attributable to WCCI’s gross negligence or willful
misconduct. 
 (vii) the rights and obligations of the Parties and their respective Affiliates provided in Sections 3.11,
7.5.5, 10.2.7, 10.2.8, 12.1, 12.2, 12.3, 12.4, 12.5, 12.6, 12.7 and 14.2 and Articles 1 and 6 hereof shall survive such termination. 
 (viii) Except as expressly set forth in this Section 10.2.7(b) and Section 10.2.8 hereof, all other rights and obligations under this Agreement shall terminate. 

10.2.8 No Impairment of Accrued or Matured Claims. Termination or expiration of this Agreement for any reason shall be
without prejudice to any claim either Party may have against the other Party, either at law or in equity that was accrued or matured prior to such termination or expiration. 
 ARTICLE 11: REPRESENTATIONS AND WARRANTIES 
 11.1 Representations and
Warranties of Both Parties. Paratek and WCCI each represents and warrants to the other, as of the Effective Date, as follows: 
 11.2.3 Tufts License Agreement. As of the Effective Date, the Tufts License Agreement is in full force and effect and Paratek is not in breach or default in the performance of its
obligations under the Tufts License Agreement. To the knowledge of Paratek, there has been no breach, default or non-compliance of Paratek under the terms of the Tufts License Agreement. There have been no
amendments or other modification to the Tufts License Agreement, except as have been disclosed to WCCI in writing. Paratek has the requisite right under the Tufts License Agreement to grant to WCCI a sublicense of Paratek’s rights under the
Tufts License Agreement and to grant to WCCI the licenses under Section 7.3 of this Agreement with respect to all of the intellectual property rights of Tufts licensed to Paratek pursuant to the Tufts License Agreement. 

  
 40 

Portions of this Exhibit, indicated by the mark “[***],” were omitted and have been filed separately with the Secretary of the Commission
pursuant to the Registrant’s application requesting confidential treatment pursuant to Rule 406 of the Securities Act of 1933, as amended. 

 11.2.4 Litigation. As of the Effective Date, there is no litigation pending
or, to the knowledge of Paratek, threatened, against Paratek with respect to Paratek Patent Rights existing as of the Effective Date. 
 11.3 Additional Representations and Warranties of WCCI. WCCI represents and warrants to Paratek as follows: 
 11.3.1 No Infringement. As of the Effective Date, to the knowledge of WCCI, the use of WCCI Technology in connection with the Backup Compound Research Program and in the manner contemplated
under this Agreement does not infringe the intellectual property rights of any Third Party. 
 11.3.2 Litigation.
As of the Effective Date, there is no litigation pending or, to the knowledge of WCCI, threatened, against WCCI with respect to WCCI Patent Rights existing as of the Effective Date that WCCI uses in the conduct of the Development. 

ARTICLE 12: INDEMNIFICATION 
 12.1 Indemnification of WCCI by Paratek. Subject to the provisions of this Article 12, Paratek shall indemnify, defend and hold harmless WCCI and its Affiliates and their respective
directors, officers, employees, and agents and their respective successors, heirs and assigns (the “WCCI Indemnitees”), against any liability, damage, loss or expense (including reasonable attorneys’ fees and expenses of litigation)
(collectively, “Losses”) incurred by or imposed upon the WCCI Indemnitees, or any one of them, in connection with any claims, suits, actions, demands or judgments of Third Parties or Affiliates of Paratek, including without limitation
personal injury and product liability matters and claims of suppliers and Paratek employees (except in cases where such claims, suits, actions, demands or judgments result from a breach of this Agreement, or negligence or willful misconduct, on the
part of WCCI or its Affiliates or any of their respective employees, agents, contractors and Sublicensees) arising out of (a) any actions of Paratek or its Affiliates or any of their respective employees, agents, contractors and sublicensees in
the performance of the Backup Compound Research Program or the Development Plan, (b) the breach of any representation or warranty of Paratek under Article 11 hereof, or (c) the breach of any covenant, agreement or obligation of Paratek
under this Agreement. 
 12.2 Indemnification of Paratek by WCCI. Subject to the provisions of this Article 12,
WCCI shall indemnify, defend and hold harmless Paratek and its Affiliates and their respective directors, officers, employees, agents, contractors and their respective successors, heirs and assigns (the “Paratek Indemnitees”), against any
Losses incurred by or imposed upon the Paratek Indemnitees, or any one of them, in connection with any claims, suits, actions, demands or judgments of Third Parties or Affiliates of WCCI, including without limitation personal injury and product
liability matters and claims of suppliers and WCCI employees (except in cases where such claims, suits, actions, demands or judgments result from a breach of 

  
 41 

Portions of this Exhibit, indicated by the mark “[***],” were omitted and have been filed separately with the Secretary of the Commission
pursuant to the Registrant’s application requesting confidential treatment pursuant to Rule 406 of the Securities Act of 1933, as amended. 

 
this Agreement, or negligence or willful misconduct, on the part of Paratek or its Affiliates or any of their respective employees, agents, contractors and sublicensees), arising out of
(a) any actions of WCCI or its Affiliates or any of their respective employees, agents, contractors and Sublicensees in the performance of the Backup Compound Research Program or the Development or Commercialization of Lead Candidates or
Products, (b) the breach of any representation or warranty of WCCI under Article 11 hereof, (c) the breach of any covenant, agreement or obligation of WCCI under this Agreement, (d) the Development, testing, production, manufacture,
promotion, import, Commercialization or use by WCCI or any of its Affiliates or Sublicensees of any Product which is manufactured or sold by WCCI or by an Affiliate, Sublicensee, distributor or agent of WCCI (other than Paratek or its Affiliates,
contractors, agents or sublicensees), or (e) the use of any Product referred to in the foregoing clause (d) by any end-user customer that acquires such Product directly or indirectly from WCCI or any
Affiliate, Sublicensee, distributor or agent of WCCI (other than Paratek or its Affiliates, contractors, agents or sublicensees). Notwithstanding anything express or implied in the foregoing provisions of this Section 12.2, WCCI shall not
indemnify any of the Paratek Indemnitees from any Losses incurred by or imposed upon the Paratek Indemnitees, or any one of them, in connection with any claims, suits, actions, demands or judgments of Third Parties or Affiliates of Paratek asserting
that the use of the Paratek Technology or the practice of the licenses granted by Paratek under the Paratek Patent Rights and/or the Paratek Technology hereunder, or any portion thereof, in accordance with the terms and conditions of this Agreement,
infringe the Technology or intellectual property rights of Third Parties or Affiliates of Paratek. 
 12.3 Conditions to
Indemnification. A Paratek Indemnitee or a WCCI Indemnitee, as applicable, seeking indemnification under this Article 12 (the “Indemnified Party”) shall give prompt notice of the claim to the WCCI or Paratek as the applicable
indemnifying party (the “Indemnifying Party”). Provided that the Indemnifying Party is not contesting the indemnity obligation, the Indemnified Party shall (a) permit the Indemnifying Party to control and dispose of any such claims,
actions, suits or demands relating to such claim (except for claims, actions, suits or demands subject to the provisions of Section 9.2.2 to the extent that Section 9.2.2 otherwise provides); provided, that, the Indemnifying Party shall
act reasonably and in good faith with respect to all matters relating to the settlement or disposition of any claim as the settlement or disposition relates to Parties being indemnified under this Article 12 and provided, further, that the
Indemnifying Party shall not settle or otherwise resolve any claim without prior notice to the Indemnified Party and the consent of the Indemnified Party (which consent shall not be unreasonably withheld, conditioned or delayed); and
(b) cooperate with the Indemnifying Party in its defense of any claim for which indemnification is sought under this Article 12. The Indemnified Party shall have the right to participate in all legal proceedings, at the Indemnified Party’s
sole cost and expense, giving rise to the right of indemnification. 
 12.4 Contribution. In the event that there
is a claim from a Third Party against either or both Parties with respect to any matter as to which each Party has an indemnification obligation to the other Party pursuant to Section 12.1 or Section 12.2, as applicable, then, in lieu of
the indemnification provisions of Section 12.1 and 12.2 hereof, either Party shall have a right of contribution against the other Party or both Parties shall have a right of contribution against each other such that the Losses incurred and
suffered by both Parties and their respective 

  
 42 

Portions of this Exhibit, indicated by the mark “[***],” were omitted and have been filed separately with the Secretary of the Commission
pursuant to the Registrant’s application requesting confidential treatment pursuant to Rule 406 of the Securities Act of 1933, as amended. 

 
Affiliates in connection with the matter that is subject to such Third Party claim are shared by both Parties in proportion to the degree of fault of the Parties and their respective Affiliates
in causing or giving rise to such matter. 
 12.5 Warranty Disclaimer. EXCEPT AS OTHERWISE EXPRESSLY PROVIDED IN
THIS AGREEMENT, NEITHER PARTY NOR SUCH PARTY’S AFFILIATES MAKES ANY WARRANTY WITH RESPECT TO ANY TECHNOLOGY, GOODS, SERVICES, RIGHTS OR OTHER SUBJECT MATTER OF THIS AGREEMENT AND HEREBY DISCLAIMS WARRANTIES OF MERCHANTABILITY, FITNESS FOR A
PARTICULAR PURPOSE AND NONINFRINGEMENT WITH RESPECT TO ANY AND ALL OF THE FOREGOING. 
 12.6 Limited Liability.
NOTWITHSTANDING ANYTHING TO THE CONTRARY IN THIS AGREEMENT, NEITHER PARATEK NOR WCCI WILL BE LIABLE WITH RESPECT TO ANY SUBJECT MATTER OF THIS AGREEMENT UNDER ANY CONTRACT, NEGLIGENCE, STRICT LIABILITY OR OTHER LEGAL OR EQUITABLE THEORY FOR
(I) ANY INDIRECT, INCIDENTAL, CONSEQUENTIAL OR PUNITIVE DAMAGES OR LOST PROFITS OR (II) COST OF PROCUREMENT OF SUBSTITUTE GOODS, TECHNOLOGY OR SERVICES. FOR PURPOSES OF THIS SECTION 12.6, IT IS HEREBY UNDERSTOOD AND AGREED THAT ANY
INDEMNIFICATION OR CONTRIBUTION CLAIM BY EITHER PARTY AGAINST THE OTHER PARTY UNDER SECTION 12.1, SECTION 12.2 OR SECTION 12.4, AS APPLICABLE, WITH RESPECT TO AMOUNTS OWED, PAID OR REQUIRED TO BE PAID BY AN INDEMNIFIED PARTY TO A THIRD PARTY SHALL
NOT BE LIMITED BY VIRTUE OF THIS SECTION 12.6. 
 12.7 TUFTS DISCLAIMER. EACH OF THE PARTIES ACKNOWLEDGES THAT
TUFTS MAKES NO REPRESENTATIONS, EXTENDS NO WARRANTIES OF ANY KIND, EITHER EXPRESS OR IMPLIED (INCLUDING, WITHOUT LIMITATION, ANY WARRANTIES OF MERCHANTABILITY OR FITNESS FOR PURPOSE), AND ASSUMES NO RESPONSIBILITIES WHATSOEVER, WITH RESPECT TO THE
PATENTS OR TECHNOLOGY OR THE USE THEREOF, OR THE MANUFACTURE, POSSESSION, USE, MARKETING, SALE, OR OTHER DISPOSITION BY TUFTS, THE PARTIES, OR ANYONE ELSE, OF LICENSED PRODUCT(S) OR ANY OTHER PRODUCTS OF SERVICES (INCLUDING, WITHOUT LIMITATION,
PRODUCTS MADE BY TUFTS, AND TUFTS SERVICES, THAT ARE OR WERE FURNISHED TO A PARTY AT ANY TIME BEFORE, ON, OR AFTER THE EFFECTIVE DATE), EXCEPT ONLY AS EXPRESSLY STATED BELOW IN THIS SECTION 12.7. Without limitation of the foregoing generality,
nothing contained herein or in any disclosure of the Patents or Technology (as the terms “Patent Rights” and “Technology” are defined in the Tufts License Agreement) made by or on behalf of Tufts shall be construed as extending
any representation or warranty with respect to the Patents or Technology or Products or the results to be obtained by the use of the Patents or Technology or any Products, or that anything made, used, or sold by use of the Patents or Technology or
any part thereof, alone or in combination, will be free from infringement of patents of third parties. TUFTS SHALL NOT BE LIABLE TO EITHER PARTY, ITS SUBSIDIARIES, ITS SUBLICENSEES, OR ANY OTHER PARTY, REGARDLESS OF THE FORM OR THEORY OF ACTION
(WHETHER CONTRACT, TORT, INCLUDING NEGLIGENCE, STRICT 

  
 43 

Portions of this Exhibit, indicated by the mark “[***],” were omitted and have been filed separately with the Secretary of the Commission
pursuant to the Registrant’s application requesting confidential treatment pursuant to Rule 406 of the Securities Act of 1933, as amended. 

 
LIABILITY, OR OTHERWISE), FOR ANY SPECIAL, INCIDENTAL, CONSEQUENTIAL, PUNITIVE, OR OTHER EXTRAORDINARY DAMAGES ARISING OUT OF OR RELATED TO THIS AGREEMENT, PATENTS, THE TECHNOLOGY, THE PRODUCTS,
OR ANY PRODUCTS OR SERVICES FURNISHED OR NOT FURNISHED BY TUFTS, EVEN IF TUFTS HAS BEEN ADVISED OF THE POSSIBILITY THEREOF. 

12.8 Insurance. 
 12.8.1 Clinical Trial Liability. Paratek and WCCI hereby agree that, if required in order for Paratek to comply with its obligations under the Tufts License Agreement, not later than thirty
(30) days prior to WCCI’s commencement of any human clinical trial, if at all, of a Product and at all times thereafter until the expiration of all applicable statutes of limitation pertaining to such trial (whether same occurs or exists
during or after the existence of the Tufts License Agreement or during or after the License Period as defined in the Tufts License Agreement), WCCI will, at its own expense, obtain and maintain in full force and effect an insurance program
consisting of a combination of a self-insurance and third party insurance coverage as further described below, protecting WCCI, Tufts and Paratek against all claims, suits, obligations, liabilities and damages, based upon or arising out of actual or
alleged bodily injury, personal injury, death or any other damage to or loss of persons or property caused by WCCI’s activities in the conduct of such clinical trial. WCCI’s third party insurance coverage portion of such insurance program
shall consist of a comprehensive general liability insurance policy or policies that include coverage of clinical trial liability. Such insurance policy or policies shall be issued by companies rated by A. M.. Best as A VIII or better (or other
companies acceptable to Tufts), shall name each of Tufts and Paratek as an additional named insured, shall have limits of [***] dollars ($[***]) in the aggregate for all covered claims, shall be non-cancelable
except upon thirty (30) days prior written notice to each of Tufts and Paratek and shall provide for coverage only in excess of the limits of WCCI’s self-insurance program and shall provide that as to any loss covered by such policy or
policies and also by any policies obtained by any additional named insured under WCCI’s policies, WCCI’s policies shall provide primary coverage for such additional named insured and such additional named insured’s policies shall be
considered excess coverage for such additional named insured. Notwithstanding anything express or implied in the foregoing provisions of this Section 12.8.1 to the contrary, the rights of Tufts under this Section 12.8.1 shall only be
applicable in the case that WCCI commences a human clinical trial of a Product that is a Licensed Product (as “Licensed Product” is defined in the Tufts License Agreement). 

12.8.2 Product Liability. Paratek and WCCI hereby agree that, if required in order for Paratek to comply with its
obligations under the Tufts License Agreement, not later than thirty (30) days before WCCI shall make, use, or sell, on a commercial basis, a Licensed Product (as “Licensed Product” is defined in the Tufts License Agreement) and at
all times thereafter until the expiration of all applicable statutes of limitation pertaining to any such manufacture, marketing, possession, use, sale or other disposition of a Licensed Product (whether same occurs or exists during or after the
existence of the Tufts License Agreement or during or after the License Period as defined in the Tufts License Agreement) by WCCI, WCCI will, at its expense, obtain and maintain in full force and effect Third Party insurance coverage consisting of a
combination of a self-insurance and third party insurance coverage as further 

  
 44 

Portions of this Exhibit, indicated by the mark “[***],” were omitted and have been filed separately with the Secretary of the Commission
pursuant to the Registrant’s application requesting confidential treatment pursuant to Rule 406 of the Securities Act of 1933, as amended. 

 
described below protecting WCCI and Tufts against all claims, suits, obligations, liabilities and damages, based upon or arising out of actual or alleged bodily injury, personal injury, death or
any other damage to or loss of persons or property caused by any such manufacture, marketing, possession, use, sale, or other disposition. WCCI’s third party insurance coverage portion of such insurance program, shall consist of a comprehensive
general liability insurance policy or policies that include coverage of product liability. Such insurance coverage shall consist of a comprehensive general liability insurance policy or policies that include coverage of product liability. Such
insurance policy or policies shall be issued by companies rated by A. M. Best as A VIII or better (or other companies acceptable to Tufts), shall name Tufts as an additional named insured, shall have limits of [***] dollars ($[***]) in the aggregate
for all covered claims, shall be non-cancelable except upon thirty (30) days prior written notice to Tufts, and shall provide that as to any loss covered thereby and also by any policies obtained by Tufts
itself, WCCI’s policies shall provide primary coverage for Tufts and Tufts’ policies shall be considered excess coverage for Tufts. 
 ARTICLE 13: DISPUTE RESOLUTION 
 13.1 Dispute Resolution.

 13.1.1 Escalation to Executive Officers. In the event of any dispute arising between the Parties in connection
with this Agreement, the construction thereof, or the rights, duties or liabilities of either Party and such Party’s Affiliates, then such dispute shall be escalated to the respective Executive Officers of the Parties for resolution. If the
Executive Officers cannot resolve such dispute within thirty (30) days, then, except as otherwise set forth herein, such dispute shall be resolved by binding arbitration as set forth in Section 13.1.2 below. 

13.1.2 Arbitration. Binding arbitration shall occur under the then current Rules for
Non-Administered Arbitration and supervision of the American Arbitration Association (the “AAA”), except as otherwise provided herein. If the dispute involves a claim for money in the amount of
$[***] ([***] dollars) or less and does not involve any claims relating to ownership, use, or disclosure of intellectual property (other than a claim of unlawful ownership, use or disclosure of intellectual property arising solely from a failure to
pay a license fee or royalty), the arbitration shall be before a single neutral arbitrator whom WCCI and Paratek shall select from a panel of persons knowledgeable in the field of drug and pharmaceuticals development and distribution; otherwise, the
arbitration shall be before three arbitrators, one selected by WCCI, one selected by Paratek, and the third selected by the two arbitrators selected. Within thirty (30) days after initiation of arbitration, each Party shall select one person to
act as arbitrator and the two Party-selected arbitrators shall select a third arbitrator within thirty (30) days of their appointment. If the arbitrators selected by the Parties are unable or fail to agree upon the third arbitrator, the third
arbitrator shall be appointed by the AAA. In the event the arbitrators seek the guidance of the law of any jurisdiction, the laws of the State of New York shall govern. All arbitration proceedings will take place in New York, New York. Either Party
may apply to the arbitrators for interim injunctive relief until the arbitration decision is rendered or the dispute is otherwise resolved. Either Party also may, without waiving any right or remedy under this Agreement, seek from any court having
jurisdiction any injunctive or provisional relief necessary to protect the rights or property of that Party pending resolution of the dispute pursuant to this 

  
 45 

Portions of this Exhibit, indicated by the mark “[***],” were omitted and have been filed separately with the Secretary of the Commission
pursuant to the Registrant’s application requesting confidential treatment pursuant to Rule 406 of the Securities Act of 1933, as amended. 

 
Section 13.1.2. The arbitrator or arbitrators shall not have the power to award punitive or exemplary damages. The decision and award of the arbitrator or arbitrators shall be final and
binding and the award rendered may be entered in any court having jurisdiction. WCCI and Paratek shall each pay its own attorney’s fees associated with the arbitration, and shall pay the other costs and expenses of the arbitration as the rules
of the AAA provide. The arbitrators shall make their decision known to both Parties as quickly as possible by delivering written notice of their decision to both Parties. The Parties shall agree in writing to comply with the proposal selected by the
arbitration panel within five (5) days of receipt of notice of such selection. The decision of the arbitrators shall be final and binding on the Parties, and specific performance may be ordered by any court of competent jurisdiction.
Notwithstanding the provisions of Section 13.1.1 hereof or this 13.1.2, Paratek and WCCI may each petition a court of law for injunctive relief to protect its respective intellectual property or confidential information. 

ARTICLE 14: MISCELLANEOUS 
 14.1 Notices. All notices and communications shall be in writing mailed via certified mail, return receipt requested, courier, or facsimile transmission addressed as follows, or to such
other address as may be designated from time to time: 
  

			
	 If to WCCI:
	  	If to Paratek:
		
	 Warner Chilcott Company Inc.
	  	Paratek Pharmaceuticals, Inc.
	 PO Box 1005
	  	75 Kneeland Street
	 Fajardo, Puerto Rico 00738
	  	Boston, MA 02111
	 Attn: Director, Business Management
	  	Attn: Chief Executive Officer
	 Fax: (787) 863 5355
	  	Fax: (617) 275-0039
		
	 With a copy to:
	  	With a copy to:
		
	 Warner Chilcott (US), Inc.
	  	Mintz, Levin, Cohn, Ferris, Glovsky
	 100 Enterprise Dr.
	  	and Popeo, PC
	 Rockaway, NJ 07866
	  	One Financial Center
	 Attn:General Counsel
	  	Boston, Massachusetts 02111
	 Fax: (973) 443 3310
	  	Attention: Jeffrey M. Wiesen, Esq.
		  	Tel: (617) 542-6000
		  	Fax: (617) 542-2241

 Except as otherwise expressly provided in this Agreement or in writing by both Parties, any notice, communication or
payment required to be given or made shall be deemed given or made and effective (i) when delivered personally; (ii) when delivered by telex or telecopy (if not a payment); or (iii) when received if sent by overnight express or mailed
by certified, registered or regular mail, postage prepaid, addressed to parties at their address stated above, or to such other address as such Party may designate by written notice in accordance with accordance with the provisions of this
Section 14.1. 

  
 46 

Portions of this Exhibit, indicated by the mark “[***],” were omitted and have been filed separately with the Secretary of the Commission
pursuant to the Registrant’s application requesting confidential treatment pursuant to Rule 406 of the Securities Act of 1933, as amended. 

 14.2 Governing Law. This Agreement shall be governed by and construed in
accordance with the laws of New York, without regard to the application of principles of conflicts of law. 
 14.3 Binding
Effect. This Agreement shall be binding upon and inure to the benefit of the Parties and their respective legal representatives, successors and permitted assigns. 
 14.4 Headings. Article, section and subsection headings are inserted for convenience of reference only and do not form a part of this Agreement. 

14.5 Counterparts. This Agreement may be executed simultaneously in two or more counterparts, each of which shall be deemed
an original. 
 14.6 Amendment; Waiver. Except as otherwise expressly provided in this Agreement in connection
with the amendment, modification or updating from time to time of certain Exhibits and Schedules to this Agreement, this Agreement may be amended, modified, superseded or cancelled, and any of the terms may be waived, only by a written instrument
executed by each Party or, in the case of waiver, by the Party or Parties waiving compliance. The delay or failure of any Party at any time or times to require performance of any provisions shall in no manner affect the rights at a later time to
enforce the same. No waiver by any Party of any condition or of the breach of any term contained in this Agreement, whether by conduct, or otherwise, in any one or more instances, shall be deemed to be, or considered as, a further or continuing
waiver of any such condition or of the breach of such term or any other term of this Agreement. 
 14.7 No Third Party
Beneficiaries. Except as set forth in Sections 7.4 and 12.7 hereof with respect to Tufts and with respect to the WCCI Indemnitees and the Paratek Indemnitees, no Third Party, including any employee of any Party to this Agreement, shall have
or acquire any rights by reason of this Agreement. 
 14.8 Purposes and Scope. Nothing in this Agreement shall be
construed (a) to create or imply a general partnership between the Parties, (b) to make either Party the agent of the other for any purpose, (c) to alter, amend, supersede or vitiate any other arrangements between the Parties with
respect to any subject matters not covered hereunder, (d) to give either Party the right to bind the other Party or such other Party’s Affiliates, (e) to create any duties or obligations between the Parties except as expressly set
forth herein, or (f) to grant any direct or implied licenses or any other right other than as expressly set forth herein. 

14.9 Assignment and Successors. Neither this Agreement nor any obligation of a Party hereunder may be assigned by either
Party without the consent of the other which shall not be unreasonably withheld, except that each Party may assign this Agreement and the rights, obligations and interests of such Party, in whole or in part, (i) to any of its Affiliates or
(ii) to any purchaser of all of its assets and/or all of its assets to which this Agreement relates or to any successor corporation resulting from any merger or consolidation of such Party with or into such corporation (an
“Acquiror”); provided, however, that in the case of any Affiliate of a Party, such Affiliate shall be bound by all of the terms and provisions of this Agreement that apply to the 

  
 47 

Portions of this Exhibit, indicated by the mark “[***],” were omitted and have been filed separately with the Secretary of the Commission
pursuant to the Registrant’s application requesting confidential treatment pursuant to Rule 406 of the Securities Act of 1933, as amended. 

 
rights or obligations assigned to such Affiliate, all to the same extent that the assigning Party is bound, and in the case of any such Acquiror, such Acquiror shall execute a written instrument
for the benefit of the non-assigning Party agreeing to become bound by all of the terms and provisions of this Agreement to the same extent that the assigning or selling Party is bound. Whenever any provision
of this Agreement expressly provides that any Affiliate or Affiliates of a Party shall be entitled to enjoy any right under this Agreement or shall be burdened or required to be burdened by any obligation under this Agreement, then such Affiliate or
Affiliates shall be deemed and treated as permitted assignees of such Party with respect to such right, to the extent that such Affiliate or Affiliates shall actually exercise such right, and shall be deemed and treated as permitted assignees of
such Party with respect to such obligation, in either case without any assignment or assumption agreement or any other act being required to be taken by such Party or such Affiliate or Affiliates to evidence the assignment of such right or
obligation, as the case may be. Each Party shall be responsible and liable to the other Party for any failure by any Affiliate of such Party to perform any obligation that is expressly provided by the terms of this Agreement to be performed by such
Affiliate. Any permitted assignment under this Section 14.9 shall not operate as a release or discharge of any obligations of the assigning Party under this Agreement, and each Party shall be responsible and liable to the other Party for any
failure by any permitted assignee of such Party to perform any obligation under this Agreement that has been assigned or deemed to be assigned by such Party to such permitted assignee. Nothing in this Section 14.9 shall be construed to limit in
any way the right to grant sublicenses in accordance with the provisions of Section 7.3.4 hereof. 
 14.10 Force
Majeure. Neither WCCI nor Paratek shall be liable for failure of or delay in performing obligations set forth in this Agreement, and neither shall be deemed in breach of its obligations, if such failure or delay is due to a Force Majeure. In
event of such Force Majeure event, the Party affected thereby shall use reasonable efforts to cure or overcome the same and resume performance of its obligations hereunder. 
 14.11 Interpretation. The Parties hereto acknowledge and agree that: (a) each Party and its counsel reviewed and negotiated the terms and provisions of this Agreement and have
contributed to its revision; (b) the rule of construction to the effect that any ambiguities are resolved against the drafting Party shall not be employed in the interpretation of this Agreement; and (c) the terms and provisions of this
Agreement shall be construed fairly as to both Parties and their respective Affiliates and not in a favor of or against either Party or such Party’s Affiliates, regardless of which Party was generally responsible for the preparation of this
Agreement. 
 14.12 Integration; Severability. This Agreement is the sole agreement with respect to the subject
matter hereof and supersede all other agreements and understandings between the Parties with respect to the same. In the event any one or more of the provisions contained in this Agreement should be held invalid, illegal or unenforceable in any
respect, the validity, legality and enforceability of the remaining provisions contained herein shall not in any way be affected or impaired thereby, unless the absence of the invalidated provision(s) adversely affect the substantive rights of the
Parties. The Parties shall in such an instance use their best efforts to replace the invalid, illegal or unenforceable provision(s) with valid, legal and enforceable provision(s) that, insofar as practical, implement the purposes of this Agreement.

  
 48 

Portions of this Exhibit, indicated by the mark “[***],” were omitted and have been filed separately with the Secretary of the Commission
pursuant to the Registrant’s application requesting confidential treatment pursuant to Rule 406 of the Securities Act of 1933, as amended. 

 14.13 Further Assurances. Each of Paratek and WCCI agrees to duly execute and
deliver, or cause to be duly executed and delivered, such further instruments and do and cause to be done such further acts and things, including, without limitation, the filing of such additional assignments, agreements, documents and instruments,
that may be necessary or as the other Party hereto may at any time and from time to time reasonably request in connection with this Agreement or to carry out more effectively the provisions and purposes of, or to better assure and confirm unto such
other Party its rights and remedies under, this Agreement. 
 [Remainder of page intentionally left blank.] 

  
 49 

Portions of this Exhibit, indicated by the mark “[***],” were omitted and have been filed separately with the Secretary of the Commission
pursuant to the Registrant’s application requesting confidential treatment pursuant to Rule 406 of the Securities Act of 1933, as amended. 

 IN WITNESS WHEREOF, the Parties have caused this Agreement to be executed by their duly
authorized representatives. 
  

			
	PARATEK PHARMACEUTICALS, INC.
		
	By:	 	 /s/ Thomas J. Bigger

	Name:	 	Thomas J. Bigger
	Title:	 	President and CEO
	
	WARNER CHILCOTT COMPANY, INC.
		
	By:	 	 /s/ Anthony D. Bruno

	Name:	 	Anthony D. Bruno
	Title:	 	Executive Vice President

  
 50 

Portions of this Exhibit, indicated by the mark “[***],” were omitted and have been filed separately with the Secretary of the Commission
pursuant to the Registrant’s application requesting confidential treatment pursuant to Rule 406 of the Securities Act of 1933, as amended. 

 Exhibit A 

Development Plan 

  
 Exhibit A-1

 Portions of this Exhibit, indicated by the mark “[***],” were omitted and have been filed separately with the Secretary of the
Commission pursuant to the Registrant’s application requesting confidential treatment pursuant to Rule 406 of the Securities Act of 1933, as amended. 

 [***] 
 Exhibit A pg. 1 of 9 

  
 Portions of this Exhibit,
indicated by the mark “[***],” were omitted and have been filed separately with the Secretary of the Commission pursuant to the Registrant’s application requesting confidential treatment pursuant to Rule 406 of the Securities Act of
1933, as amended. 

 [***] 
 Exhibit A pg. 2 of 9 

  
 Portions of this Exhibit,
indicated by the mark “[***],” were omitted and have been filed separately with the Secretary of the Commission pursuant to the Registrant’s application requesting confidential treatment pursuant to Rule 406 of the Securities Act of
1933, as amended. 

 [***] 
 Exhibit A pg. 3 of 9 

  
 Portions of this Exhibit,
indicated by the mark “[***],” were omitted and have been filed separately with the Secretary of the Commission pursuant to the Registrant’s application requesting confidential treatment pursuant to Rule 406 of the Securities Act of
1933, as amended. 

 [***] 
 Exhibit A pg. 4 of 9 

  
 Portions of this Exhibit,
indicated by the mark “[***],” were omitted and have been filed separately with the Secretary of the Commission pursuant to the Registrant’s application requesting confidential treatment pursuant to Rule 406 of the Securities Act of
1933, as amended. 

 [***] 
 Exhibit A pg. 5 of 9 

  
 Portions of this Exhibit,
indicated by the mark “[***],” were omitted and have been filed separately with the Secretary of the Commission pursuant to the Registrant’s application requesting confidential treatment pursuant to Rule 406 of the Securities Act of
1933, as amended. 

 [***] 
 Exhibit A pg. 6 of 9 

  
 Portions of this Exhibit,
indicated by the mark “[***],” were omitted and have been filed separately with the Secretary of the Commission pursuant to the Registrant’s application requesting confidential treatment pursuant to Rule 406 of the Securities Act of
1933, as amended. 

 [***] 
 Exhibit A pg. 7 of 9 

  
 Portions of this Exhibit,
indicated by the mark “[***],” were omitted and have been filed separately with the Secretary of the Commission pursuant to the Registrant’s application requesting confidential treatment pursuant to Rule 406 of the Securities Act of
1933, as amended. 

 [***] 
 Exhibit A pg. 8 of 9 

  
 Portions of this Exhibit,
indicated by the mark “[***],” were omitted and have been filed separately with the Secretary of the Commission pursuant to the Registrant’s application requesting confidential treatment pursuant to Rule 406 of the Securities Act of
1933, as amended. 

 [***] 
 Exhibit A pg. 9 of 9 

  
 Portions of this Exhibit,
indicated by the mark “[***],” were omitted and have been filed separately with the Secretary of the Commission pursuant to the Registrant’s application requesting confidential treatment pursuant to Rule 406 of the Securities Act of
1933, as amended. 

 Exhibit B 

Tufts License Agreement 
 [See Exhibit 10.18 filed herewith] 

  
 Exhibit B-1

 Portions of this Exhibit, indicated by the mark “[***],” were omitted and have been filed separately with the Secretary of the
Commission pursuant to the Registrant’s application requesting confidential treatment pursuant to Rule 406 of the Securities Act of 1933, as amended. 

 Schedule 1 

Lead Candidate List 

  
 Schedule 1-1

 Portions of this Exhibit, indicated by the mark “[***],” were omitted and have been filed separately with the Secretary of the
Commission pursuant to the Registrant’s application requesting confidential treatment pursuant to Rule 406 of the Securities Act of 1933, as amended. 

 [***] 
 Schedule 1 pg. 1 of 1 

  
 Portions of this Exhibit,
indicated by the mark “[***],” were omitted and have been filed separately with the Secretary of the Commission pursuant to the Registrant’s application requesting confidential treatment pursuant to Rule 406 of the Securities Act of
1933, as amended. 

 Schedule 2 

Backup Compound List 

  
 Schedule 2-1

 Portions of this Exhibit, indicated by the mark “[***],” were omitted and have been filed separately with the Secretary of the
Commission pursuant to the Registrant’s application requesting confidential treatment pursuant to Rule 406 of the Securities Act of 1933, as amended. 

 [***] 
 Schedule 2 pg. 1 of 2 

  
 Portions of this Exhibit,
indicated by the mark “[***],” were omitted and have been filed separately with the Secretary of the Commission pursuant to the Registrant’s application requesting confidential treatment pursuant to Rule 406 of the Securities Act of
1933, as amended. 

 [***] 
 Schedule 2 pg. 2 of 2 

  
 Portions of this Exhibit,
indicated by the mark “[***],” were omitted and have been filed separately with the Secretary of the Commission pursuant to the Registrant’s application requesting confidential treatment pursuant to Rule 406 of the Securities Act of
1933, as amended. 

 Schedule 3 

Joint Press Release 

  
 Schedule 3-1

 Portions of this Exhibit, indicated by the mark “[***],” were omitted and have been filed separately with the Secretary of the
Commission pursuant to the Registrant’s application requesting confidential treatment pursuant to Rule 406 of the Securities Act of 1933, as amended. 

 

 
 Warner Chilcott and Paratek Pharmaceuticals Sign Collaboration Agreement 

for Novel, Narrow-Spectrum Agents for Acne and Rosacea 
 FAJARDO, Puerto Rico and BOSTON, Mass., July 9, 2007 - Warner Chilcott Company, Inc. and Paratek Pharmaceuticals, Inc. announced today that the two companies have entered into an exclusive license
agreement for the development and commercialization of novel, narrow-spectrum tetracyclines for the treatment of acne and rosacea. 
 Tetracycline antibiotics are the leading approved systemic treatments of moderate to severe inflammatory acne. Discovered decades ago as broad-spectrum systemic antibiotics, tetracyclines have been shown
to be potent anti-acne agents. Paratek has utilized its expertise in chemistry to develop novel narrow-spectrum antibacterial tetracyclines with improved anti-inflammatory activity, tolerability and other properties for the next generation treatment
of acne and rosacea. These compounds represent the first tetracycline-derived new molecular entities ever to be synthesized specifically as improved therapeutics for dermatologic diseases. 

“We look forward to a productive collaboration with Paratek as we work together to progress Paratek’s novel tetracycline
products through the development process and into commercialization” said Roger Boissonneault, Chief Executive Officer and President of Warner Chilcott. 
 “We are pleased to announce our collaboration with Warner Chilcott, a proven leader in the development and commercialization of dermatology products,” said Stuart B. Levy, M.D., Co-founder and Chief Scientific Officer of Paratek Pharmaceuticals. “For years, dermatologists have sought therapies with a more targeted spectrum of activity. While effective, currently marketed tetracyclines
possess antibacterial activity against a broad number of organisms not associated with acne or rosacea, which can lead to adverse consequences such as resistance development among life-threatening bacteria and persistent side effects. Paratek’s
proprietary compounds have been designed to circumvent these issues by better targeting the causative bacteria and retaining potent anti-inflammatory properties.” 

  
 Portions of this Exhibit,
indicated by the mark “[***],” were omitted and have been filed separately with the Secretary of the Commission pursuant to the Registrant’s application requesting confidential treatment pursuant to Rule 406 of the Securities Act of
1933, as amended. 

 Under the terms of the agreement, Warner Chilcott will assume responsibility for clinical
development of the tetracycline derivative products and will have exclusive rights to market the products in the United States. Paratek received an up-front payment and will be eligible to receive additional
payments upon achievement of certain development and regulatory approval milestones. Warner Chilcott will pay a royalty to Paratek on sales of any product under the agreement. 
 The leading candidate under the agreement is in preclinical development and expected to enter clinical development in 2008. 
 Warner Chilcott Company Inc. is a subsidiary of Warner Chilcott Limited (Nasdaq: WCRX). 
 About
Warner Chilcott 
 Warner Chilcott is a specialty pharmaceutical company focused on developing, manufacturing, marketing and
selling branded prescription pharmaceutical products in women’s healthcare and dermatology in the United States. 
 Read
more on www.warnerchilcott.com. 
 About Paratek Pharmaceuticals 
 Paratek Pharmaceuticals, Inc. is engaged in the discovery and commercialization of new therapeutics that treat serious and life-threatening diseases, with a particular focus on the growing worldwide
problem of antibiotic resistance. Paratek is advancing novel compounds that can circumvent or block bacterial resistance involving technology initially developed by Paratek co-founder Dr. Stuart
Levy’s laboratory at Tufts University School of Medicine, and licensed by Paratek. In addition to its tetracycline-derived antibacterials, Paratek is developing small molecule drugs that can prevent infection by interfering with Multiple
Adaptational Response (MAR) mechanisms in bacteria. 
 Outside the antibacterial therapeutic area, Paratek has also established
an effort to exploit its novel tetracycline derivatives and their unique mechanism of action in selected anti-inflammatory and neurodegenerative conditions. Paratek has an active chemical synthesis effort to produce novel and diverse small
molecules, with the goal of developing non-antibacterial compounds with improved activity in serious inflammatory and neurodegenerative diseases based upon a growing body of clinical and basic research
supporting this approach. 

  
 2 

Portions of this Exhibit, indicated by the mark “[***],” were omitted and have been filed separately with the Secretary of the Commission
pursuant to the Registrant’s application requesting confidential treatment pursuant to Rule 406 of the Securities Act of 1933, as amended. 

 Paratek is privately held and headquartered in Boston, Massachusetts, USA. For more
information, visit Paratek’s website at http://www.paratekpharm.com/. 
 Warner Chilcott’s Forward-Looking Statements

 This press release contains forward-looking statements, including statements concerning our product development efforts.
These statements constitute forward-looking statements within the meaning of Section 27A of the Securities Act of 1933 and Section 21E of the Securities Exchange Act of 1934. The words “may,” “might,” “will,”
“should,” “estimate,” “project,” “plan,” “anticipate,” “expect,” “intend,” “outlook,” “believe” and other similar expressions are intended to identify
forward-looking statements. Readers are cautioned not to place undue reliance on these forward-looking statements, which speak only as of their dates. These forward-looking statements are based on estimates and assumptions by our management that,
although we believe to be reasonable, are inherently uncertain and subject to a number of risks and uncertainties. 
 The
following represent some, but not necessarily all, of the factors that could cause actual results to differ from historical results or those anticipated or predicted by our forward-looking statements: our substantial, indebtedness; competitive
factors in the industry in which we operate; our ability to protect our intellectual property; a delay in qualifying our manufacturing facility to produce our products or production or regulatory problems with either third party manufacturers upon
whom we rely for some of our products or our own manufacturing facility; pricing pressures from reimbursement policies of private managed care organizations and other third party payors, government sponsored health systems, the continued
consolidation of the distribution network through which we sell our products, including wholesale drug distributors and the growth of large retail drug store chains; the loss of key senior management or scientific staff; an increase in litigation,
including product liability claims and patent litigation; government regulation affecting the development, manufacture, marketing and sale of pharmaceutical products, including our ability and the ability of companies with whom we do business to
obtain necessary regulatory approvals; our ability to successfully complete the implementation of a company-wide enterprise resource planning system without disrupting our 

  
 3 

Portions of this Exhibit, indicated by the mark “[***],” were omitted and have been filed separately with the Secretary of the Commission
pursuant to the Registrant’s application requesting confidential treatment pursuant to Rule 406 of the Securities Act of 1933, as amended. 

 
business; our ability to manage the growth of our business by successfully identifying, developing, acquiring or licensing and marketing new products, obtain regulatory approval and customer
acceptance of those products, and continued customer acceptance of our existing products; and other risks detailed from time-to-time in our annual report for 2006 filed
with the Securities and Exchange Commission on Form 10-K, our financial statements and other investor communications. 
 We caution you that the foregoing list of important factors is not exclusive. In addition, in light of these risks and uncertainties, the matters referred to in our forward-looking statements may not
occur. We undertake no obligation to publicly update or revise any forward-looking statement as a result of new information, future events or otherwise, except as may be required by law. 

# # # 
  

			
	Warner Chilcott Limited	  	Paratek Pharmaceuticals, Inc.
	Rochelle Fuhrmann	  	Kate Boxmeyer
	Director, Investor Relations	  	Director of Finance
	+1-973-442-3200	  	+1-617-275-0040 ext. 238
	rfuhrmann@wcrx.com	  	kboxmever@paratekpharm.com

  
 4 

Portions of this Exhibit, indicated by the mark “[***],” were omitted and have been filed separately with the Secretary of the Commission
pursuant to the Registrant’s application requesting confidential treatment pursuant to Rule 406 of the Securities Act of 1933, as amended.

Source: [{"source": "alea-institute/alea-institute/kl3m-data-edgar-agreements/train-00243-of-00352.parquet"}, [{"source": "alea-institute/alea-institute/kl3m-data-edgar-agreements/train-00243-of-00352.parquet"}]]